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SYNOPSIS 
Multiple sclerosis (MS) is a chronic demyelinating disease characterized by 
perivascular accumulation of infiammatory cells, resulting in numerous (multiple) 
plaques (sclerosis), in the central nervous system (CNS). 
Despite ample research efforts both etiology and pathogenicity of the disease 
remain largely unknown. Due to the complexity of clinical manifestations the 
unequivocal diagnosis of MS is difficult to make. It is generally accepted that the 
effector phase of the disease depends on an autoimmune reaction. Notwithstanding 
the fact that oligoclonal antibodies can be found in the cerebrospinal fluid during 
disease, the roJe of antibDdies in MS is still unclear. In order to investigate the 
involvement of autoantigen specific antibodies in the pathology of MS, we 
performed a study to detect antigen specific B-cells (AFCs) in CNS tissues of MS 
patients. Using a new immunohistochemical technique we have revealed that a 
significant part of the APes localized in MS brain is specific for myelin basic protein 
(MBP). This provides further evidence for the local involvement of anti-MBP 
antibodies in the pathogenesis of MS_ Production of antibodies by B-cells is critically 
dependent on T-cell help. It has been shown that interactions between the gp39 
T-cell marker and its CD40 ligand on B-cells are essential for B-cell activation. In 
our experiments we have revealed gp39 positive T-cells in the same affected eNS 
tissue areas (plaques) in which we have detected the MBP specific AFe. The 
presence of both gp39 t Th-cells and MBP specific B-cells in plaques of MS patients 
eNS tissues indicates that autoantigen specific B-cells can be activated directly 
within the CNS. 
The relevance, of this new obseIVation in human tissue, was further 
established when it was shown that blockade of the gp39/CD40 interaction in EAE 
mice, resulted in dramatic suppression of the disease. Both from studies in mice and 
man it became clear that ill vivo blockade, of gp39/CD40 interactions, has a 
significant potential in the treatment of MS and other autoimmune diseases. An 
alternative approach to induce long term antigen specific suppression is the 
induction of oral tolerance. Tolerance can be induced by oral administration of large 
doses of putative auto-antigens. Live non-pathogenic microorganisms, transformed to 
produce antigens, are useful for oral delivery of antigens as they have many 
advantages over conventional feeding. Here we show that oral administration of 
genetically modified lactobacilli, which secrete antigen, leads to the induction of 
tolerance. In contrast, in a parallel line of research we show that oral administration 
of lactobacilli which express antigens on the outer membrane leads to induction of 
immunological memory and can thus he employed for vaccination against infectious 
diseases. Whether the immune system is stimulated or suppressed not only depends 
on the way the (auto-)antigen is presented (i.e. secreted or surface bound) but also 
on the intrinsic adjuvant properties of the Lactobacillus strain used. This indicates 
that modulation of immune responses can lead to suppression of disease in animals 
and possibly in MS. 
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CHAPTER 1 
INTRODUCTION 
1.1 General 
Multiple sclerosis (MS) is a demyelinating disease of the central nervous 
system (CNS). It is widely assumed that the pathology is a result of autoimmune 
responses directed against CNS antigens, possibly triggered by an environmental 
factor, in a genetically susceptible individual. 
This thesis describes investigations concerning the role of antibodies and 
antibody forming cells in immunopathogenesis and immunomodulation in MS. In this 
chapter we introduce some basic understandings with regard to the central nervous 
system, the pathogenesis and etiology of MS and the presently best available animal 
model for MS, experimental autoimmune encephalomyelitis (EAE). The aim of the 
study and experiments are described in "Outline of the thesis" (1.8). 
1.2 The central nel"VOUS system 
Most body functions are actively controlled by the CNS. The CNS receives 
information from sensory organs. Upon processing of this information, the eNS 
generates and controls body responses. In addition, the information may also be 
stored in the CNS for future use. The information to and from the CNS is 
transported via the peripheral nervous system. The major compartments within the 
CNS are the brain and the spinal cord, which are surrounded by the cerebrospinal 
fluid (CSF) and protected by the skull and vertebral column, respectively. CNS 
tissues are a complex of nerve cells (neurons), supporting cells (glia cells or 
neuroglia) and blood vessels. Three basic types of glia cells can be identified: 
astrocytes and microglia, both contributing to the structure and function of nervous 
tissue, and oligodendrocytes. Nerve fibres are protected by an isolating myelin 
sheath. The myelin around the axons in the CNS, is formed by layers of 
oligodendrocyte cell cytoplasm and membranes, which are wrapped many times 
around one or more axons (figure 1). The myelin sheaths in the peripheral nervous 
system are formed, in a similar way, by Schwann cells (England and Wakely, 1991). 
Demyelination is associated with an impaired conductivity, which leads to a 
vadety of neurological signs and symptoms. Several demyelinating diseases are 
known of both the peripheral nervous system, e.g. Guillain Barre syndrome, and 
CNS, e.g. acute demyelinating encephalomyelitis, subacute sclerosing pan-
encephalitis. MS is characterized by multi-focal demyelination of CNS white matter, 
accompanied with perivascular infiltrates of mononuclear cells. 
Since demyelination in MS-patients is restricted to the CNS, it is possible that 
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Figure 1 
The Myelin sheaths arc formed by thin layers of oligodendrocyte cytoplasm and membranes which 
are wrapped around the axons. Artistic impression. 
demyelination is associated with a defect concerning the eNS specific 
oligodendrocytes. Mutations within the gene coding for proteolipid protein (PLP). 
may cause hypomyelination and premature death of oligodendrocytes as was 
observed in the jimpy mouse model and patients with Pelizaeus-Merzbacher disease 
(Vermeesch et aI., 1990; Pratt et aI., 1991). PLP is one of the major proteins in eNS 
myelin which is considered to be synthesized exclusively by oligodendrocytes (Lees 
and Brostoff, 1984; Macklin, 1988). 
1.3 Diagnosis and clinical aspects 
Dependent on the severity and localization of the demyelinated areas 
(plaques or scars) in the eNS, a variety of clinical signs may become manifest in 
MS. Neurological signs and symptoms include fatigue, weakness or paralysis, 
disturbed gait, balance abnormalities, vision abnormalities (double vision, partial or 
complete blindness, nystagmus), bladder and bowel difficulties, sexual difficulties and 
psychiatric and cognitive defects (Ron and Feinstein, 1992; Matthews, 1991). The 
sequence of appearance and severity of clinical signs and symptoms, is highly 
diverse. As a consequence, it is very difficult to diagnose MS in an early stage. 
Several sets of criteria have been developed to score the level of disability of 
patients in order to support the diagnosis of MS. Allison and Millar (1954) 
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developed criteria for MS based on neurological signs and symptoms. Using these 
criteria patients may be classified as A) probable MS, B) early probable or latent 
MS and C) possible MS. The sets of criteria developed by Schumacher and 
coworkers (1965) requires for a definite MS diagnosis that neurological signs and 
symptoms are attributed to more than one lesion and neurological signs and 
symptoms have become n~anifest in hvo Of more separate periods. Most other 
developed criteria are variants to the above mentioned sets. The currently most 
general used criteria, which relies on both neurological signs and symptoms and 
laboratOlY data, are those developed by Posner et al (1983). These criteria 
distinguish patients into: A) clinically definite MS (2 subcategories), B) laboratory 
supported definite MS (3 subcategories), C) clinically probable MS (3 subcategories) 
and D) laboratory supported probable MS. As there is no single specific test to 
diagnose MS, in general a combination of clinical and laboratory tests is used for 
diagnostic purposes. 
By means of computerized tomography (Cf), lesions can be identified, in 
particular when Cf is combined with contrast enhancement (Aita et aI., 1978). An 
other technique to identify plaques is magnetic resonance imaging (MRI) (figure 2). 
Small lesions (10·12 mm') can still be identified (Young et aI., 1981). MRI presently 
is the most sensitive technique to confirm diagnosis and course of the disease 
(Uhlenbrock et aI., 1988). In addition, MRI scanning allows quantitative 
measurements of lesions before and after treatment. Gadolinium diethylenetriamine 
acetic acid enhancement, increases the sensitivity of MRI and makes it possible to 
distinguish between early inflammation and chronic lesions (Thompson et aI., 1989). 
However, using MRI many silent lesions were identified that often fail to correlate 
with clinical signs (Ormerod et aI., 1987; Oger et aI., 1987; Willoughby et aI., 1989). 
Electrophysiological studies to investigate the visual, auditory and somatic 
sensory pathways can provide evidence on lesions in the eNS (McDonald and 
Halliday, 1977). In addition, electrophysiological studies may be useful in evaluating 
the progression of the disease. 
With regard to the course of disease in MS, four major phases in the disease 
can be distinguished (figure 3). 
- A) Relapsing remitting (RR) MS; In most MS-patients the disease starts with 
periods in which some of the typical clinical signs become manifest (exacerbations), 
alternating with periods in which clinical signs are absent (remissions). The 
appearance of the exacerbations is unpredictable and the remissions vary in 
duration. In the early stages of the disease the remissions are usually associated with 
nearly complete restoration of normal neurological functions. This phase of disease 
is designated as relapsing remitting MS. 
- B) Secondary progressive MS; In one third of the MS patients the RR phase of 
disease is foHowed by a second more progressive phase in the disease. This phase of 
disease is characterized by the development of an increasing disability over at least 
six months. 
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Figure 2 
Magnetic resonance images of MS patient brain (horizontal plane). showing periventricular plaques 
(left) and several focal plaques (right) (arrows). Courtesy of Dr. F. Backhof, VU hospital, 
Amsterdam, The Netherlands. 
Disease 
severity/disability 
Primairy progressive MS 
Secondary progressive MS 
Relapsing/Remittmg MS 
Figure 3 
Disease Courses 
The clinical COllfSe of MS exhibits a number of patterns. Four main clinical subgroups can be 
distinguished: 
w Benign MS, minimal or no disability after 10 years of disease duration. 
- Relapsing remitting MS, a history of relapses and remissions without progressive deterioration. 
- Primary progressive MS, progressive from the onset. 
- Secondary progressive MS, after an initially relapsing-remitting course, progressive deterioration 
for at least six months, with or without superimposed relapses. 
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- C) Benign MS; A relative mild form of MS is benign MS, in which the patients can 
remain relatively asymptomatic for many years. The condition of RR-MS patients, 
which have an expanded disability status scale score of 3 or less, according to the 
criteria developed by Kurtzke (1983a), after a period of at least 10 years is defined 
as benign MS. 
- D) Primary progressive MS; A minor part of MS patients will develop, over a few 
weeks or months, a progressive course of disease from the onset of disease without 
relapses or remissions, this course of disease is called primary progressive MS. 
Primary progressive MS can be terminal within a few months. 
In most patients the onset of the disease lies between their 20th and 40th 
year of age. The first appearance of typical MS clinical signs or symptoms in 
children or adults over 55 year of age has been reported occasionally (Gall et aI., 
1958; Low and Carter, 1956; Ghezzi et aI., 1978). In The Netherlands the prevalence 
of MS is 60 cases per 100.000 inhabitants and the yearly incidence is 1.9 (de Graaf 
et aI., 1988). In women, MS is diagnosed approximately twice as often as compared 
to the frequency of diagnoses of MS in men. The average age at which MS patients 
decease is 63 year. In most cases of MS the cause of death is found in accompanying 
secondary diseases, mainly infections. 
1.4 Histo-pathology 
MS is primarily a demyelinating disease, in which the myelin sheaths are 
selectively damaged leaving the axons relatively unaffected. The colour of the 
demyelinated areas or plaques correlates with the age of plaques. New plaques are 
pink whereas old plaques are grey (Adams and Sidman., 1968). Plaques can be 
found throughout the complete CNS. Cortical and peri-ventricular plaques have 
been found in the majority of MS patients (Lumsden, 1970). Two types of plaques 
can be distinguished: acute plaques and chronic plaques (Adams, 1983). Acute 
plaques are not clearly demarcated and they contain T-ceHs, B-ceHs, macrophages 
and myelin fragments which is indicative for demyelination activity (Traugott and 
Raine, 1982; Traugott et aI., 1983; Lumsden, 1970). Periventricular cuffs, 
accumulations of lymphocytes around the ventricles, are often found in the vicinity 
of active plaques and suggest migration of lymphocytes from the ventricles into the 
CNS tissues. Re-myelination and oligodendrocyte proliferation is observed in the 
majority of acute plaques (Prineas, 1985). Chronic plaques contain hypertrophic 
astrocytes, microglia and plasma cells, producing antibodies of unknown specificity. 
Axons without a myelin sheath can also be found in chronic plaques. Re-myelination 
occurs to a limited extent in chronic plaques, however the newly formed myelin 
sheaths are thinner (Prineas and Connell, 1979). 
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1.5 Therapy 
The factors that lead to development of MS have not been identified yet. 
Based on the premise that MS is mediated by an aberrant immune response, both 
immuno-suppressive and immunopotentiating therapies have been applied to MS 
patients. However, one can presume that therapy affecting symptomatology in the 
peripheral immune system only, like plasmapheresis and plasma exchange, will have 
no or little effect on the continuity of immune processes within the CNS. In addition, 
most drugs with immunosuppressive or immunopotentiating effects, do not cross the 
blood brain barrier when applied systemically. 
A temporarily stabilizing effect on chronic progressive MS was observed with 
intensive immunosuppression based on the administration of cyc1ophosphamide Of 
total lymphoid irradiation (Hauser et a!., 1983; Weiner et a!., 1985; Cook et a!., 
1986). A 10-14 day treatment of high doses cyclophosphamide and 
adrenocorticotropic hormone (ACTH) stabilized progressive MS for an average of 
18 months (Carter et aI., 1986). In MS patients treated with a combination of 
cyclophosphamide and ACTH a decrease was demonstrated in spontaneous T-cel! 
proliferation and changes in certain T-cel! populations (Hafler et al., 1991). Chronic 
administration of azathioprine is only effective in MS patients with mild, Of recent 
onset of disease (Caputo et aI., 1987). Other forms of therapy which are under study 
or have been studied are; the administration of monoclonal antibodies directed 
against putative reactive T-cel!s (Hafler and Weiner, 1988; Hafler et aI., 1986); 
induction of tolerance by oral administration of myelin basic protein (MBP) (Weiner 
et ai., 1993); the induction of an immune response against the antigen receptor of 
autoantigen reactive T-cells by the administration of pepUdes analogous to 
sequences of the T-cel! receptor (Vandenbark et aI., 1993); immunosuppression by 
cyclosporin A treatment (Calder et aI., 1987); inununopotentiation especially by 
interferons (Panitsch et aI., 1985; 1987; Knobler et aI., 1984; Greenstein et al., 1987; 
Rice et a!., 1985); acupuncture; diets (Swank, 1991) and drugs which enhance 
remyelination or improve the axonal conductivity (Tourtelotte and Baumhefner, 
1983). 
Recently, Interferon-p waS approved in the United States for prophylactic 
treatment of relapsing-remitting MS (Amason and Reder, 1994). However, most of 
the mentioned therapies have proved to be of limited value only. The administration 
of gamma-interferon to MS patients produces even the opposite effect (Panitsch et 
aI., 1987). 
1.6 Etiology 
Despite intensive clinical and experimental research, the etiology of MS is still 
unknown. Several factors have been hypothesized to be involved in the induction 
and/or enhancement of the disease. A) Geographic location; The involvement of an 
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environmental factor is supported by the geographical distribution of MS (Kurtzke, 
1983b). B) Genetic factors; The susceptibility to MS is linked to certain genetic 
backgrounds. C) (Auto)immunity; The putative commitment of the immune system 
and autoimmune processes particular in MS is largely based on the resemblance of 
MS with the animal model, experimental autoimmune encephalomyelitis. D) 
Infection; The occurrence of MS epidemics points to an infectious agent as the 
environmental factor. Although none of the factors mentioned in itself can be 
regarded as the causative factor of MS, it is still possible that a combination of the 
factors, i.e. the combination of the environmental factors in a genetic and/or 
immunological susceptible subject, may lead to the development of MS. In the next 
section the involvement of the factors in the etiology of MS will be discussed. 
1.6.1 Geographical distribution and genetic factors 
The geographic distribution of MS suggests the influence of an environmental 
and/or a genetic factor in the initiation of the disease. Regions of high prevalence 
are found in areas with a moderate climate between the 45 and 65 latitudes 
(Kurtzke, 1980a; 1983b) (figure 4). The prevalence of MS in Asia and Africa is 
approximately a factor 10 lower as compared to the prevalence in The Netherlands. 
However, immigrants from regions with a low prevalence do not have a higher risk 
of developing MS when they move to areas with a high prevalence, unless they are 
15 years of age or less at the time of migration (Alter et a!., 1978). 
There are clear genetic influences on the susceptibility to MS. In studies of 
familial MS it was revealed that in 26% of monozygotic twin pairs both twins were 
affected, whereas MS was diagnosed in only 2.3% in both twins of dizygotic twin 
pairs (Ebers, 1986). Furthermore, the risk of developing MS is slightly increased in 
first and second degree relatives of MS patients (McAlpine et a!., 1972). However, 
the increased incidence of MS in relatives and dizygotic twins may also be due to a 
common environmental factor shared by family members and twins respectively. 
1.6.2 Immunological factOl's 
In a normally functioning organism, the immune system is quite capable of 
recognizing and effectively dealing with foreign antigens leaving the host cells and 
tissues unaffected. Moreover, the immune system does not react with foreign 
functional antigens, like food constituents. However, sometimes this delicate balance 
is disturbed and the immune system fails to maintain this so called self tolerance, 
resulting in destruction of (self) cells and tissues. Although many distinctive cells of 
the immune system are involved in autoimmunity, only B and T~ceJls are involved in 
the actual recognition and discrimination between self- and nonself antigens. B~cells 
can recognize unprocessed (auto )antigen directly by their antigen receptors, the 
membrane bound antibodies. In contrast T~cells can only recognize processed 
18 
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Figure 4 
The global prevalence of multiple sclerosis as of 1980. Areas with high, medium and low frequencies 
of MS are indicated in black, dark grey and light grey respectively. No data are available on nOIl-
coloured areas. From Dr. J.F. Kurtzke, Acta Neurol Scand 62:65, 1980, Reproduced with permission 
of Acta Ncurologica Scandinavic..1. 
(auto)antigens which are presented to the T-cell receptor (TCR) by the major 
histocompatibility complex (MHC) expressed on antigen presenting cells. 
1.6.2.1 MHC 
Like many other autoimmune diseases, MS i3 associated with the presence of 
specific antigens of the major histocompatibility complex (Batchelor et aI., 1978). In 
man the MHC region is the human lymphocyte antigen (HLA) gene cluster located 
on chromosome 6. The MHC proteins play a role in interactions between 
lymphocytes and in interactions between lymphocytes and antigen presenting cells. 
Three types of MHC molecules, class I, II and III, have been identified in both mice 
and man. Processed antigens in association with MHC class I products are primarily 
recognized by cytotoxic T-cells. Processed antigens associated with MHC class II 
products are recognized by T-helper cells. MHC class III genes are encoding for 
components of the complement system, a complex group of serum proteins which 
mediate a variety of inflammatory reactions. 
In MS patients in Northern Europe, North America and Australia the disease 
is linked to MHC antigens Dw2, DI\v2 and HLA-A3 and B7. The association of MS 
with HLA-A3 and 87 antigens has not been found in northern Italy and Israel 
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(Kurdi et aI., 1977). Analysis of Drw antigens in northern Italy and Jordan has 
demonstrated a correlation between MS and MHC antigen Drw4. MHC antigen 
Drw6 is associated with MS in patients in Japan (Batchelor at aI., 1978). The results 
indicate that the disease may be linked to more than one different genetic haplotype 
backgrounds, which means that there is not one single gene which increases the 
susceptibility to MS exclusively. 
1.6.2.2 T-cell reactivity 
T-cells can functionally be divided into cytotoxic T-cells (Tc) and T-helper 
(Th) cells. The Tc-cells are involved in the lysis of transformed or infected target 
cells. Th-cells function as regulatory cells and provide help to B·cells and T-cells to 
proliferate and differentiate. The T~cells recognize proteinuantigens as processed 
peptides. The processing involves the uptake of antigens by antigen presenting cells, 
like B-cells, dendritic cells and macrophages, a subsequent controlled proteolytic 
fragmentation and the association of the immunogenic peptides with MHC proteins. 
The complex of immunogenic peptide and MHC will be expressed on the membrane 
of the antigen presenting cells. Subsequently, the immunogenic peptides in context 
of MHC proteins will be recognized by the T-cell receptor. MHC class I and II 
molecules itself do not have the ability to discriminate between self derived peptides 
and peptides originating from foreign antigens. As a consequence both self- and 
nonself pep tides will be bound to the MHC molecules and presented to T-cell 
receptors. 
In a normally functioning organism, no response will be evoked against self 
antigens, in other words the T-cell is tolerant to self-antigens. In general, two major 
mechanisms for induction of T-cell tolerance can be distinguished. A) In an early 
stage of development, the presentation of self antigens in the thymus to T-cells leads 
to the elimination of the T-cells which recognize the self-antigens. This process is 
called thymic tolerance or clonal deletion. However, not all self-antigens are 
transported to the thymus, or transported only in very low concentrations, especially 
self-antigens originating frol11 immune privileged sites like the CNS or testis. B) For 
these antigens, another tolerance induction system, i.e. clonal anergy, is thought to 
be operational. T-cells, which are anergic to autoantigens, will not be activated when 
autoantigens are presented to them and as consequence autoimmunity will not 
occur. Although the precise mechanisms by which the T-cells are deleted or 
anergized remain to be revealed, it is possible that a defective T-cell tolerance 
induction or even a renewed sensitization of T-cells to myelin components may lead 
to the generation of an autoreactive T-cell popUlation as observed in MS patients. 
Autoreactive T-cells may contribute to autoimmunity in MS patients in two 
ways: directly as effector cell or indirectly as regulatory cell by activating 
autoreactive B-cells and other autoreactive T-cells. Extensive, partly conflicting, data 
have been presented concerning the presence, distribution and function of T -cells 
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specific for myelin components in peripheral blood and CSF, which seems to 
fluctuate with the clinical course of MS (Freedman and Antel, 1988). As compared 
to other putative antigenic components of the myelin sheaths, MBP is the most 
extensively investigated protein for its involvement in MS. MBP specific T-cells have 
been detected in the sera and cerebrospinal fluid of both MS patients and patients 
with other neurological diseases (Ota et aI., 1990; Gorey et aI., 1983). Overlapping 
synthetic pep tides of MBP were used to identify the antigenic determinants 
recognized by human T-cells. Some determinants (MBP aminoacid sequences 5-25, 
35-47, 65-75 and 81-100) were recognized by T-cells derived from more than one 
individual (Burns et aI., 1991). Because of the similarity in epitope specificity 
between T-ceHs isolated from various individuals, it was suggested that these 
epitopes are particularly immunogenic in humans. Zhang et al. (1990) used MBP 
fragments derived by proteolytic cleavage and synthetic peptides to reveal the 
epilope specificity of seventeen MBP reactive T-cell clones generated from four MS 
patients. The T-cell clones showed a striking similarity in reactivity with the C-
terminal MBP peptide 149-171. Almost the same MBP epitope, sequence 154-172 
was recognized by a majority of the MBP reactive T-cell clones derived from both 
MS patients and healthy subjects (Martin et aI., 1990). The MBP sequence 149-171, 
which is recognized by human T-cells, overlaps the MBP epitope which can induce 
CNS demyelination in rhesus monkeys (Karkhanis et al., 1975). However, the 
association between the MBP epitope 149-171 and encephalitogenicity in humans 
remains to be established. 
Myelin proteolipid protein (PLP) can induce a T-cell-mediated demyelinating 
disease in the Hartley guinea pig (Yoshimura et aI., 1985), the Lewis rat (Yamamura 
et aI., 1986) and in rabbits (van der Veen et aI., 1986). Therefore, PLP is considered 
to be an important putative autoantigen in the pathogenesis of MS as well. T-cells 
reactive with PLP have been isolated from patients with early relapsing remitting 
MS (Trotter et aI., 1991). PLP reactive T-cells were also detected in blood and CSF 
from control patients, but these cells were detected in much lower numbers as 
compared to the frequency in MS patients (Sun et al., 1991). No difference in 
reactivity to PLP peptide 139-151, a peptide which can induce demyelination in 
SILII mice, was measured between T-cells from peripheral blood from MS patients 
as compared to T-cells from normal subjects and from patients with other 
neurological diseases. These data indicate that the presence of T-cells reactive with 
putative CNS antigens in sera by itself is not leading to CNS demyelination. Possibly, 
the autoreactive T-cells are recruited specifically to the site of immune attack, i.e. 
the CNS tissues, in MS patients and not in healthy subjects or in patients with other 
neurological diseases. 
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1.6.2.3 B-cell reactivity 
B-cells are characterized by their ability to produce and secrete antibodies. 
Circulating antibodies can be found in most body fluids, although the antibody 
concentration in the CSF of healthy subjects is relatively low. Antibodies are multi-
functional molecules, consisting of two identical antigen binding sites (the Fab 
fragments) and an Fc portion which can activate complement and interact with Fc 
receptors, which are expressed on the surface of various cell types of the immune 
system. Neutrophils and most specialized antigen presenting cells express Fe 
receptors on their membranes, which allow them to phagocytose antigen-antibody 
complexes for intracellular degradation. Furthermore, antibodies can sensitize target 
cells for attack of cytolytic cells. The mechanism of this antibody mediated immune 
defence is called antibody dependent cellular cytotoxicity (ADCC). Several cells, like 
macrophages, eosinophils, cytotoxic T-cells, natural killer- and killer cells, can attack 
target cells making use of the ADCC mechanism. 
Antibodies recognize self- or nonself antigens which are in solution or 
expressed on cell surfaces. The antigen binding to antibodies initiates a cascade of 
cellular reactions including G protein activation, phospholipase activation and Ca2+ 
mobilization, which leads to the ultimate activation of the B~celJ. However, not all 
antigens can activate B-cells directly but require additional help of T-cells. These 
antigens are called thymus dependent (TD) antigens. The TD antigens will be 
internalized, processed and subsequently antigenic peptides are presented in context 
of MHC class II molecules to Th-cells. In turn, the recognition of the processed 
antigens in association with MHC class II molecules by the Th-cell receptor activates 
CD4+ Th-cells. The activated Th-cells will produce and secrete cytokines and will 
express the gp39 membrane activation marker (Armitage et a!., 1992, Noelle et a!., 
1992). The binding of the gp39 marker to its B-cell ligand CD40, is required for an 
optimal stimulation of B-cells to proliferate and to differentiate (Paulie et a!., 1989) . 
Direct B-cell activation without help of other cells can be accomplished by mitogenic 
components like lipopolysacharide (LPS) or by crosslinking the membrane bound 
antibodies on the B-cell by antigens. These kind of antigens are called the thymus 
independent antigens. The putative autoantigens in MS are considered to be, TD 
antigens and as a consequence clonal deletion or anergy of Th~ceHs will prevent the 
ultimate activation of autoreactive B~ceHs as well. 
Although the role of antibodies and B-cells specific for myelin components in 
MS is less well documented, there is circumstantial evidence of antibody and 
antibody forming cell (AFC) involvement in the process of demyelination. Persistent 
oligoclonal IgG synthesis in the CSF (Walsh and Tourtelotte, 1983) and a high 
antibody specificity index (ASI) (ASI is the ratio QAb;QIgG, whereas QAb and 
QIgG are the CSF/serum quotient of specific antibodies and total IgG levels 
respectively; Felgenhauer and Reiber, 1992) are indicative for a sustained B-cell 
activation within the CNS of MS patients. In both CSF and sera of MS patients, 
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antibodies directed against components of brain tissue (Henneberg et aI., 1991) and 
a variety of putative CNS antigens like cerebellar soluble lectin (Zan etta et aI., 
1990a, 1990b), glycolipids (Endo et aI., 1984; Hirsch and Parks, 1976), MBP (Link et 
aI., 1990), PLP (Sun et aI., 1991) and myelin associated glycoprotein (Baig et aI., 
1991) were detected. Warren and Catz detected antibodies in MS patients, directed 
against myelin components, particularly during exacerbations of clinical signs 
(Warren and Catz, 1986). In contrast, this correlation was not observed by Link and 
coworkers (Link et aI., 1990). Gorey reported the detection of elevated frequencies 
of anti-MBP antibodies in CSF of MS patients and patients with other neurological 
diseases (aND) as compared to healthy controls (Gorey et aI., 1983). Others were 
not able to demonstrate a statistical difference in anti-MBP antibody titers in CSF 
(Chou et aI., 1983) nor, in the frequencies of anti-MBP APCs in blood (Jingwu et 
aI., 1991) between MS patients and healthy controls. Recently MBP specific 
antibodies were isolated from suspensions of CNS tissues of MS patients (Warren 
and Catz, 1993). 
1.6.2.4 Molecular mimicl'}' 
The autoantigen itself is not always required for the activation of autoreactive 
cells. It is possible that autoreactive cells are activated by cross-reactive epitopes of 
pathogenic agents like bacteria and viruses. This phenomenon, sharing of antigenic 
determinants, is called molecular mimicry. Making use of computer analysis to 
compare microbial protein sequences to human protein sequences, many homologies 
have been identified. Subsequently, making use of peptides corresponding to these 
shared epitopes, immunological cross reactivity has been identified for some of those 
sequences. These findings indicate that epitopes of nonself antigens, which are 
homologous to self proteins, may drive autoreactive B~ or T~cell clones to expand 
and cause autoimmune pathogenesis. Therefore, molecular mimicry is considered to 
be a potentially important mechanism which plays a role in the induction of MS. 
When the mechanisms of elimination or inactivation of selfreactive cells are 
somehow overridden, the recognition of autoantigens, or cross reactive epitopes of 
foreign antigens, leads to the activation of selfreactive T- and B-cells. However, the 
presence of activated autoantigen reactive T~ and B~cells or antibodies per se does 
not imply the organism will automatically develop an autoimmune disease. One of 
the reasons the autoimmune response will not occur, is the lack of an appropriate 
amount of selfantigen, or antigen with cross reactive epitopes, to stimulate the 
selfreactive cells continuously. Furthermore, the presence of autoantigen-reactive T-
and B-cells and antibodies, does not necessarily imply that these cells or the 
autoantibodies are involved in the induction or enhancement of the autoimmune 
disease. EspeciaHy the role of autoantibodies in the process of several autoimmune 
diseases remains unclear. Myasthenia gravis is the only autoimmune disease, in 
which the direct involvement of anti-acetylcholine antibodies as pathogenic effector 
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molecules was established (Fuji et aJ., 1988). However, throughout the spectrum of 
autoimmune diseases studied, ranging from organ specific autoimmune diseases like 
Hashimoto's thyroiditis (Delves and Roitt, 1984) and multiple sclerosis to non-organ 
specific autoimmune diseases like systemic lupus erythematosus (SLE) (Lehman et 
aJ., 1984), autoantibodies have been detected. Although these findings make the 
production of autoantibodies one of the hallmarks of autoimmunity and MS in 
particular, it is not known whether these autoantibodies are an epi~phenomenon, a 
secondary event, or if they are directly involved in the pathogenesis of the disease. 
In addition, the fact that autoantibodies can easily be detected, not only in the 
serum of persons with MS but also in the serum of healthy individuals, makes the 
role of autoreactive antibodies and B-ceUs in the process of autoimmunity even 
more controversial. 
1.6.3 Infectious agents 
Although genetic components can not be excluded, the occurrence of MS 
epidemics also points to an infectious agent, as the environmental factor. MS 
epidemics were observed on the Faroe islands and Iceland (Kurtzke and Hyllested, 
1979; Kurtzke et aJ., 1980b). On the Faroe islands no cases of MS were diagnosed 
before 1940, while three epidemics occurred in 1946, 1957 and 1969 respectively, 
following occupation by the British military during World War II. These data suggest 
that an infectious agent was introduced into the young population of the Faroe 
islands during the World War II. Although many viruses have been implicated in 
MS, including measles (Salmi et aJ., 1973; Miyamoto et aJ., 1976; Adams et aI., 
1970), herpes (Catalano, 1972), canine distemper virus (Cook et al., 1979), corona 
virus (Burks et aJ., 1979) and rubella (Horikawa et aJ., 1973), no particular virus can 
be regarded as the MS causing antigen. On the other hand, it has been 
hypothesized, that numerous neurotropic budding viruses could provide a carrier 
effect for CNS (host derived) glycolipid haptens. In turn, glycolipids presented to the 
immune system, whether or not in combination with viral membrane proteins, could 
induce an anti-glycolipid immune response, which subsequently leads to 
demyelination (Webb and Fazakerley, 1984). According to this hypothesis, many 
different viruses may be involved in the etiology of MS. 
1.7 Animal models 
Direct sampling of MS target tissues is almost impossible due to the 
inaccessibility of the CNS. Observations made in experiments performed with CSF 
and blood samples of MS patients give secondary information on processes in the 
CNS only. These problems have led to the extensive use of animal models to study 
the process of demyelination. Animal models provide important knowledge with 
respect to basic mechanisms used by the immune system to discriminate between 
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self and foreign antigens. Although there are many differences between the 
experimental animal diseases and their human autoimmune counterparts, the 
experimental animal models are generally the only tool to obtain knowledge 
concerning the fundamental mechanisms involved in disease induction or 
enhancement. 
The principle of experimental autoimmune disease induction in general is 
based on interference with the immune system in such a way that the naturally 
occurring tolerance is overruled. Autoimmune diseases can be induced by two 
distinct procedures. First, by the adoptive transfer of autoreactive cells to naive 
recipients. Autoreactive ceBs can be isolated from animals with autoimmune diseases 
Of can be isolated after ill vitro stimulation with autoantigen. Second, autoimmune 
diseases can be induced by the artificial presentation of an excess of autoantigen to 
the immune system. The introduction of autoantigen can be accomplished in two 
ways. Autoantigens can be introduced indirect by the inoculation of viruses which 
cause tissue damage, upon which as a consequence autoantigens will be released and 
presented to the immune system. Subsequently, due to tissue damage, autoantigens 
will be released, presented to the immune system and autoantigen reactive cells will 
be activated. Inoculation of animals with Theiler's murine virus (Dal Canto and 
Lipton, 1975), Semliki Forest virus (Suckling et aI., 1978) or murine coronavirus 
JHM (Weiner, 1973) induces experimental autoimmune diseases which resemble 
human autoimmune demyeHnation. However, the most commonly used method for 
the introduction of autoantigens is the direct administration of autoantigens to 
animals by immunization. Because a normal functioning animal will be tolerized to 
the administered autoantigens, the use of strong adjuvants is often an essential 
requirement. 
Experimental autoimmune encephalomyelitis (EAE), which mimics the 
effeclor phase of MS, is generally considered to be the best available animal model 
for MS. The most commonly general used method for EAE induction is 
subcutaneous immunization of susceptible rodents or primates with whole eNS 
homogenates or with separated and purified autologous or heterologous eNS 
protein components like MBP and PLP, emulsified in Freunds complete adjuvant 
(Paterson et aI., 1976). The precise mechanisms which lead to the damage of myelin 
sheaths remain to be investigated. However, it is hypothesized that the autoantigens 
in the inoculum will be presented to T-cells, which will proliferate and differentiate. 
The autoantigen primed T-cells, and probably antigen specific B-cells as well, will 
enter the eNS (Meyermann et aI., 1987). A second contact of these immune 
competent T- and B-cells with eNS autoantigens, to which they were primed, will 
activate the T- and B-cells again and an immune response against the antigens wHl 
be the result. Another method for EAE induction is the adoptive Iransfer of myelin 
reactive T-ceHs isolated from animals immunized with myelin components or 
obtained after il/ vitro activation with myelin components (Mokhtarion et aI., 1984; 
Veen et aI., 1989; Pettinelli and McFarlin, 1979). More recently it became possible 
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to induce EAE in susceptible rodents also with selected sequences corresponding to 
amino acid sequences from myelin sheath proteins. Although the myelin sheath 
consist of several protein components, EAE induction has been established by the 
immunization with amino acid sequences of MBP and PLP only (table I). 
In this thesis the EAE model in SJLjJ mice, induced by immunization with 
PLP synthetic pep tides, has been used. The use of synthetic pep tides for induction of 
autoimmune diseases has many advantages as compared to the use of intact 
autoantigens for induction of autoimmune diseases. Induction of autoimmune 
diseases with synthetic peptides in general leads to a higher disease incidence than 
use of the intact autoantigen. Since the autoantigen is well demarcated, the immune 
response is restricted and as a consequence less complicated to analyse. 
Although it is possible to induce EAE with individual proteins and with 
peptide sequences, this does not imply that these proteins Of sequences are the 
specific antigens Of epitopes responsible for the BAE induction as obseJVed in EAE 
elicited with spinal cord homogenate. To identify the 139-encephalitagenic proteins 
and epitopes in the spinal cord homogenate, the ill vitro proliferative responses of 
lymphoid cells isolated from animals with spinal cord homogenate induced EAE 
were determined to myelin sheath proteins and MBP and PLP pep tides (Whitham et 
aI., 1991b). Lymph node cells only responded with PLP peptide 139-151, but not 
with PLP peptide sequence 141-152 nor with MBP or MBP synthetic peptides. 
Mononuclear cells, isolated from the CNS of animals with spinal cord induced EAE, 
reacted preferentially with PLP synthetic peptides. In addition, PLP peptide lSI 
specific cells from mice immunized with spinal cord homogenate transferred EAE 
into naive recipients. These data suggest that this PLP sequence is one of the major 
encephalitogenic epitopes in SJLjJ (H-2') mice. 
Based on the course of appearance of clinical signs, two types of EAE can be 
distinguished. First, acute EAE which is characterized by only one single period in 
which clinical signs are manifest. Second, chronic relapsing-remitting EAE (CR-
EAE), which is characterized by two or more periods with clinical or 
neuropathological signs (Raine, 1985; Pol man et aI., 1988). The course of 
appearance of clinical signs in CR-EAE resembles the appearance of clinical signs in 
MS more closely as compared to the course of appearance of clinical signs in acute 
EAE (Alvord, 1985). The severity of clinical signs, the sequence of appearance of 
clinical signs and which clinical signs will be manifest is highly dependent on the 
antigen dose, the myelin components in the inoculum and the animal strain. In SJLjJ 
mice, immunized with PLP peptide 139-151 in Freunds complete adjuvant, the first 
clinical signs are in general observed 11-12 days after immunization. Clinical signs 
include: partial or complete paralysis of the tail, paresis of the hind legs, partly or 
complete paralysis of the hind legs and paralysis up to the diaphragm. Clinical signs 
in SJLjJ are always accompanied with a significant body weight loss. Although some 
animals die due to EAE, most animals usually recover 20-21 days after 
immunization. 
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Table 1 
Encephalitogenic aminoacid sequences for EAE induction in rodents. 
m:telin basic Ilrotein se!;Juences: 
strain haplotype residues reference 
mouse 
PL/J H-2' 1-37 Fritz et a!., 1985. 
1-11 Zamville et a!., 1986. 
SJLjJ H-2' 84-102 Su et a!., 1992. 
87-114 Kana et a!., 198B. 
87-98 Kana et a!., 1988. 
88-98 Kono et a!., 1988. 
89-169 Pettinelli et a!., 1982. 
89-104 Su et a!., 1992. 
89-98 Kana et a!., 1988. 
91-103 Su et al., 1992. 
91-104 Kana et al., 1988. 
SWR H-2' 89-101 Jansson et a!., 1991. 
B10.T(6R) H-2' 89-169 Pettinelli et a!., 1982. 
NFR/N H-2' 89-101 Jansson et a!., 1991. 
BIORlIl H-2' 89-169 Pettinelli et a!., 1982. 
89-101 Jansson et a!., 1991. 
rat 
Lewis RT-ll 1-88 Levine et a!., 1990. 
45-88 Levine et a!., 1990. 
63-88 Levine et a!., 1990. 
LOU/M RT-1w 110-129 Hashim et al., 1991. 
Buffalo 87-99 Jones et al., 1992. 
groteoliQid I1rotein se!;Juences: 
strain haplotype residues reference 
mouse 
PLjJ H-2' 35-47 Zamville et al., 1988. 
43-64 Whitham et a!., 1991a. 
SJL/J H-2' 139-151 Tuohy et a!., 1988, 1989. 
141-150 Kuchroo et a!., 1991. 
141-149 Kuchroo et a!., 1991. 
SWR H-2' 103-116 Sobel et a!., 1991. 
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Not all strains of an animal species are equally susceptible to EAE induction. 
Dunkin Hartley guinea pigs, Lewis rat and SJL/J, SWR, NFR/N and PL/J mice are 
susceptible to induction of EAE (Raine and Stone, 1977; Offner et aI., 1987; 1989; 
Brown and McFarlin, 1982; Cross et aI., 1991; Fritz et aI., 1985; Zamvill et al., 1986). 
Brown Norway rats and BALB/C mice are resistant to EAE induction. In general 
the differences in susceptibility to EAE induction are attributed to MHC class II 
restriction. On the other hand, quantitative changes in local MHC class II expression 
might influence the susceptibility to disease as well. Animals which are highly 
susceptible to EAE induction appears to have an increased expression of MHC class 
II molecules in the CNS (de Groot et aI., 1991). Furthermore, susceptibility to EAE 
induction is decreased in aging mice. In addition, there are some indications that a 
decreased susceptibility to EAE induction is caused by a disturbed antigen 
recognition of T-cell receptors (Endoh et aI., 1990; Zamvill and Steinmann, 1990). 
1.8 Outline of the thesis 
Many abnormalities affecting the immune system are associated with MS. 
These abnormalities can also be observed in other autoimmune diseases. In addition, 
immune competent cells directed against components of the CNS can be detected in 
MS patients. These observations suggest that MS is a CNS specific disease, in which 
autoimmune processes are involved. Furthermore the eNS of MS patients is charac-
terized by perivascular lymphocytic infiltrates. Although these infiltrates contain both 
T-cells, B-cells and macrophages, immunological research has been focused largely 
on the involvement of T-cells in the pathology of MS only. This T-cell focused 
research is mainly based on experiments in which EAE was induced by passive 
transfer of myelin component specific T-ceHs to naive recipients. In addition, there 
are many similarities in immuno~ and neuro-pathological changes, during the process 
of demyelination, in both EAE animals and MS patients. Though the presence of 
oligoclonal IgG in the CSF is still used as one of the characteristics to diagnose MS, 
not much is known about the specificity of these antibodies and the role of 
antibodies and antibody forming cells in the pathogenesis and etiology of MS. The 
potential effector functions of antibodies together with the detection of antibodies 
directed against several putative antigens in the circulation of MS patients suggests 
that antibodies may playa role in the pathogenesis of multiple sclerosis. However, in 
MS, antibodies can only be pathogenic if the antibodies or the AFCs can enter the 
CNS tissues. Therefore we decided to develop methods for the detection of antigen 
specific antibody forming cells in CNS tissue section of MS patients (chapter 2). 
Antigen specific cells can be detected applying immunohistochemistry making 
use of antigen-enzyme conjugates. The approach and the principle of this technique 
are introduced in chapters 2.1 and 2.2. Improvement of the technique and the 
construction of MBP-enzyme conjugates are described in chapters 2.3 and 2.4, 
respectively. MBP-enzyme conjugates were used to localize MBP specific cells in 
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autopsy CNS tissues of MS patients (chapter 2.5). The significance of the 
localization of myelin component specific AFCs in the CNS of MS patients is 
discussed in chapter 2.6. 
After confirmation of the presence of autoantigen specific AFCs in the CNS 
tissues of MS patients we investigated the presence of Th-cells, necessary for B-cell 
activation. Activated CD4+ Th-cells express the gp39 marker on their membranes. 
Monoclonal antibodies directed against gp39 have been shown to block the ability of 
Th-cells to activate B-cells, indicating that the interactions between the Th-cell gp39 
marker and its CD40 ligand on B-cells are important to T-cell dependent B-cell 
activation. Using enzyme labelled monoclonal antibodies directed against the gp39 
marker, gp39+ T-cells were detected, in the same affected CNS tissues of MS 
patients in which we have detected the MBP-specific AFCs (chapter 3). 
Based on the assumption that MS is an autoimmune disease most therapeutic 
approaches are focused on intervention of the immune response. One of the 
approaches to modulate the immune response is the blockade of co-stimulatory 
signals required for lymphocyte activation. In chapter 3, we studied the blockade of 
the gp39/CD40 by anti-gp39 monoclonal antibodies on the development of EAE in 
mice. 
An other approach of immune modulation is suppression of the immune 
response by induction of tolerance. Tolerance can be induced by oral administration 
of putative auto-antigens. Live transformed microorganisms can be used for an 
efficient oral delivery of antigens. The presentation of antigens delivered by 
microorganisms to the immune system may result not only in tolerization of the 
immune system to the presented antigens but may result in the induction of a 
cellular and/or humoral immune response to the presented antigens as well. The 
principles and advantages of lIsing microorganisms as antigen carrier are described 
in chapter 4.1. A plasmid transformation system was developed for Lactobacillus 
species, to generate a safe nonwpathogenic, live antigen delivery system. In addition, 
Lactobacillus was examined for the ability to deliver a model antigen, trinitrophenyl 
(TNP), via the oral route to the immune system to generate a humoral immune 
response (chapter 4.2). Trinitrophenyl specific AFCs were localized ill silll after oral 
administration of Lactobacillus-TNP constructs (chapter 4.3). In chapter 4.4 we 
studied the induction of tolerance by the oral administration of genetically modified 
Lactobacillus secreting antigen. In addition, we have studied the influence of the oral 
administration of encephalitogenic PLP peptides and Lactobacillus on the 
development of EAE in mice. Finally, implications of the data described in chapters 
2w4 is discussed in chapter 5 for our understanding of MS-pathogenesis and 
development of therapeutic approaches. 
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IN SITU B-CELL RESPONSES IN MS AND EAE 
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CHAPTER 2.1 
INTRODUCTION TO 
IN SITU B CELL RESPONSES IN MS AND EAE 
B-cells in MS 
Although the main interest in experimental autoimmune encephalomyelitis 
(EAE) and multiple sclerosis (MS) has been focused on T-cell immunity, many of 
the immunological abnormalities found in MS patients are B-cell related and these 
clinical features are routinely used for diagnostic purposes. Since the putative 
autoantigens in MS are considered to be TO antigens, autoreactive B-cells will only 
be activated in cooperation with T-cells and therefore B-cell reactivity may be 
regarded to be a read-out system for T-cell reactivity. On the other hand B-cells or 
their products may function, directly or indirectly, as effector cells in MS 
immunopathology as well. First B-cells may induce T-cell reactivity by functioning as 
autoantigen presenting cells. Secondly autoantigen reactive antibodies may be 
involved in complement activation and in antibody-dependent cell mediated 
cytotoxicity (AOCC). Many cells, including NK-cells, possess Fc receptors which 
allow them to act as effector cells in ADCC. 
High levels of IgG in the cerebrospinal fluid (CSF) and a high anti-body 
specificity index are typical hallmarks of MS. High antibody levels have also been 
detected in central nervous system (CNS) tissues of MS patients. Warren and Catz 
(1986) detected antibodies in the CSF of MS patients, directed against myelin 
components! particularly during exacerbations. Such a correlation was not observed 
by Link and coworkers (Link et aI., 1990). Gorny et al (1983) reported the detection 
of antibodies directed against myelin basic protein (MBP) and oligodendrocytes in 
CSF of MS patients and patients with other neurological diseases. Others were not 
able to detect antibodies directed against MBP in CSF (Chou et aI., 1983) or were 
not able to detect a difference between the frequencies of anti-MBP AFCs in blood 
(Jingwu et aI., 1991) of MS patients and healthy controls. The IgG in the CSF of MS 
patients appears to be oligo-clonal when examined by electrophoresis. This can be 
explained in two ways. The observed oligoclonal response is due to an uncontrolled 
activation of a restricted number of B~cells clones, which are not necessarily reactive 
with auto-antigens. On the other hand, it may be possible that due to the release of 
a limited number of autoantigens, during the process of demyelination, only a 
limited number of B-cell ciones are activated. Although the antigen specificity of 
most of the oligoclonal CSF IgGs remains to be identified, the specificity of at least 
a part of the antibodies in CSF, eNS tissues and serum has been revealed. 
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Antibody specificities 
In both CSF and sera of MS patients, antibodies directed against components 
of brain tissue (Henneberg et aI., 1991) and a variety of other putative CNS antigens 
were detected. Myelin basic protein (MBP) is probably the most intensively 
investigated antigen in this respect. Oligoclonal anti-MBP IgG was detected in the 
CSF of 32% of a panel of MS patients, but not in the CSF of a control group of 
patients with other neurological diseases (Cruz et aI., 1987). Epitope specificity of 
anti-MBP antibodies in CSF of MS patients was revealed making use of synthetic 
peptides (Warren and Catz, 1992a). In MS patients, epitope specificity of non-
antigen complexed anti-MBP antibodies from CSF was identical to the epitope 
specificity of non-antigen complexed anti-MBP antibodies isolated from cerebrum of 
MS patients. Both tissue derived complexed anti-MBP antibodies from cerebrum 
and antigen complexed anti·MBP antibodies from CSF are directed to a more 
restricted number of epitopes as compared to non·complexed anti-MBP antibodies 
in MS patients (Warren and Catz, 1993). Also immune complexes in sera of MS 
patients were found to contain MBP (Dasgupta et aI., 1983). Complexed anti-MBP 
antibodies, were also found in sera of MS patients (Coyle and Procyk-Dougherthy, 
1984). However, this finding was not confirmed in recent experiments (Geffard et 
aI., 1993). 
Also other myelin components may playa role in immunopathology of MS. 
Apart from MBP, the major component of the myelin sheath proteins, the drastic 
loss of myelin associated glycoprotein (MAG), a minor constituent of the CNS 
myelin sheaths (Quarles et aI., 1973), in plaques in MS patient CNS suggests that 
MAG is a target protein in MS immunopathology (Johnson et aI., 1986; Moller et 
aI., 1987). Antibodies to MAG have been detected in the CSF of MS patients 
(Wajgt and Gorny, 1983; Moller et aI., 1989). Anti-MAG antibody forming cells 
(AFCs) together with anti-MBP AFCs were detected in the CSF of the same MS 
patient by Baig et al. (1991). In addition there are indications that myelin 
oligodendrocyte glycoprotein (MOG) might function as an autoantigen. MOG is a 
quantitative minor component of the myelin sheath and is similar to the M2 protein 
that it is a target for antibody mediated demyelination in guinea pig (Lebar et aI., 
1986). The presence of anti-MOG antibodies in the CSF of MS patients was 
reported by Xiao et al. (1991). 
Another candidate autoantigen is proteolipid protein (PLP). This claim is 
mainly based on animal experiments. Like MBP, PLP can induce experimental 
autoimmune encephalomyelitis in animals when inoculated together with Freunds 
adjuvant (Paterson, 1976). PLP reactive B-cells were detected in patients with 
multiple sclerosis (Sun et aI., 1991). Furthermore, antibodies reactive with a variety 
of other minor CNS components, including cerebellar soluble lectin and glycolipids 
have been detected in both serum and CSF of MS patients (Hirsch and Parks, 1976; 
Enda et aI., 1984; Zanetta et aI., 1990a; 1990b). 
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Titers of antibodies directed against a variety of viruses, including mumps 
(Norrby, 1978), measles (Salmi et aI., 1973) and herpes (Catalano, 1972) in CSF or 
MS patients are increased as compared to the antibody titers in CSF of healthy 
controls. However, it was not possible to associate the presence of anti~virus 
antibodies with one of the IgG bands and thus far it has not been possible to 
demonstrate that one particular virus is associated with the etiology of MS. 
Detection of antibodies 
Autoantigen specific antibodies or the autoantigen specific B-cells should be 
detectable in elevated quantities in the vicinity of affected areas of the CNS in 
patients with active disease and undetectable in those areas of the eNS which are 
not affected, if antiMautoantigen antibodies are involved in the pathogenesis of 
demyelination. However, most investigations into antibody and/or AFC involvement 
in the process of demyelination performed so far, were restricted to the 
determination of the presence or specificity of antibodies and AFCs isolated from 
sera, CSF or eNS tissues. However, from these studies no firm conclusion can be 
drawn with respect to possible correlations hetween the local presence of 
autoantigen specific antibodies or AFCs and the induction or enhancement of local 
tissue damage in the CNS. Therefore we decided to determine both localization and 
antigen specificity of AFCs in CNS tissue. 
The classical methods of detecting antibody forming cells ill s;W are based on 
the use of monoclonal antibodies specific for the isotype of the antibodies produced 
by the AFCs, which allow visualization of the cells of interest. These assays are 
carried out on fixed tissues. The fixation procedure used should not change the 
antigenicity of the antibodies produced by the AFCs. The visualization may be 
obtained with direct or indirect procedures. The direct procedure uses the "AFC 
detectinglt antibodies conjugated directly to an enzyme, fluorescent label Of a 
radio label. The indirect procedure uses the labelled antibodies in the second step to 
detect the "APe detecting antibodiesll , 
A disadvantage of both direct and indirect methods is that these methods 
require purified antibody preparations for the conjugation procedure. Furthermore, 
the capacity of the antibodies to bind antigen may be lost or perturbed due to the 
conjugation procedure. This last disadvantage can be circumvented by using the 
unlabelled staining procedure as was described by Sternberger et al. (1970). In this 
procedure anti-enzyme antibody and enzyme is applied in an additional third step. 
No matter which of the above remarked classical methods will be used for the 
ill situ detection of AFCs, detection by using labelled antibodies will only provide 
quantitative information on the localization of the AFC and the isotype of the 
produced antibodies but not on the antigen specificity of the antibodies. By using a 
newly developed immune histochemical technique for the ill situ detection of AFCs, 
it is possible to obtain information on the localization and antigen specificity of the 
34 
------------------111 situ B·eell respollses ill MS alld EAE 
AFCs simultaneously. 
The principle of this technique, which utilizes antigen-enzyme conjugates, is 
described in chapter 2.2. An improvement of the conjugation procedure, which was 
made applicable even for insoluble peptide antigens, is described in chapter 2.3. In 
chapter 2.4 we describe the construction and validation of MBP horse radish 
peroxidase (MBP.HRP) conjugates. Subsequently the MBp·HRP conjugates were 
used to localize MBP specific AFCs in autopsy brain tissue sections of MS patients 
(chapter 2.5). The relevance of the presence of autoantigen specific AFCs in the 
eNS of MS patients will be discussed in chapter 2.6. 
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CHAPTER 2.2 
NEW IMMUNO-ENZYME-CYTOCHEMICAL STAININGS 
FOR THE IN SITU DETECTION OF EPITOPE SPECIFICITY 
AND ISOTYPE OF ANTIBODY FORMING B-CELLS IN 
EXPERIMENTAL AND NATURAL (AUTO)IMMUNE 
RESPONSES IN ANIMALS AND MAN 
E Claassen, K Gerritse, JD Laman and WJA Boersma 
TNO Medical Biological Labomtmy, Rijswijk, The Netherlallds 
J Immunol Methods 150:207-216, 1992 
Summary 
Immuno-enzyme staining techniques in histo-cytochemistry can be used for 
the detection of antigen specific antibody forming cells (AFCs) in tissue sections. 
Here we describe the epitope specific detection of APes in various tissues based on 
the application of antigen-enzyme conjugates. Using antigen-enzyme conjugates rare 
AFCs can easily be detected and enumerated. Even multiple antibody specificities 
can be visualized in a single tissue sample and tissue compartments. This approach 
allows careful localization and investigation of compartimentation of AFC 
subpopulations. We established the development of a method for the detection of 
epitope specific APes in human lymphoid and central nervous system tissues in 
order to investigate how B-cells may contribute to the pathogenesis of autoimmunity 
in man. 
Introduction 
As we reviewed before, we have developed a direct double~immunoenzyme 
approach for the detection of antigen specific antibody forming B-cells (AFC) ill 
sint. In animal studies with model antigens (such as albumins and y-globulins) 
specificity of the antibodies in tissue sections could be demonstrated after incubation 
with antigen~enzyme conjugates and their isotype could be simultaneously 
determined by using an anti~jmmunoglobulin (Fc~chain specific )~enzyme conjugate 
followed by appropriate (double) enzyme-chemistry (Van Rooijen and Claassen, 
1986). 
By means of hapten~enzyme and hapten~carrier conjugates made with haptens 
such as trinitrophenyl (Claassen and Van Rooijen, 1984), penicilloyl (Boorsma et aI., 
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1986) and arsonate (Brown and Claassen, 1988), immune responses against thymus-
dependent and T-independent (Claassen et aI., 1986a-b) and/or soluble versus 
particulate carriers (Claassen et aI., 1987a) could be studied. The method was 
adapted for use in other lymphoid tissue such as that associated with the gut 
(Jeurissen et aI., 1985; Gerritse et aI., 1991a) or the lung (Van del' Brugge 
Gamelkoorn et aI., 1986). 
After modification in conjugation and staining procedures this technique was 
also used for the simultaneous ill situ detection of crossreacting idiotype and anti~ 
idiotype APc, In other assays the rapid clearance of Id-anti-Id complexes and the 
technical demands of quantitating auto-anti-Id makes these studies very complicated 
(Brown and Claassen, 1991). 
In rabbits we studied B-cell development (Claassen et aI., 1986c) and 
persistence in adoptive immunity (Claassen et aI., 1987b) and we were also able to 
demonstrate both an experimental and a spontaneous auto-anti-allotype immune 
response which could not be detected by means of any other assay (Claassen and 
Adler, 1988). 
In all our studies special emphasis was placed on the development and 
localisation of APC in lymphoid tissues as a function of the carriertype which was 
used (Van Rooijen et aI., 1989; Laman et aI., 1991b). The relation of these APC 
with different other splenic celltypes was established ill vivo/ill situ by means of 
several double staining techniques as summarised in table 1. We found the ill situ 
approach offered a number of advantages such as the unequivocal detection of rare 
APC (1:10'), detection of multiple (crossreactive- or auto-) antibody specificities in a 
single sample and the determination of tissue compartments, done size and 
distances between cells (Brown and Claassen, 1988). However, the use of 
experimental antigens and animal studies, as described in the above studies, could 
not solve major questions arising in virus induced pathogenicity (Laman et al., 1989) 
or autoimmunity. We therefore started alit to develop a method for the detection of 
epitope specific APC ill silll in human lymphoid tissues involved in natural (auto)-
immuneresponses. In this paper we will outline the principle of a new technique for 
the detection of such APC, based on the use of synthetic peptides, with special 
emphasis on (previously unpublished) detailed technical demands and properties. 
Principle of the method fOl" epitope specific detection of 
antibodies 
As shown schematically in figure 1 the method works as follows: selected 
synthetic peptides (9-25 aminoacids long) are covalently coupled to enzymes such as 
horseradish peroxidase (PO), alkaline phosphatase (AP) or {i-galactosidase (GL). To 
obtain a configuration that most resembles that of the native protein a coupling 
method which provides a random orientation of the peptides is preferred (Zegers et 
aI., 1990). Cryostatsections (8 ,urn, -20°C) of lymphoid tissue from experimental 
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animals (Laman et a!., 1990; Gerritse et aI., 1991) or human autopsy/biopsy material 
(Laman et al., 1991a) are incubated with the conjugate. When antibodies cross-
reactive with the peptide-epitope(s) are present in the section the conjugate is 
bound (lb) and the cell will be coloured after appropriate cytochemistlY. Antibodies 
visualised in this way can be both cytoplasmic (APC) or extracellular, the latter in 
the form of e.g. immUne~C01l1plexes (colour pictures in: Laman et al., 1990) Of on 
memory B-cells (Liu et aI., 1988). By making use of an isotype specific antibody 
(labeled with a different enzyme) directed against the Fe portion of the Ig molecule 
the isotype can be simultaneously determined (Ie), due to the resulting intermediate 
violet colour in cells binding both conjugates (singly stained cells are specific for 
either the peptide or the isotype. under study). 
Selection of peptides 
Peptides are selected primarily based on the biological question under study, 
e.g. neutralising epitopes from (putative, subunit-) vaccines. Numerous peptide 
sequences possibly involved in auto-immunity (e.g. from myelin basic protein) have 
already been put forward and tested in ;11 vitro assays and/or animal experiments 
(Wucherpfennig et aI., 1991). Ir the case of a suspected molecular mimicry involved 
in auto-immunity or pathogenesis (Laman et aI., 1989) one should select those 
epitopes from the protein that resemble native antigenic structures, e.g. parts of a 
virus that have sequence homology with human proteins (Lernmark et a!., 1988). An 
educated guess, based on comparison in databases, can in this case be supported by 
making use of methods for the ill vifm study and simulation of antigen/protein 
processing and the release of :mmunogenic peptides by proteolytic enzymes (Van 
Noort et a!., 1989). 
For the selection of the (':xact peptide-:iequences and the construction of these 
conjugates we used computer prediction plograms and knowledge obtained in a 
parallel line of research in which we generated diagnostic antibodies by means of 
selected synthetic peptides, as we reviewed in detail elsewhere (Boersma et al., 
1991). A lIumber of new coupling procedures was developed to amplify the 
proportion of antibodies that re.,ognise the synthetic peptide and also crossreact with 
the native protein (Deen et al., 1990; Zegers et a!., 1990). By adapting these 
procedures we were able to conjugate synthetic peptides to enzymes such as AP 
Figure 1 (next page) 
Synthetic pep tides are covalently coupled, in a random orientation, to enzymes such as horseradish 
peroxidase, alkaline phosphatase or {J-galaclosidase. Cryostatsections of lymphoid tissue arc incubated 
with the conjugate, and this can be bound by antibodies cross-reactive with the epitope.s present in 
the peptide. By making use of an isotype specific antibody (labeled with a different enzyme) directed 
against the Fc portion of the 19 molecule the isotype can be simultaneously determined. TIle number 
of B-cell epitopcs, recognised by the antibodies in the section may vary from one to several and is 
depending on the length and nature of the peptide. 
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Figure 1 
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(Laman et a!., 1990), HRP and GL (Laman et aI., 1991c). Controlled conditions 
enabled the production of conjugates without loss of enzyme activity and with 
excellent binding capacities of the synthetic pep tides to antibodies ill vitro (ELISA) 
and in situ. These conjugates were successfully used to detect both APe and 
immunecomplexes directed against selected, B-cell epitopes of HIV-l proteins such 
as gp120 (Laman et a!., 1991a). 
Selection and coupling of enzymes 
Basically we have employed three enzymes: alkaline phophatase, Horse radish 
peroxidase and fl-galactosidase (table 1 and 2). 
Alkaline phosphatase 
As table I shows AP was most frequently used, mainly because it can be 
readily modified with the dialysis glutaraldehyde method to provide simple coupling 
through aminoresidues present in immunoglobulins (Claassen and Adler, 1988) and 
pep tides (Zegers et a!., 1990). The advantage of this modification of the classical 
one-step glutaraldehyde method are that no homopolymers (enzyme-enzyme or 
peptide-peptide) are formed and much less antigen is needed (Zegers et a!., 1990). 
Furthermore, this conjugation can also be performed in 8M ureulll with otherwise 
poorly soluble peptides without significant loss of enzyme activity (Gerritse et a!., 
1991b). In addition to this AP can be revealed as a bright transparent blue (Claassen 
et a!., 1986b) or red (Brown and Claassen, 1988) colour, both extremely well suited 
for immuno-enzyme-cytochemical double and triple stainings (for colour pictures 
Laman et aI., 1991b). The red reaction product obtained through the use of Fast 
Red TR is also fluorescent and can thus be used for quantitation or fluorescent 
double/triple labelings (Claassen, 1991). 
Horseradish peroxidase 
In double staining the blue reaction product of AP we have found HRP in 
combination with the red immunodecoration by 3-amino-9-ethylcarbazole to yield 
best results. The more frequently used dye diaminobenzidine is not suited for double 
staining with AP substrates in our method because the dye is not transparent but 
(electron)dense. Coupling of peptides to HRP can not be obtained through 
aminoacid residues on HRP (e.g. by glutaraldehyde) since not enough (only 1-2) are 
available. Coupling of synthetic peptides should be performed by making use of the 
periodate oxidation method (Laman et aI., 1991c). HRP is more difficult to couple 
but on the other hand it is simple to use, cheap (also the substrate), can be easily 
amplified and the conjugates can be frozen down (-20°C). 
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Table 1 
SIMULTANEOUS DETECTION OF SPECIFIC AFC AND OTHER CELLTYPES BY IMMUNOENZVME DOUBLE STAINING 
Cell type Marker Enzyme Antigen Enzyme Colours Species Selected reference 
APC isotype (various possible combinations and species) Van Rooijen and Qaassen, 1986 
Ag specificity (or Ab specificity for three non crossractive epitopes) Qaassen et ai, 1986d 
idiotype AP arsonate-KLH HRP B,R, V mice Brown and Claassen, 1988 
allotype HRP TNP-KLH AP R,B, V rabbits Claassen et ai, 19S6c 
a-allotype HRP allotype AP R,B, V,- rabbits Claassen and Adler, 1988 
a-idiotype HRP idiotype AP R,B,- mice Brown and Claassen, 1991 
crossreactive B-celis antigen specificity HRP related antigen AP R,B, V rabbits Van Rooijen et al., 1989 
auto-reactive B-cells self-antigenJpeptide AP viral protein HRP B, R, V humans Laman et ai, 1991a 
resting B-cells membrane IgM HRP TNP-ficoll AP R,B, V mice Laman et ai, 1991b 
memory B-celis a-antigen IgM HRP various AP R,B, V rats Liu et ai, 1988 
resting T-cells Thy-l.2, CD4, CDS HRP TNP-ficoll/KLH AP R,B,V mice Van den Eertwegh et ai, 1991b 
CK producing T-cell a-interferon-y AP various HRP B, R,- mice Van den Eertwegh et at, 1991a-b 
natural killer cells asialo-OM-l AP TNP-ficoll AP R,B, V mice Van den Eertwegh et ai, 1991a 
aU macrophages acid phosphatase 1NP-liposomes AP R, B,- mice Claassen et ai, 19S7b 
macrophages of MZ MAbED3 HRP TNP-ficoll/KLH AP R, B,- rats Claassen et al., 19S6b 
antigen a-antigen MAb GL TNP-ficoll AP G,B, - mice Laman et ai, 1991b 
Ab = antloody; Ag = antigen; AP = alkaline phosphatase; a = anti; CK = cytokine; HRP == horseradish peroxidase; GL = ,B-galactosidase; B == blue; 
R == red; G == green-blue; V = violet; - == no single cells double stained; KLH == keyhole limpet haemocyanin; MAb == monoclonal antibody; MZ == 
marginal zone of the spleen; TNP = trinitrophenyl. 
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Table 2 
APPLICATIONS OF ANTIGEN·ENZThIE CONJUGATES IN THE DETECTION OF ANTIGEN SPECIFIC ANTIIlODIES. 
Antigen Analyte Sensitivity" Linearity Precision Interferences Selected reference 
IN SITU TECHNIQUE 
Hapten arsonate HRI" 10 10·50 100% Background over 200,ug/ml Brown and Claassen, 1991 
TNP HRl" 50 50·200 100% Occasional natural a-1NP Ab Oaassen and Van Rooijen. 1985 
AI' 2 2-25 100% Endogenous AP in gut and kidney Oaassen and Van Rooijen. 1984 
Peptide AI' 8 8-40 100% Adjuvant induced AFe (controls) Laman et al. 1990 
HRl'/GL 5110 10-40 100% Adjuvant induced AFe (controls) Laman et at, 1991c 
Peptide in 8M urea or DMF AI' 5 10·25 100% Pro-zone effect at high concentrations Gerritse et at, 1991b 
Protein < 160 kd AI'/HRI' 5 10·20 100% Van Rooijen and Claassen, 1986 
160 kd (lgG) AI'/HRI' 1 5·20 100% Claassen and Adler, 1988 
> 160 kd HRI' 50 50-200 NA Voorbij, 1989 
Bacteriae AI'/HRI' >100 Conjugates to large Vervelde et al., submitted 
Virusses HRI' 100 100·200 NA Proteolytic enzymes present in antigen Claassen et al., submitted 
EUSA HRl'/GL 0.01 0.05·2 100% Laman et ai, 1991c 
(competitive) AI' NA 0.2-10 100% Gerritse et aI., 1991b 
SPOT·EUSA AI' 5 5-15 100% Purity of catching antibody Vos et al., 1990 
Legend see also table I, a sensitivity is defined as the smallest amount of conjugate which still stains 100% of the APe expressed in micrograms of 
conjugate per ml., linearity is defined as the range which is used for efficient double staining. b conjugate prepared by bridging v.ith bovine serum 
albumin, c conjugate prepared by bridging with poly~l-lysine; DMF = dimethyl fonnamide; Ig = immunoglobulin G; NA = not assessed. 
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p-galactosidase 
This enzyme was chosen because its greenish blue substrate provides an 
opportunity for cytochemical triple and quadruple stainings in combination with AP 
(blue + red) and PO (red/brown, NB: GL can be double stained even with 
diaminobenzidine). Furthermore, after acetone fixation of lymphoid tissue absolutely 
no background due to endogenous enzyme activity is observed. This latter fact 
provides the possibility for prolonged staining times (2-4 hours) and we have found 
assays with GL conjugates to be far more sensitive than those using PO or AP (Van 
den Eertwegh et ai., submitted). 
Fixation 
For superior results we have found it very effective to keep the freshly cut 
tissue sections (on glass slides) overnight at room temperature in an atmosphere 
with very high humidity (e.g. closed box with wet tissues). Sections are air dried for a 
few hours before fixing or stored, wrapped in aluminium foil, at -20°C. In almost all 
studies we have routinely used acetone (pro analyse quality, dried) fixation for 10 
minutes at room temperature. In those cases where HRP was used 0.02% hydrogen 
peroxide was added, just before fixation, to inhibit virtually all endogenous 
peroxidase activity. However, acetone does not effectively inactivate all infectious 
agents and fixations like 0.37% v/v formaldehyde in PBS or 0.5% 
paraformaldehyde(w/v) in PBS, for 10 min at room temperature are the methods of 
choice under biohazard conditions (Laman et ai., 1991d). 
Immunochemistry and amplification 
Enzymes are revealed as described in detail elsewhere, AP as brilliant blue 
with Naphtol AS MX phosphate as the substrate and Fast Blue BB Base (in the 
presence of levamisole to inhibit endogenous AP; Claassen et al., 1986c), or as 
bright red (also fluorescent) with Fast Red TR Salt (Brown and Claassen, 1988; 
Claassen, 1991) as the indicator dye. PO as bright red with 3-amino-9-ethylcarbazole 
(Claassen et ai., 1986) or brown with 3,3-diaminobenzidine-tetrahydrochloride (Van 
Rooijen et ai., 1989). GL as greenish blue with 5-bromo-4-chloro-3-indolyl-fl-D-
galactoside (Bondi et al., 1982). 
The presumed insensitivity of direct techniques does not, in our hands, apply 
to the detection of AFC with antigen-enzyme conjugates, however in these rare 
cases where low staining intensity is observed a number of amplification steps can be 
used. Efficient amplification can be performed by prolonged incubation in the 
substrate medium only with GL, with both PO and AP it is advisable to change to 
fresh substrate solution for a second staining after 10 (PO) and 25 (AP) minutes 
respectively. Amplification before (and even after the first staining period) is also 
possible by a second incubation step with enzyme labeled anti-enzyme antibodies or 
43 
Chapler2.2-------------------------
with enzyme-anti-enzyme-antibody camplexes (PAP or AP AAP; Mason and 
Sammons, 1978). Furthermore, specialised conjugates with several enzyme molecules 
can be prepared, e.g. by the use of poly-I-lysine palymerised PO (Claassen and Van 
Raaijen, 1984) or polymerisation af AP with glutaraldehyde. 
Controls 
Normal controls should include: enzyme only, substrate only, and at least one 
irrelevant conjugate (i.e. same enzyme with different peptide). In animal studies 
animals injected wHh medium and/or adjuvant-only serve as negative controls, in 
human studies lymphoid tissue-sections of healthy (or unrelated disease) persons 
must be included on the same glass slide. Furthermore the staining must be inhibited 
when free (or conjugated) antigen is added to the incubation medium. 
In using synthetic peptides we found it necessary to incorporate a positive 
control, this being an enzyme conjugate of the native protein. Upon double staining 
with a peptide-enzyme-X conjugate and a native-protein-enzyme-Y conjugate, all 
cells staining for peptide reactivity should alsa stain for the protein. This serves as a 
100% control far the three dimensional configuration of the peptide in relation to 
the native protein (Laman et al., 1990). 
The double staining with an anti-isatype-enzyme conjugate does not only 
provide detailed information on the isotype distribution of the specific AFC but also 
enables confirmation of the fact that B-cells are stained (positive control). Further 
experimental and technical controls (when necessary) and additional caveats can be 
deduced from the paper on limitations of the antigen-enzyme approach (Van 
Rooijen, 1987). 
Simultaneolls identification of other markel's 
The main strength in the method for detecting specific AFC lies in the fact 
that particularly those cells actively involved in a given il/ vivo immune response 
against a defined antigen (or even a single epitope thereol) can be identified. This is 
in sharp contrast to studies using only anti-Ig stainings in which all immunoglobulin 
forming cells (also IIbystandersll) are detected (these cells can also be observed, as a 
bonus, in the double label technique we use, as singly stained cells, see fig. 1). In 
addition to this, the development and localisation of the specific AFC can be studied 
in relation to e.g.: the localisation of the antigen, antigen presenting cells (e.g. 
macrophages), T-helper and T-suppressor cells, cytokine producing cells and several 
other celltypes involved in induction or regulation of the response (as summarised in 
table 1). In some cases these double stainings may result in an intermediate, violet, 
colour, indicating that both markers under investigation reside in the same cell. 
Furthermore this can be done ill situ, offering an integral picture, complete with cell M 
cell interactions ill vh1o, of the immune response (see also Laman et aI., 1991b). 
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Applications of the technique 
Assays 
Antigen-enzyme conjugates can be effectively used for the detection of 
specific antibodies ill situ, as described here (table 2), but also with superior results 
in developing of anti-Ig coated, antibody catching, ELISA (enzyme linked sorbent 
assay; Vas et al., 1990; Laman et al. , 1991c) and the even more sensitive variant: the 
competition-ELISA (Gerritse et aI., 1991b). In a spot-ELISA, which is an improved 
modern version of the classical plaque forming cell assay, these conjugates 
dramatically enhanced the sensitivity of the assay (10-20 times; Vas et aI., 1990). 
Experiments 
The method we describe here is the only way to analyse the ill situ 
interactions which occur during an immune response (Laman et aI., 1991b). This is 
of particular importance when one wants to study the relation of antibody formation 
with local histopathological effects or pathogenicity (relation with clinical stage; 
Laman et aI., 1991a). In aU cases where one can not efficiently evaluate an immune 
response due to lack of material (or only frozen tissue available) this method is very 
suitable, since only little material is needed and the method is sensitive enough to 
pick up rare AFC. In those cases where antibodies bind directly to the target antigen 
(e.g. autoimmunity) and are therefore not obselved in the blood or liquor (CSF) this 
is also the method of choice. Furthermore we use it in tissues where lymphoid cells 
(and AFC) are scarce such as skin and parts of the lamina propria of the gut. 
Discussion 
The use of antigen-enzyme conjugates for the detection of specific AFC ill 
vivo offers several important advantages (Brown and Claassen, 1988; Claassen and 
Adler, 1988). The method we describe here for the epitope specific detection of 
AFe in animals and man with synthetic peptides has additional advantages over 
other methods. The main advantage is the fact that one can now study the immune 
response against natural antigens in sifu/in vivo, in its anatomical context, in relation 
with other cell types, mediators, or the inducing antigen itself. Also notable is the fact 
that this can be done without suspending the tissue, thereby destroying cell-cell 
interactions and possible feed~back mechanisms. Furthermore this is one of the few 
methods with which one can study antibody formation in stored material, thereby 
opening up the possibility of retrospective studies on frozen tissue. 
This new technique for the epitope specific detection of antibodies ill vivo is 
now used in routine analysis of biopsy material from HIV ~ 1 infected persons. 
Furthermore, with synthetic peptides specific for CNS proteins, it is applied to study 
the initiation of auto-antibodies ill sifU in CNS~tissue from Multiple sclerosis patients. 
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CHAPTER 2.3 
CONJUGATE FORMATION IN UREA: 
COUPLING OF INSOLUBLE PEPTIDES TO ALKALINE 
PHOSPHATASE FOR ELISA AND IN SITU DETECTION 
OF ANTIBODY FORMING CELLS 
K Gerritse, MJ Fasbender, WJA Boersma and E Claassen 
TNO Medical Biological LahomtDlY, Rijswijk, 171e Netherlallds 
J Histochem Cytochem 39:987-992, 1991 
Summary 
We report here a new method to produce synthetic-peptide/alkaline 
phosphatase (AP) conjugates in the presence of urea. The method allows the use of 
peptides which are not soluble to a sufficient degree in aqueous buffers. The 
presence of 8M urea during the construction of the synthetic-peptide/AP conjugates 
does not influence enzyme activity nor the affinity of the anti-peptide antibodies for 
the conjugated peptide. We demonstrate that these synthetic-peptide/AP conjugates 
can be used for detection of specific anti-peptide antibody forming cells (AFC) ill 
vivo. This method for constructing enzyme conjugates with insoluble proteins Of 
pep tides suggests not only new possibilities for detection of specific AFC ill vivo, but 
also for applications in receptor-ligand studies, ELISA (enzyme linked immuno-
sarbent assay) and spot-ELISA for detection of antibody secreting cells ill vitro. 
Introduction 
Since the first use of antibody-enzyme conjugates in an ELISA, there has been 
considerable progress in the application of protein/protein- and protein/peptide 
conjugates in immunological studies (Boarsma, 1988). Several investigations have 
indicated the potential of synthetic-peptide conjugates as vaccines (AskelOf et a!., 
1988; Heckels et a!., 1990). Conjugates of synthetic-peptides and carrier-proteins can 
also be used to raise mono-specific polyclonal and monoclonal antibodies which 
cross-react with the native protein from which the peptide sequence was derived 
(Boersma et a!., 1988; 1989; Gerritse et a!., 1990a). In addition protein- or 
peptide/enzyme conjugates can be utilized for detection of specific antibody 
secreting cells ill vitro or ill vivo. Vos et a!. (1990) used human-insulin/AP conjugates 
to detect murine cells secreting anti-insulin antibodies of different IgG subclasses in 
a spot-ELISA assay. Several protein/protein or protein/hapten conjugates have been 
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developed for immunocytochemical detection of specific AFC (for review, Van 
Rooijen, 1989). In a recent paper (L1man et aI., 1990) we presented a new method 
which provides a tool for studying the fine specificity of the humoral immune 
response against any antigen in situ, by the use of synthetic-peptide/enzyme 
conjugates for the ill vivo detection of antigen-specific APe. However, to construct 
or use these conjugates it is, for most of the mentioned applications, necessary that 
the proteins or protein conjugates be soluble. One of the artificial methods to 
solubilize proteins or peptides, which have only a very low solubility in aqueous 
buffers, is the use of urea. Klasen et al. (1982, 1983) used urea to solubilize protein 
fragments and peptides for ELISA coating purposes to detect haemoglobin mutation 
specific antibodies. 
In this report we describe a conjugation method for the construction of 
peptide/enzyme conjugates with the use of 8M urea in order to achieve a sufficient 
concentration of peptides for successful conjugation. Conjugation in the presence of 
urea was compared to conjugate formation in dimethylformamide (DMF) and 
phosphate buffered saline (PBS). 
Material and methods 
Peptide synthesis, purification, characterization and conjugation 
The synthesis of peptides 082 and 013 (SP082, SP013) was carried out, 
according to the Biosearch synthesis protocol (Biosearch; San Rafael, California, 
USA) on polystyrene resin (1 % crosslinking) to which the first amino-acid already 
was attached. SP082 is a 20-mer derived from human apolipoprotein E3-Leiden 
(Havekes et aI., 1986) with the sequence Arg-Gly-Glu-Val-Gln-Ala-Met-Leu-Gly-
Glu-Val-Gln-Ala-Met-Leu-Gly-Gln-Ser-Thr-Cys. SPOl3 is a ll-mer sequence, analog 
to amino-acid residues 231-241 of the heavy chain constant region 2 of human IgG2 
with the sequence Ala-Pro-Pro-Val-Ala-Gly-Gly-Pro-Ser-Val-Cys (Boersma et aI., 
1989). Both sequences were synthesized with an additional cysteine at the 
carboxy terminal to enable coupling via the thiol residue. The synthesis was carried 
out with tertiary-butyl-oxycarbonyl amino-acids, following the solid phase method as 
described by Merrifield (1963). To prevent side chain formation during synthesis 
some of the amino~acids were protected as follows: argmme, tosyl (p~ 
toluenesulfonyl); cysteine, p-methylbenzyl; glutamic acid, benzyl ester; serine and 
threonine, benzyl. 
Peptide cleavage and side chain deprotection of the completed peptide was 
performed by hydrogen fluoride (HF) treatment as described by Bhatnager et al. 
(1983). After HF cleavage and purification, as we described before (Van Denderen 
et aI., 1989), the amino acid composition of the synthetic peptide was determined by 
high performance liquid chromatography (HPLC) analysis according to the method 
of Janssen et al. (1986). 
Coupling of SP082 to keyhole limpet haemocyanin (KLH) with the use of m-
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maleimido-benzoyl-N-hydroxysuccinimide-ester (MBS) was carried out as described 
by Kitagawa and and Aikawa (1976) with some modifications (Van Denderen et a!., 
1989). The peptide-KLH conjugate (KLH-MBS-SP082) was used for immunization 
purposes. Coupling of peptide SP082 to bovine sera albumin (BSA) witb the use of 
l-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) was performed following the 
method described by Deen et a!. (1990). The peptide-BSA conjugate (BSA-EDC-
SP082) was used for coating purposes in the inhibition ELISA. 
Itnmunization 
Female BALB/c mice aged 12-15 weeks, were kept in macrolon cages under 11 
h dark/13 h light regimen at 20'C and were given acidified water (pH 3) and 
pelleted mouse food (Hope Farms, Woerden, The Netherlands) ad libitum. 
Experiments were performed under the auspices of the Dutch Veterinary Inspection, 
according to the law on Animal Experiments. In order to obtain tissue sections with 
anti-SP082 AFe's and specific anti-SP082 antisera, a group of four female BALB/c 
mice was immunized intraperitoneally with 75 I'g KLH-MBS-SP082 conjugate 
emulsified in 50% specol (Bokhout et a!., 1981) and boosted with the same amount 
of conjugate emulsion four weeks after the initial injection. Seven day's after the 
booster injection, mice were sacrificed by CO2 euthanasia. Blood samples of the 
mice were collected by heart puncture and left for 30 min at 37'C. Sera were 
obtained after centrifugation at 300 g for 10 min at 4'C. The spleens were removed 
and stored in liquid nitrogen. Tissue sections of the organs were used to screen the 
different SP082-AP conjugates for staining properties. 
Synthetic peptide - alkaline phosphatase conjugation 
The peptide/AP conjugation was carried out as was described in detail by 
Zegers et a!. (1990). Briefly, AP (10 mg. mI'!) was dialysed against 0.2% 
glutaraldehyde in PBS for 16 h at 4'C. The activated AP was dialysed against PBS 
for several hours, and transferred to a reaction vessel. Peptide SPOH2 was added to 
urea (8M, pH 7.0, 1 mg.ml·!), DMF (pH 7.0, 1 mg. mi'!) and 0.1 M PBS (pH 7.2, 1 
mg. mi'!) respectively. The solutions/suspensions were stirred extensively and 
centrifuged (300 g) for 10 min at room temperature. The solubilized pep tides were 
added to GA activated AP in a molar ratio of 100 molar equivalents. The mixtures 
were stirred for 16 h at 4'C. To block the remaining active GA groups, 100/t! 0.2 M 
Iysine-HCI was added to the mixtures followed by a 2 h incubation period at 4'C. 
The excess peptide and lysine molecules were removed by dialysis against PBS. The 
obtained conjugates were encoded SP082-AP(urea), SP082-AP(PBS) and SP082-
AP(DMF), dependent on the solvent in which the coupling was carried out. The 
peptide-enzyme conjugate formation was examined in an inhibition ELISA. 
Alkaline phosphatase activity 
The enzyme activity of the non-conjugated AP and of the peptide-AP 
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conjugates in the presence of urea was revealed on PVC micro titer plates (Titertek). 
An AP solution (14 mg.ml·\ 3.0 M NaCI, Sigma P6774) and a solution of peptide-AP 
conjugate (5 mg AP.ml·\ in PBS) were diluted (2 log dilutions from 1:1.10') in 8M, 
4M, 2M, 1M urea in PBS, respectively. The dilutions were added to a microtiter 
plate (50 I'I/well) together with 50 Itl para-nitro·phenylphosphate (Boehringer, 
Mannheim, FRG) (1 mg.ml·\) in 10 mM Diethanolamine/l mM MgCI" pH 9.8. After 
30 minutes at 2YC the absorption was determined at 405 nm in a Titertek 
Multiskan apparatus (Flow Laboratories, Irvine, Scotland). 
Inhibition ELISA 
PVC microtiter plates (Titertek) were coated with BSA-EDC-SP082 (5 I'g.ml·\ 
in PBS, 501'1/well). After overnight incubation at 4"C the supernatant was removed. 
To block non-specific binding a second coating of gelatine (5 mg.ml·\ in PBS, 50 
Iti/well) was applied and incubated for 30 min at 25"c' The plates were washed five 
times with 0.05 % Tween-20 in PBS (PBS-T). Peptide-induced antisera diluted 1/100 
in a solution of gelatin (0.1 mg.ml·\ in PBS·T (PBS-T-G)) were preincubated for one 
hour at 25"C with dilutions of peptide/enzyme conjugates (32 to 0.03 Ilg.ml·\ in PBS-
T-G) and control antigens before they were added to the wells in 50 III aliquots. The 
plates were incubated for 1 h at 25"C and washed five times with PBS-To The plates 
were incubated for 1 h at 25"C with AP-Iabelled goat anti-mouse IgG (H + L) 
(KPL, Inc., Gaithersburg, USA) 1:2000 in PBS·T-G. After washing with PBS-T, 50,,1 
of a para-nitro-phenylphosphate (Boehringer, Mannheim, FRG) solution (1 mg.ml·\ 
in 10 mM Diethanolamine/l mM MgCI" pH 9.8) was added to the wells. After 30 
minutes at 25"C the absorption was determined at 405 nm in a Titertek Multiskan 
apparatus (Flow L,boratories, Irvine, Scotland). 
Tissue preparation and immunocytochemical staining 
Ciyostat tissue sections (8'1'01) were fixed for 10 min in acetone containing 
0.02 % (v/v) hydrogen peroxide. For determination of SP082 specific AFC in the 
spleen, tissue sections were incubated overnight at 4°C with various concentrations 
(100 to 12.5,lg.ml'\) SP082-AP conjugates in a solution of BSA (I mg.ml'\) in PBS. 
After incubation the sections were rinsed thrice in PBS and incubated for 5 min at 
room temperature in PBS. Slides were stained for AP activity according to the 
method of Burstone (1958) with some modifications (Claassen et al., 1986d). A 
solution of 8 mg naphthol AS-MX phosphate in 400//1 N,N-dimethylformamide was 
added to 65 ml Tris-HCI buffer (0.1 M, pH 8.5, 37"C). A solution of 16 mg sodium 
nitrite in 4001'1 H,o was added to 16 mg Fast Blue BB base in 4001'1 2N HCI. 
After 1-2 min this mixture was added to the Tris-HCL buffer containing naphthol 
AS-MX phosphate. To prevent endogenous alkaline phosphatase activity, levamisole 
in a final concentration of 2 mM was added to the substrate solution. The solution 
was paper filtered to remove any precipitate. The slides were incubated vertically in 
Coplin jars for 20 min in substrate buffer at 37°C. To prevent avera or understaining, 
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staining was monitored with a light microscope. Staining was stopped by incubation 
in PBS for 3 min at room temperature. The sections were counterstained for 5 
seconds with a solution of hematoxilin (Gurr). The slides were mounted in glycerol-
gelatin. Staining with the three different peptide-AP conjugates were performed on 
alternating tissue sections of spleens of four mice. From each mice fifty sections per 
conjugate were stained. Control stainings were performed with the SPOS2-AP 
conjugates on spleen tissue sections from non-immunized mice and mice immunized 
with a non-relevant peptide conjugate. In addition spleen tissue sections from mice 
immunized with KLH-EDC-SP082 were stained with a non-relevant peptide-AP 
conjugate. AFC were counted and calculated per square mm using a digital image 
processor (Imaging Research Inc., Brock University, Ontario, Canada). 
Results 
Determination of alkaline phosphatase activity 
The enzyme activity of non-conjugated AP in the presence of urea is depicted 
in figure 1a. The activity of AP dissolved in 4M, 2M and 1M is comparable with the 
activity of AP dissolved in PBS. However, when AP was dissolved in SM urea the 
enzyme activity decreased. Enzyme activity of peptide-AP conjugate in the presence 
of urea is depicted in figure lB. The peptide-AP conjugate dissolved in PBS, shows 
the lowest activity compared to the conjugates dissolved in urea. The activities of the 
conjugates are comparable from dilution 1:2.10'. Only in the 1:10' dilutions are some 
differences observed. The highest activity was measured in the solution of peptide-
AP conjugate dissolved in SM urea. 
Inhibition ELISA 
The SPOS2-AP(PBS) and SPOS2-AP(urea) conjugates were able to inhibit the 
interaction of the anti-sp082 antisera with the coating of BSA-EDC-SP082 as was 
demonstrated in figure 2. The interaction was completely inhibited when an amount 
of 32 I'g peptide-AP conjugate was used. The same degree of inhibition was 
observed with the (positive) control antigens BSA-EDC-082 and non-conjugated 
SP082. The OS2-AP(DMF) conjugate inhibits the interaction of the anti-SP082 
antisera with the coating of BSA-EDC-082 only if a large amount of conjugate is 
used in the preincubation period. An amount of 16 Ilg or less does not inhibit the 
interaction at all. 
Immunocytochemical detection of SP082 a specific AFC's 
Specific anti-SP082 AFC were detected in all spleen tissue sections of KLH-
MBS-SPOS2 i.p. immunized mice, independent of the type of SPOS2-AP conjugate 
used (figure 3 a~c). No APe were detected in tissue sections of the same mice when 
stainings were performed with a non-relevant peptide/enzyme conjugate nor with 
tissue sections of non-immunized mice or mice immunized with a non-relevant 
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Figure 1 
Enzyme activity of dilutions of the non-conjugated AP (figure lA) and of pcptidc-AP conjugate 
(figure IB) was determined in various concentrations urea (as indicated). 
peptide conjugate stained with the SP082-AP conjugates. The localization of the 
APe was similar to the localization as was described before (Van Rooijen et al., 
1986). However, the number of specific APe in the alternating spleen sections is 
dependent on the type and concentration of the conjugate used (figure 4). 
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Figure 2 
Coupling efficiency between SP082 and AP was evaluated by the capacity of the conjugates 082-
AP(PBS), SP082-AP(DMF) and SP082(urea) 10 inhibit the interaction between the sp082 antisera 
and a coating of BSA-EDC-SP082. The BSA·EDC-SP082 and SP082 wece selected as positive control 
inhibitors, SP013 was used as a negative control inhibitor. Alkaline phosphatase labelled goat anti-
mouse IgG and para-nitro-phenylphosphatc as substrate wcce used for detection. 
Samples (concentration groups) were analysed by the two-sample Student's t-test for 
comparison of two empirical means in a normally distributed population (Sachs, 
1984). Differences were assumed significant for p < 0.05. The highest number AFC 
were detected in the sections stained with the conjugates in a concentration of 12.5 
I'g.ml- I , although the number AFC in these sections did not differ significantly from 
the number AFC detected in the sections stained with conjugates in a concentration 
of 25 Jlg.mf l • The number AFC detected with the SP082(urea) and SP082-AP(PBS) 
conjugates in a concentration of 25 I'g.ml·1 differ significantly (p < 0.4 and p < 0.2) 
from the number AFC detected with less diluted (50 I'g.ml- I ) SP082-AP(urea) and 
SP082-AP(PBS) conjugates. Further dilution of the conjugates (6.25 I,g.ml- I (not 
shown)) did not result in a significant increase in number of detected AFC. 
Figure 3 (next page) 
The spleens of mice, which were immunized ip with KLH-MBS-SP082 conjugate were removed on 
day seven after booster injection. Alternating tissue sections of spleens were stained with 082-
AP(DMF) (a), 082-AP(PBS) (b) and 082-AP(urea) (c) respectively (conjugate concentration 12.5 
Ilg,ml'\ Original magnification x 100. Bar is 25 pm. 
52 
---------------------- Conjugale [onnalion in Urea 
Figure ~ 
53 
Chapter2.3-------------------------
'Or----------------------------
Figure 4 
~ SP082-AP (UREA) 
[IT] SP082-AP (PBS) 
~ SP082-AP (DMF) 
'00 '0 
" Conjugate concentrations (ug/ml) 
u.s 
Number of specific anti-SP082 antibody forming cells in alternating spleen tissue sections, on day 
seven after booster injection, per square mill, TIle cells were detected by staining with dilutions of 
SP082-AP(urea), SP082-AP(PBS) and SP082-AP(DMF) conjugates. Standard error of mean is 
indicated. 
In all conjugate concentration groups (group 100 to 12.5 Itg.m)") the lowest 
number of AFC was detected in the sections stained with the SP082-AP(DMF) 
conjugate. Although there are some small differences between the numbers AFC in 
the tissue sections stained with SPOS2-AP(urea) and SPOS2-AP(PBS) within one 
conjugate concentration group, those differences were not significant. 
Discussion and conclusions 
In this study we show that peptide/AP conjugate formation can be performed 
in the presence of 8M urea. The peptides were dissolved in urea to obtain a 
sufficient concentration necessary for a successful conjugation. Besides a suitable 
peptide concentration, two other basic conditions for an appropriate conjugation 
between an enzyme and a protein or peptide are required. 
First, conjugation or the circumstances in which the conjugate formation occurs 
must not affect the biological-activity of the conjugated enzyme. As was revealed, 
the activity of the non-conjugated AP in the presence of SM urea decreased 
remarkably compared to the activities of the enzyme measured in solutions with 
lower urea molarities or when measured in PBS. The activities of the enzyme 
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determined in 1M, 2M, 4M or in PBS are of the same magnitude (figure la). More 
important than the activity of the non-conjugated enzyme is the activity of the 
conjugated enzyme determined under conjugative conditions. We observed that the 
activity of the peptide/AP conjugate under these conditions was remarkably higher 
than the activity measured in PBS (figure Ib). This suggested better availability of 
the enzyme active sites in the conjugate in the presence of urea. 
Second, the immunological properties of the conjugated protein or peptide 
must not be altered by the conjugation method. In other words, anti~peptide 
antibodies must recognize the conjugated peptide in the same way as the non-
conjugated peptide. In the inhibition ELISA SP082-AP(urea)- and SP082-AP(DMF) 
conjugates, inhibited the interaction between anti-SP082 antibodies and a coating of 
BSA-EDC-SP082 in a way comparable to inhibition of the same reaction by non-
conjugated SP082 (figure 2). This suggests that in spite of the presence of lysine 
blocked glutaraldehyde groups on the peptide and a possible sterical interference of 
the enzyme, the conjugation method did not influence the immunological properties 
of the conjugated peptide. In addition, the fact that both SP082-AP(urea) and 
SP082-AP(PBS) conjugates produced a comparable degree of inhibition, suggests 
that the same amount of peptide was conjugated to the enzyme in both conjugates. 
On the other hand, the SP082-AP(DMF) conjugate inhibited the interaction between 
the anti-SP082 antibodies and the coated antigen only when it was added in a high 
concentration, which indicates a lower peptide/AP ratio as compared to the other 
conjugates. Since the SP082-AP conjugates may in some instances block only one 
combining site of an anti-SP082 antibody and thereby allowing the other free site to 
bind to the BSA-EDC-SP082 coating of the micro titer plate, the AP from the SP082-
AP conjugates may also contribute to the observed signal. The AP-peptide conjugate 
bound in this way would increase the apparent level of the signal in the assay. 
Although, such interference may be relatively small, it will only contribute in a 
positive way to the inhibition level. Therefore the conjugates might even be better 
than concluded. The use of a peroxidase labelled Goat anti-mouse conjugate in the 
inhibition assay instead of an AP labelled conjugate would rule out this presumed 
interference. 
The presumed low peptide/AP ratio- or partial denaturation of the SP082-
AP(DMF) conjugate was confirmed by staining of spleen tissue sections of BSA-
EDC-SP082 immunized mice. The lowest number of specific AFC per square mm 
were detected by staining with SP082-AP(DMF) conjugate, independent of the 
conjugate concentration (figure 4). Furthermore there was a remarkable qualitative 
difference between the conjugates. The cells stained by SP082-AP(DMF) were not 
of the same intensity as the cells stained by SP082-AP(urea) and SP082-AP(PBS), 
respectively (figure 3a versus 3b-3c). 
The SP082-AP(urea)- and SP082-AP(DMF) conjugate demonstrated a pro-
zone effect when used in a concentration of 100 l,g.ml·1 up to 50l'g.ml-1 and further 
dilution of the conjugates did not lead to a significant increase in the number of 
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detected APc, A pro-zone effect (i.e. lower signal at higher concentration) is a 
frequently observed phenomenon in ELISA or cell staining experiments when 
antibodies or conjugates are used in high concentrations. There is no significant 
difference in the numbers of APC per square mm detected by both the SP082-
AP(urea)- or SP082-AP(DMF) conjugates independent of the conjugate 
concentrations. The presence of urea did not affect the enzyme activity nor the 
immunological properties of the coupled peptide and therefore this method can be 
used for the detection of AFC in situ (Van Rooijen and Claassen, 1986; Van 
Rooijen et aI., 1989) and direct immunological double staining methods (Boorsma, 
1988). 
This method permits and expands the use of peptides and proteins, which are 
normally not readily soluble in aqueous solutions, for construction of peptide/protein 
and protein/protein conjugates for use in e.g. immunochemistry and sub-unit vaccine 
development. This study suggests that conjugation in the presence of urea for the 
formation of conjugates wHh proteins or peptides, may be a useful additional tool to 
the existing methods. 
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CHAPTER 2.4 
IN SITU DETECTION OF SELF REACTIVE EPITOPE 
SPECIFIC ANTIBODY FORMING CELLS IN THE 
CENTRAL NERVOUS SYSTEM OF EAE RHESUS MONKEY 
SummatJ' 
K Gerritse, B Slierendregt*, C Deeo, MJ Fasbender, 
WJA Boersma and E Claassen 
TNO Prevelltioll alld Health, Leidell, Tlte Netherlallds 
*TNO Illstinae for Applied Radiobiology alld Immllllology, 
Rijswijk, Tlte Netherlallds 
EOS J Immunol Immunopharmacol 13:63-65, 1993 
The structural protein components of the myelin sheaths, surrounding the 
neuronal axons, are considered to be putative target antigens for immune competent 
cells, which play a role in the pathogenesis of multiple sclerosis or experimental 
allergic encephalomyelitis (EAE). Whether or not antibody forming cells (AFCs) 
playa role in the pathogenesis of MS or EAE is unclear, because the experiments 
performed safar concerned the detection of APes and antibodies, directed against 
myelin protein components, in the sera and/or cerebrospinal fluid only. By making 
use of myelin protein component-enzyme conjugates it is possible to detect anti-
myelin protein component APes locally in the tissues of the central nervous system 
(CNS), which are actually affected. We have constructed and validated a conjugate 
of horse radish peroxidase and myelin basic protein (MBP), one of the major CNS 
myelin protein components, to determine the presence of the anti-MBP AFCs in the 
spleens of mice and cerebrum of rhesus monkeys after induction of EAE. 
Intt'oduction 
Multiple sclerosis (MS) is a chronic disease of the central nervous system 
(CNS), characterized by the occurrence of demyelinated areas (plaques), 
dissemination and perivascular accumulation of inflammatory cells. Although the 
exact etiology and pathogenesis of MS is unknown, it is generally accepted that 
autoimmunity is involved in the disease. The immune response in the cerebrospinal 
fluid is reflected by elevated numbers of mononucleated cells in 30-50 % of the 
patients and oligoclonal bands in almost 100 % of the MS patients. 
One of the major components of eNS myelin to be considered a target 
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antigen is myelin basic protein (MBP). MBP has been a subject of many 
investigations because of its capacity to induce experimental allergic 
encephalomyelitis (EAE) in a variety of laboratory animals (Eyler et aI., 1971). 
Whether anti-MBP antibodies play any role in the pathogenesis of MS or EAE is 
unclear. Results considering the detection of antiRmyelin antibodies or anti-myelin 
antibody forming cells (AFC) are conflicting. However, most experiments concerned 
the detection of antibodies and cells in the peripheral blood and/or cerebrospinal 
fluid and not in the tissues in which the damage actually takes place. By making use 
of antigen enzyme conjugates it is possible to detect specific AFe's and extracelluar 
antibodies in situ (rev. Claassen et aI., 1992). Here we describe the construction of 
MBP-hOl'seradish peroxidase (PO) conjugates and the validation of these conjugates 
in immune-and CNS tissues of EAE-mice and rhesus monkey respectively. 
Matedal and methods 
Immunizations 
Female SJLlJ mice, 12 week old, were immunized with MBP to obtain anti-
MBP AFC containing lymphoid tissues to examine antigen-enzyme conjugation. Mice 
were immunized in the peritoneal cavity (Lp.) three times with a two week intelval 
with 200 J.'g bovine MBP (Sigma). The first dose was suspended in Freund's 
complete adjuvant (CFA, 9/11 v/v) with a total volume of 200 1'1. The second and 
third dose were suspended in Freunds incomplete adjuvant. All mice received 1 h 
after each immunization a single dose of 2.10' killed Bordetella pertllssis (i.p., 100 It! 
in PBS). Control mice received adjuvant suspended in PBS only. Mice were 
sacrificed on day 5 after the third immunization by CO2 euthanasia, the spleen was 
removed, snap frozen in liquid nitrogen and stored at _70°C for further use. 
Rhesus monkeys were born and raised in the Primate Centre TNO in 
Rijswijk, The Netherlands. Monkeys were immunized subcutaneous with an emulsion 
containing 1 ml antigen preparation and 1 ml CFA with 1 mg Mycobacterillm 
butyricllm (Van Lambalgen and Jonker, 1987). The inoculum was equally divided 
over four sites on the back. The antigen preparation consisted of 5 mg bovine MBP. 
Control monkeys received CFA suspended in saline only. Animals were sacrificed 
when they were moribund. Brain tissue samples were snap frozen and stored at 
-20'C for further use. 
Conjugate formation 
MBP was conjugated to PO with the two step glutaraldehyde (GA) method as 
was described by Van Rooijen and Claassen (1986) with some modifications. Briefly, 
PO was dissolved (10 mg) in 0.2 ml, 1.25% (v/v) GA in 0.1 M phosphate buffer (pH 
6.8) and incubated overnight at room temperature. The PO-GA fraction was isolated 
on a PD-1O sephadex G-25M column (Pharmacia LIm, Uppsala, Sweden) after 
elution with PBS. The PO-GA fraction was concentrated by membrane filtration 
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(Amicon PM 30, Grace & Co., USA) to a final concentration of 10 mg.ml". MBP (2 
mg, Sigma, St. Louis, USA) was dissolved in a mixture of 40 I'g 1M carbonate· 
bicarbonatebuffer (pH 9.8) and 360 III PBS (concentration 5 mg.ml"). The MBP 
solution was added to 440 III PO solution, 440 1'1 PBS and 160 III 1M carbonate· 
bicarbonate buffer (pH 9.8) and stirred overnight at 4°C. A solution of 0.2M glycine 
(80 Ill) was added to block the remaining active GA groups and incubated 2 h at 
room temperature. The MBP·PO solution was concentrated by membrane filtration 
(Amicon PM 30, Grace & Co., USA) to 5 mg.ml", diluted (1:1 v/v) with glycerol and 
stored at ·20°C. 
MBP·PO coupling was examined by ELISA. PVC microtiter plates (Flow 
Laboratories, Irvine, Scotland) were coated with anti·MBP monoclonal antibodies 
(Boehringer Mannheim, Germany) (5 I'g.ml" PBS, 50 pI/well) and incubated 
overnight at 4°C. The supernatant was removed and the wells were incubated 30 min 
at 25°C with a solution of gelatine 0.2 mg.ml" in PBS to block non·specific binding. 
The plates were washed (5x) with 0.01 % Tween·20 (v/v) in PBS (PBST) and 
subsequently incubated for 1 h at 25°C with MBP·PO conjugate in a solution of 
gelatine (0.1 mg.ml") in PBS. The plates were washed (5x) with PBST and a solution 
of o·phenylenediamine (2 mg.ml", Eastman Kodak 107 8054, Rochester, NY, USA) 
in phosphate·citrate buffer pH 5.0 (37°C) was added to each well (501'1/well). Prior 
to use 0.5 ,ll hydrogen peroxide (30 %) per ml substrate buffer was added to the 
solution. The plates were incubated in the dark at 25°C. After 15 minutes the 
absorption was determined at 450 nm in a Titertek Multiskan apparatus (Flow 
Laboratories, IIVine, Scotland). 
Control incubations were performed with substrate solution only and an 
irrelevant protein·PO conjugate (proteolipid protein· PO, PLP·PO). In addition the 
MBP·PO conjugate was incubated on plates coated with an irrelevant catching 
antibody (anti·mollse Lambda chain). 
Immuneghistochemistry 
Stainings were performed to detect specific anti·MBP AFC's. Eight 
micrometer cryostat mice spleen cross sections and monkey cerebrum coronal 
sections were fixed for 10 min in acetone containing 0.02 % (v/v) hydrogen 
peroxidase and dried for 10 min at room temperature. Fixed tissue sections were 
first pre-stained for non-specific peroxidase activity by incubation for 10 min in a 
solution of 4·chloro·l·naphthol, according to the method of Nakane, 1968. The 
reaction was stopped by incubation for 10 min in PBS. Subsequently tissue sections 
were incubated overnight at 4°C with MBP·PO conjugate dilutions in 0.1 % bovine 
sera albumin (BSA) in PBS (w/v). The slides were rinsed twice for 5 min in PBS and 
the PO activity was revealed with 3·amino·9·aminocarbozole, according to the 
method of Claassen et al. (1986d). The reaction was stopped after 10 min by 
incubation in PBS for 10 min at room temperature. All slides were counterstained 
with haematoxylin according to standard procedures. 
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In contra] experiments mice spleen tissue sections and monkey cerebrum 
tissue section were separately incubated with: substrate solution and an irrelevant 
protein-PO conjugate. Subsequently the specific peroxidase activity was inhibited by 
simultaneous incubation with non-conjugated MBP. In addition spleen and brain 
tissue sections of non-immunized mice and monkey respectively and spleen sections 
of mice immunized with an irrelevant antigen were incubated with the MBP-PO 
conjugate. 
Results and Discussion 
By making use of the two-step glutaraldehyde coupling method it is possible 
to construct MBP-PO conjugates. Since the conjugate could be detected in a direct 
ELISA (figure 1) in which the MBP part of the conjugate was recognized by an anti-
MBP catching antibody, it could be concluded that the antigenicity of the MBP was 
not modified by the conjugation procedure. 
To determine whether or not the conjugate could be used for ill situ detection 
of specific anti-MBP AFC's, spleen tissue sections of EAE mice and brain tissue 
sections of EAE rhesus monkey were incubated with the conjugate. As is shown on 
photograph I and 2, groups of specific anti-MBP AFC's were detected in both 
tissues. 
To prevent non-specific peroxidase staining the tissue sections were pre-
incubated with 4-chloro-l-naphtilOl. The use of this substrate demonstrated the best 
visible difference between the specific and non-specific stained cells as compared to 
the use of other substrates (results not shown). The MBP-PO conjugates will now be 
used to detect specific anti-MBP AFC's in autopsy eNS tissues of MS patients. To 
reveal the epitope specificity of the specific MBP AFC's we have started 
experiments with conjugates of synthetic peptides derived from MBP and PO. 
Photogruph 1·2 (next page) 
1) Spleen tissue sections of MBP immunized SJL/J mice were stained for nOil-specific peroxidase 
activity with 4-chloro-l-naphthol and specific anti-MBP APC's respectively. Groups of anti-MBP 
AFC's are indicated with arrows. 
2) Anti-MBP AFe's (red) wcrc detected in brain tissue sections of EAE rhesus monkey. Specific 
cells were detected in areas of innammalion. 
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MBP~PO conjugate formation was analyzed In a direct ELISA Oil a coating of anti·MBP monoclonal 
antibodies. The MBP-PO conjugate was added to the wells in various concentrations as indicated on 
the horizontal axis. No signal was observed when a non-specific conjugate (PLP.PO) was added to 
the wells. 
Photograph 1-2 
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CHAPTER 2.5 
THE INVOLVEMENT OF SPECIFIC ANTI MYELIN 
BASIC PROTEIN ANTIBODY FORMING CELLS IN 
MULTIPLE SCLEROSIS IMMUNOPATHOLOGY 
K Gerritse, C Deen, MJ Fasbender, R Ruvid*, 
WJA Boersma and E Claassen 
TNO Medical Biological Labomtory TNO, Rijswijk, The Netherlallds 
'The Netherlands Braill Balik, Amsterdam, The Netherlallds 
J Neuroimmunol 49:153·159, 1994 
Summary 
Irrespective of the large body of literature on the putative role of antibodies 
in the development of multiple sclerosis (MS), the detection of specific antibody 
forming B·cells (AFCs) in the central ne,vous system (CNS) tissues has not been 
described. In this study we show that autoantigen specific APes can be found in 
CNS tissue sections of MS patients. Applying a newly developed myelin basic 
protein (MBP)·enzyme conjugate technique, we have detected MBP specific AFCs 
in autopsy periventricuiar white matter and cerebellum tissue sections, of MS 
patients. We demonstrated the presence of MBP specific AFCs in CNS tissue 
sections in five out of twelve MS patients. Whereas no MBP specific APes were 
detected in eNS tissue sections of eleven patients with other neurological diseases, 
such as Parkinson's and Alzheimer's disease, nor in brain tissue sections of eight 
deceased persons without neurological diseases. In MS patients, anti·MBP AFCs 
were present in brain tissue sections both with and without p1aques. The proportion 
of MBP specific AFCs in some of the MS patient brain tissues reached over 50 
percent of ali AFCs. The high relative frequency of the anti·MBP AFCs and their 
localization in periventricu1ar white matter and cerebellum of MS patients only, 
suggests that anti·MBP AFCs represent a celi population, which could play an 
important role in MS immunopathology. 
Introduction 
MuHip1e sclerosis is an inflammatory disease which affects the central nervous 
system. The disease is characterized by breakdown of the mu1ti~lamellar myelin 
sheaths around the axons, resulting in demyelinated lesions or plaques. The exact 
ethiology of the disease and pathogenetic mechanisms of demyelination are at 
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present unknown. It is widely accepted that jmmune~ and autoimmune processes are 
involved in the development of the disease. The myelin breakdown is accompanied 
by an inflammatory response that includes T-cell subsets, B-cells and macrophages, 
resulting in perivascular infiltrates in the white matter parenchyma (Weller, 1985). 
Conflicting, data have been presented concerning the presence, distribution and 
function of T-cells specific for myelin components in peripheral blood and 
cerebrospinal fluid (CSF) wlncl, seems to fluctuate with the clinical course of MS 
(Freedman and Antel, 1988). 
Although the role of antibodies and B-cells specific for myelin components in 
MS is less well documented, there is circumstantial evidence of antibody and 
antibody forming cell involvement in the process of demyelination. Persistent 
oligoclonal IgG synthesis in the CSF (Walsh and Tourtelotte, 1983) and a high 
antibody specificity index (Felgenhauer and Reiber, 1992) are indicative for a 
sustained B-cell activation within the CNS of MS patients. In both CSF and sera of 
MS patients, antibodies directed against components of brain tissue (Henneberg et 
al., 1991) and a variety of putative CNS antigens like cerebellar soluble lectin 
(Zanella et aI., 1990a; 1990b), glycolipids (Endo et aI., 1984; Hirsch and Parks, 
1976), myelin basic protein (MBP) (Link et aI., 1990), proteolipid protein (Sun et al., 
1991) and myelin associated glycoprotein (Baig et aI., 1991) were detected. Of all 
putative CNS antigens MBP is the probably the most investigated antigen. Epitope 
specificity of anti-MBP antibodies in CSF of MS patients was revealed making use of 
synthetic peptides (Warren and Catz, 1992a). Epitope specificity of free anti-MBP 
from MS CSF is identical to the epitope specificity of free anti-MBP isolated from 
MS cerebrum. Both tissue bound anti-MBP antibodies from MS cerebrum and 
bound anti-MBP antibodies from MS CSF are directed to a more restricted number 
of epitopes as compared to non-bound anti-MBP antibodies (Warren and Catz, 
1993). Immune-complexes in sera of MS patient en were found to contain MBP 
(Coyle and Procyk-Dougherthy, 1984; Dasgupta et al., 1983). Bound anti-MBP 
antibodies, i.e. as component of immune complexes, were also found in sera of MS 
patients (Coyle and Procyk-Dougherthy, 1984). However, the presence of MBP in 
immune complexes isolated from sera of MS patients could not be confirmed in 
recently performed experiments (Geffard et aI., 1993). 
Warren and Catz (1986) detected antibodies in MS patients, directed against 
myelin components, particularly during exacerbations. Such a correlation was not 
observed by Link and coworkers (Link et aI., 1990). Gorcy reported the detection of 
elevated frequencies of anti-MBP antibodies in CSF of MS patients and patients 
with other neurological diseases (OND) as compared to healthy controls (Gorcy et 
aI., 1983). Others were not able to demonstrate a statistical difference in anti-MBP 
antibody titers in CSF (Chou et aI., 1983) nor in the frequencies of anti-MBP APCs 
in blood (Jingwu et al.,1991) of MS patients and healthy controls. 
Most investigations into antibody and/or APC involvement in the process of 
demyelination performed, were restricted to the determination of the presence or 
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specificity of antibodies and AFCs in sera or CSF. From these studies no definite 
conclusion can be drawn with respect to possible correlations between the local 
presence of specific antibodies or AFCs and the induction or enhancement of local 
tissue damage in the CNS. We decided to determine the presence and specificity of 
AFCs in CNS tissue. To this end we made use of a newly developed ill sitll 
immunohistochemical technique (reviewed by Claassen et aI., 1992). 
Material and methods 
Immuno~histochemistry 
A myelin basic protein horse radish peroxidase (MBP-PO) conjugate was 
constructed (Gerritse et aI., 1993) and used for the detection of specific MBP AFCs 
in a panel of CNS tissue sections from MS patients, control aND patients and non-
neurological controls. 8 Ilm cryostat coronal sections of cerebrum periventricular 
white matter and cerebellum were fixed for 10 min in acetone containing 0.02 % 
(vlv) hydrogen peroxide and dried for 10 min at room temperature. Subsequently 
tissue sections were incubated overnight at 4°C with MBP-PO conjugate (20,tg.ml·') 
in 0.1 % bovine sera albumin in PBS (wlv). In order to determine the total number 
of IgG producing cells, serial sections were incubated with PO conjugated mouse 
anti-human IgG, clone 335-2.1 (2.5 mg.ml·' in 0.1 % bovine sera albumin in PBS 
(wlv». All slides were rinsed three times for 5 min in PBS and the PO activity was 
revealed with 3-amino-9-aminocarbazole, as was described by Claassen (Claassen et 
aI., 1986b). The reaction was stopped after 10 min by incubation in PBS for 10 min 
at room temperature. All slides were counterstained with haematoxylin according to 
standard procedures. Tissue sections were evaluated by light microscopy. The 
frequency of anti-MBP specific AFCs was calculated as a proportion of all IgG 
APes in serial sections. 
In control experiments human brain sections were incubated with substrate 
solution only or with irrelevant protein (bovine serum albumin)-PO conjugate. 
Furthermore spleen tissue sections of MBP immunized mice, non-immunized mice 
and mice immunized with an irrelevant antigen (ovalbumin) were separately 
incubated with: the MBP-PO conjugate, substrate solution only and an irrelevant 
protein (bovine serum albumin)-PO conjugate. Subsequently, the specific binding of 
the MBP-PO conjugate was inhibited by simultaneous incubation with non-
conjugated MBP. 
Area determination 
To express the number of AFCs per surface unit, the area of the brain tissue 
sections was determined by video imaging, using the micro computer imaging device 
and accompanying BRS2 software from Imaging Research Inc. (Brock University, St. 
Catherines, Ontario, Canada). The level of inflammation in the tissues was evaluated 
by counting the number of peri-venous inflammatory cell clusters. A cell cluster was 
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defined as an individual local accumulation of 10 cells or more. Cell and cluster 
numbers were used to calculate Spearman's Rho correlation coefficient. 
Human tissues 
Autopsy brain tissues were obtained from The Netherlands Brain Bank in 
Amsterdam (coordinator Dr. R. Ravid). Autopsy data are listed in table 1. 
Results 
Application of immuno-histochemistIy with the MBP-PO conjugate, revealed 
MBP specific APCs (photograph 1) in CNS tissue sections in five out of twelve MS 
patients. MBP specific APCs were located in white matter only. The average area of 
cerebellum and cerebrum periventricular white matter tissue sections analyzed 
quantitatively per patient was 19 cm' and 43 cm' respectively. The frequency of 
MBP specific APCs detected, ranged from 6 to 95 cells per 10 cm' (table 2). 
Although not consistent in all tissues tested, the majority of the MBP specific APCs 
was detected in cell clusters, a minor part of the MBP specific APes was detected as 
individual cells and only few cens were present in perivascular cuffs. A significant 
positive correlation (p < 0.05) was determined for the frequency of MBP specific 
APCs and the number of cell clusters (Spearman's Rho correlation coefficient = 
0.58). Making use of the same immunohistochemical technique, anti-MBP APCs 
could not be detected in a panel of twelve OND patients nor in a panel of eight 
non-neurological subjects (table 2). 
The relative frequency of MBP specific APCs ranges from 3 % to 52 %. In 
two MS patients (patient code: 8 and 9) the relative frequency of MBP specific 
APCs was higher in the plaque containing tissues as compared to the non plaque 
containing tissues. In contrast, the relative frequency of MBP specific APes in 
plaque containing periventricular white matter tissue, of MS patient no. 10, was lower 
as compared to the relative frequency of MBP specific APCs in non-plaque 
containing periventricular white matter tissue (table 3). IgG producing cells, not 
specific for MBP, were detected, albeit in very small numbers, in the tissues of 
patients with other neurological diseases and non~neurological controls. However, no 
MBP specific APCs were present in serial sections of these tissues, consequently the 
relative frequencies of MBP specific AFCs of the control groups are zero (table 3). 
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Patient Date of Age' First PMD' Cause of death Diagnose 
code autopsy symptoms' 
MS patients 
1 122687 65 37 39.00 Cardiorespiratory failure Multiple sclerosis 
2 022090 57 24 24.00 Food inhalation Multiple sclerosis 
3 nk 62 nk 14.50 Pneumonia Multiple sclerosis 
4 123187 87 52 12.00 Bronchopneumonia Multiple sclerosis 
5 091288 45 25 11.30 nk' Multiple sclerosis 
6 120991 62 nk 10.10 nk Multiple sclerosis 
7 112190 55 nk 9.10 nk Multiple sclerosis 
8 030192 59 38 7.30 Septic shock Multiple sclerosis 
9 081791 63 nk 5.50 Bronchopneumonia Multiple sclerosis 
10 062791 57 21 5.20 nk Multiple sclerosis 
11 052288 43 23 5.00 Hepatic carcinoma Multiple sclerosis 
12 091290 41 ~ 4.45 Dehydration Multiple sclerosis 
mean: 58 32 10.05 
Patients with other neurological diseases 
13 062190 89 4.55 Vascular problems Alzheimer disease 
14 052990 78 4.10 Sepsis/Decubitus/Cachexia Parkinson disease 
15 071290 79 4.00 Pneumonia Alzheimer disease 
16 090889 82 4.00 Uraemia Alzheimer disease 
17 060290 89 3.45 Pneumonia Alzheimer disease 
18 071390 66 3.45 Lung infection Alzheimer disease 
19 052990 85 3.45 Bronchopneumonia Alzheimer disease 
20 071888 81 3.45 Pneumonia/Heart disease Alzheimer disease 
21 121387 88 3.45 Decompensatio cordis Alzheimer disease 
22 071490 84 3.35 Decotnpensatio cordis Alzheimer disease 
23 051490 85 3.30 Cachexia Alzheimer disease 
mean: 82 3.54 
Non-neurological disease controls 
24 060890 83 8.00 Bronchopneumonia 
25 111990 73 6.35 Heart failure 
26 111990 85 6.34 Heart failure 
27 061990 76 6.27 Lung carcinoOill 
28 052990 82 5.20 Urotheel carcinoom 
29 082890 84 4.25 Pancreatic carcinoom 
30 100490 57 4.25 Hart failure 
31 070290 74 3.45 Cardial infarct 
mean: 77 5.41 
Tnble 1 
Relevant autopsy data as stated in patients autopsy reports of The Netherlands Brain Bank in 
Amsterdam, The Netherlands (coordinator Dr. R Rav1d), were ranked according to PMD. 
a age in years; b post mortem delay in hours; C not known. 
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Photograph 1 
Anti-myelin basic protein antibody forming cells were stained with a MBP.peroxidase conjugate. An 
antibody forming cell specific for myelin basic protein is shown in a cluster of innammatory cells, 
Original magnification SOOX. Bar is 5 11m. 
Discussion 
In this study, we present new and direct evidence for the presence of, 
putative pathogenic, autoantigen specific APCs in CNS tissue sections of MS 
patients. To this end, the immunohistochemical technique making use of antigen-
enzyme conjugates, which was originally developed for the detection of APCs in 
lymphoid tissues (for review: Claassen et aI., 1992), was made applicable for the 
detection of antigen specific AFCs in CNS tissues as well. Making use of MBP-PO 
conjugates, we have detected MBP specific APCs in cerebellum and periventricular 
white matter tissue sections of MS patients. The presence of anti-MBP APCs in 
CNS tissues is highly specific for MS patients, no anti-MBP APCs were detected in a 
panel of control CNS tissues of patients with other neurological diseases or healthy 
subjects. 
III situ detection of anti-MBP AFCs in only a part of the panel of MS patients 
is in agreement with ill vitra studies performed by Cash (Cash et aI., 1992). Several 
reasons might explain why MBP specific APCs were not detected in all individual 
samples of the panel of MS patient CNS tissues tested. The most likely reason, is 
probable the large PMD by which a substantial part of the tissues was sampled. It is 
a well known phenomenon that a long PMD and a relatively high body temperature 
of the patients body during the period between decease and autopsy have a negative 
influence on the quality of the tissues and as a consequence might influence the 
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Table 2 
Frequency Myelin Basic Protein specific AFCs in brain tissne. 
Code Tissue Plaques' MBP-Specific AFCs' Total Number of 
Individual Cuffs Clusters Total Ig-AFCs' Clustersa 
MS patients 
1 cerebrum + 0 0 0 0 580 13 
cerebrum 0 0 0 0 0 1 
2 cerebrum + 0 0 0 0 102 147 
cerebrum 0 0 0 0 40 58 
3 cerebrum + 0 0 8 8 266 60 
4 cerebellum - 0 0 0 0 4 0 
5 cerebrum + 0 0 0 0 208 28 
cerebrum 0 0 0 0 65 0 
6 cerebrum + 0 0 0 0 0 0 
cerebrum 0 0 0 0 0 0 
cerebellum - 0 0 0 0 0 0 
7 cerebrum + 13 5 5 23 766 20 
8 cerebrum + 2 7 9 18 128 230 
cerebrum 7 1 4 12 66 140 
9 cerebrum + 12 2 81 95 206 220 
cerebrum 17 0 5 22 314 1190 
10 cerebrum + 1 0 9 10 67 160 
cerebrum 2 0 21 23 88 270 
cerebellum - 2 0 4 6 12 30 
11 cerebellum - 0 0 0 0 534 24 
12 cerebellum - 0 0 0 0 43 16 
OND' patients (n=l1) 
cerebrum 0 0 0 0 2 (2.8)' 0 
cerebellum - 0 0 0 0 30 (27)' 0 
Non.neurological controls (n=8) 
cerebrum 0 0 0 0 12 (11)' 0 
cerebellum - 0 0 0 0 3 (3.6), 0 
The level of inflammation in the tissues was evaluated by counting the number of peri-venous 
inflammatory cell clusters. A cell cluster is defined as an individual local accumulation of 10 ceUs or 
more. The frequency APCs and number of clusters in eNS tissue scctions is expressed per 10 cmz, 
The total MBP specific AFe frequcm:y is Ihe enumeration of the three separate frequencies of MBP 
specific AFCs, detected in cell clusters, peri.venous cuffs and individual respectively. 
a per 10 cml; b other neurological diseases; C standard deviation. 
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Table 3 
Relative frequency Myelin Basic Protein specific AFCs in brain tisslle. 
Code Tissue Plaque Relative frequency specific AFCs 
Individual Cuffs Clusters Total 
MS patients 
1 cerebrum + 0 a a a 
cerebrum a a a a 
2 cerebrum + a a 0 a 
cerebrum a a a a 
3 cerebrum + a a 3 3 
4 cerebellum - a a a a 
5 cerebrum + a a a a 
cerebrum a a a a 
6 cerebrum + a a a a 
cerebrum a a a a 
cerebellum - a a a a 
7 cerebrum + 6 2 9 17 
8 cerebrum + a 4 10 14 
cerebrum 4 2 12 18 
9 cerebrum + 5 3 38 46 
cerebrum 5 a 2 7 
10 cerebrum + 3 a 12 15 
cerebrum 6 a 20 26 
cerebellum - 2 a 50 52 
11 cerebellum - 0 a a a 
12 cerebellum - a a 0 a 
OND" patients (n=ll) 
cerebrum - a a a a 
cerebellum - a a a a 
Non-neurological controls (n=8) 
cerebrum a a a a 
cerebellum - a a 0 a 
The relative frequency MBP specific APCs in brain tissue was determined, by calculating the 
frequency of MBP specific APCs as a proportion of all IgG producing APCs in serial sections. 
a other neurological diseases. 
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detectability of AFCs. In half of MS patients the PMO to tissue sampling is 
excessive. Most CNS tissue samples of MS patients in which anti-MBP AFCs were 
detected, were frozen within 10 hours, whereas the tissues of most MS patients in 
which no anti-MBP AFCs could be detected or in which only small numbers of 
AFCs could be detected, were sampled with larger PMOs (table 1, 2). A more 
careful acquisition of tissue, i.e. tissue sampling within 10 hours in subsequent 
studies, will probably improve the results. 
A second reason why MBP specific AFCs were not detected in the whole 
panel of CNS tissues tested, might be due to the tissue section sampling method. 
Because the non plaque containing sections were sampled ad random, it is possible 
that a part of the sampled CNS tissues did not show local inflammation and AFCs 
directed to putative CNS antigens. 
CNS tissue sections of MS patients were only tested on the presence of anti-
MBP AFCs. However, it is possible that anti-MBP AFCs will not be formed during 
the entire course of the disease at all. In these cases, the causative antigens may be 
other CNS component antigens. In subsequent studies, CNS tissue sections of MS 
patients will be tested on AFCs with other specificities like proteolipid protein and 
myelin oligodendrocyte glycoprotein. 
Furthermore, we only used tissue samples obtained by autopsy, the patients 
stage of disease at the time of decease may determine whether or not specific AFCs 
will be detected. Warren and Catz (1986) showed that antibodies in the CSF of MS 
patients are especially present during exacerbations of clinical signs. Therefore, it is 
possible that the MS patients, in which we could not detect anti-MBP AFCs, did not 
show clinical exacerbations prior to the moment of decease. 
We have detected anti-MBP AFCs in both plaque containing and non-plaque 
containing CNS tissues of MS patients. Although the results do not exclude a 
putative role for MBP specific cells in the not yet affected areas of the CNS of MS 
patients, the presence of anti-MBP AFCs in both affected and non-affected areas, 
suggests that the anti-MBP AFCs are directed from the non-affected areas towards 
the affected areas. Once arrived in the affected areas the anti-MBP AFCs may play 
a role in demyelination and remyelination as well. The AFCs could function in at 
least three ways. First, the AFCs may function as antigen presenting cells to 
activated T-cells. Although antigen specificity is not a requirement for AFCs to act 
as an antigen presenting cell, the antigen specific anti-MBP AFCs present antigen 
with a higher efficiency to T-cells as compared to non-antigen specific AFCs 
(Lanzavecchia, 1985). Since, B-cells are not able to activate resting T-cells (Lassila et 
aI., 1988), the function of AFCs in the process of demyelination, as antigen 
presenting ceU, is restricted to the augmentation of the disease. 
Another mechanism by which anti-MBP antibodies and AFCs might be 
involved in demyelination is the antibody dependent cellular cytotoxicity. 
Experimental evidence for antibody involvement in cytotoxicity was obtained by 
Satoh and coworkers (Satoh et aI., 1991). They showed that ill vitro cytolysis of 
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oligodendrocytes is mediated by human K cells in the presence of anti-
oligodendrocyte antiserum or with anti-galactocerebroside antibodies. In addition, 
serum from MS patients can induce cytotoxicity to rat oligodendrocytes in culture 
(Ruijs et aI., 1990). These results, obtained with ill vitro experiments, suggests anti-
MBP antibodies and AFCs could playa similar role in vivo cytotoxic demyelination. 
Furthermore, there are some indications for suppressor cell functions of B-
cells in the process of demyelination. It is established that sera obtained from 
recovered EAE animals is able to reduce the incidence and/or severity of the disease 
when given to recipient animals after induction of the disease (Willenborg, 1981; 
Killen and Swanborn, 1982; MacPhee et aI., 1990). In addition, suppressor cell 
function is awarded to MBP primed B-cells, which can transfer protection against 
EAE, together with CD4+ T-cells, in naief recipients (Karpus and Swanborn, 1991). 
Although the evidence for the existence of suppressor B-cells in the process of 
demyelination is mainly based on data obtained with EAE animal experiments, the 
results are suggestive for suppressor B·cell function in MS patients. 
Several authors have demonstrated the presence of antibodies and AFCs 
directed against a variety of putative CNS antigens in MS patients. However, the 
experiments performed safar concerned the detection of specific APes and 
antibodies in sera and CSF only (Warren and Catz, 1990; 1992b). Because, MBP 
peptide fragments were detected in both CSF (Whitaker, 1977) and urine of MS 
patients (Whitaker, 1987), one could still assume that the presence of specific AFCs 
and antibodies in sera and/or CSF of MS patients is an epiphenomenon due to the 
release of eNS antigens in the circulation. However, the detection and localisation 
of anti-MBP AFCs in CNS tissues of MS patients only, as was shown in this study, is 
very suggestive for a specific immune-pathological role of antibodies and AFCs in 
MS patients. This implies that methods for an active interference on the level of 
APe development, activation Of function could open new possibilities for MS 
therapy development. 
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CHAPTER 2.6 
DISCUSSION 
SIGNIFICANCE OF AUTOANTIGEN SPECIFIC 
ANTIBODY FORMING CELLS IN MULTIPLE SCLEROSIS 
The role of B-cell immunity has received relatively little attention in multiple 
sclerosis (MS) research. One reason for this is that in contrast to T-cells, myelin 
specific antibodies experimentally can not transfer the disease in animals. In part, 
this is not surprising since antibodies can not pass the blood brain barrier in healthy 
animals. Blood born structures with a high molecular weight are generally excluded 
from the brain and have been found to leak into the brain only at the peak of the 
experimental allergic encephalomyelitis (EAE) attack (Lam, 1986). However, 
antibody deficient rats fail to develop clinical or histological evidence of EAE, when 
sensitized with either whole spinal cord or purified myelin basic protein (MBP) 
(Willenborg and Prowse, 1983). Intravenous injection of monoclonal antibodies 
(Mabs) against myelin oligodendrocyte glycoprotein (MOG) in EAE Lewis rat, 
resulted in augmentation of both clinical signs, inflammation and demyelination 
(Lassmann et al., 1988). Demyelination also can be induced in central nervous 
system (CNS) tissue cultures with anti-galactocerebroside serum (Saida et aI., 1979). 
Furthermore, in the presence of anti-MOG Mabs, 10-100 times less encephalitogenic 
T-cells are needed to induce EAE (Linington et aI., 1988). These results indicate 
that, at least in EAE, the inflammatory process becomes pathologically manifest in 
the presence of autoantigen reactive antibodies. 
Many experiments have been performed to detect and to identify the 
autoantigen specificity of antibodies and antibody forming cells (AFCs) from patients 
with MS. The use of classical detection methods allow to reveal the antigen 
specificity of antibodies produced by isolated cells or present in sera, cerebrospinal 
fluid (CSF) or tissues only. Applying these classical detection methods, 
autoantibodies to (MBP) and other myelin proteins, such as proteo-lipid protein, 
MOG and myelin associated glycoprotein were detected in MS-patients. The actual 
repertoire of the B-cell, e.g. the produced antibodies, in most studies has been 
measured by performing direct ELISAs with sera or CSF isolated from MS patient. 
In these studies only circulating (non-tissue or antigen bound) antibodies, were 
measured. However it is possible that an essential portion of the autoantigen 
reactive antibodies is bound, by its Fe portion, to effector cells or with its Fab 
portion to the target antigen, as a consequence these antibodies will not be 
measured in body fluids by direct ELISA. Therefore this type of experiments 
probably provides an incomplete view on the actual B-ce11 repertoire. Furthermore 
from these studies no information can be obtained with respect to possible 
correlations between the local presence of autoantigen specific antibodies or AFCs 
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and the induction or enhancement of local tissue damage in the CNS_ 
In our experiments, using a newly developed immuno-histochemical 
technique, based on the application of autoantigen-enzyme conjugates, we were able 
to determine the localization of APCs ill sifll and simultaneously determine antigen 
specificity of these APCs_ In addition, this approach circumvents problems due to ill 
vivo tissue adsorption of the autoantibodies and provides information on the quantity 
of autoantibodies produced_ 
Applying immune-histochemistry, we have shown that MBP specific APCs are 
present in autopsy brain tissue section of EAE-rhesus monkeys and MS patients_ 
The resemblance of the localization of MBP-specific APCs in affected CNS tissue 
sections of both EAE-rhesus monkey and MS patients, makes the EAE-rhesus 
monkey a useful model for following studies concerning the involvement of B-cells in 
the process of demeyelination_ MBP-specific APCs were not detected in patients 
with other non-inflammatory neurological diseases nor in healthy controls, this 
indicates that auto-reactive APCs or their produced antibodies may play a role in 
the process of demyelination in the CNS of MS patients_ However, the 
demonstration of autoantigen specific cells by itself, does not provide information 
whether these cells or the produced antibodies are involved in the primary or 
secondary process of pathogenesis of the disease_ 
Antibodies or antibody forming cells may be involved in the process of 
demyelination in three ways. First, auto-antibodies might be involved in 
demyelination by antibody dependent cellular cytotoxicity_ It was shown that ill vitro 
cytolysis of oligodendrocytes is mediated by human K cells in the presence of anti-
oligodendrocyte serum (Satoh et aI., 1991)_ In addition, serum from MS patients can 
induce cytotoxicity to rat oligodendrocytes in culture (Ruijs et aI., 1990)_ These 
results suggests that auto-antibody dependent cellular cytotoxicity could play a 
similar role in the induction or propagation of ill vivo demyelination. Second, 
antibodies specific for CNS autoantigens like MBP maybe involved in complement 
mediated demyelination (pabst et aI., 1971) or in opsonization for specific 
macrophage mediated cell lysis (Williams et a1_, 1980)_ Third, antibody forming cells 
may function as antigen presenting cells_ The recognition and binding of antigens 
with the membrane bound immunoglobulins is the initial activation signal for B-cells_ 
The immunoglobulin bound autoantigens maybe internalized, processed and 
subsequently presented in context of MHC class II molecules to T helper (Th) cells_ 
The recognition of the processed antigens in association with MHC class II 
molecules by the Th-cell receptor will activate Th-cells, which in turn will activate 
other immunological competent cells_ In this way the actual antigen repertoire of the 
B-cell influences indirectly the T-cell repertoire_ The B-cells then function as 
secondary pathogenic cells_ 
The hypothesis on a possible B-cell involvement in the pathogenesis of MS, 
would be supported by the demonstration of the presence of immunological 
components necessarily for B-cell mediated demyelination in effected areas of the 
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brain, i.e. effector cells like natural killer, macrophages and T-helper cells for B-cell 
activation. To investigate this, as described in chapter 3, autopsy CNS tissue sections 
of MS patients were examined for the presence of T-cells expressing the gp39 
activation marker which is the ligand for the B-cell CD40 surface protein. 
Furthermore we have investigated the role of gp39-CD40 interactions on the 
development of disease in EAE animals by administration of anti-gp39 monoclonal 
antibodies. 
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CHAPTER 3.1 
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IN MULTIPLE SCLEROSIS 
K Gerritse', JD Laman', RJ Noelle!, A Aruffol, JA Ledbetterl, 
WJA Boersma' and E Claassen' 
'TNO Prevelltion alld Health, Leidell, The Netherlallds 
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Summary 
Activated helper T-cells expressing CD40-ligand surface protein were found 
in multiple sclerosis patient brain sections, but not in brain tissue sections of normal 
controls or patients with other neurological diseases. CD40-ligand positive cells were 
co-localized with CD40 bearing cells in active lesions (perivascular infiltrates or 
plaques). Most of these CD40 bearing cells proved to be of the monocytic lineage 
(macrophages, microglial cells), and relatively few were B-cells. 
To functionally evaluate CD40-CD40-ligand interactions, experimental allergic 
encephalomyelitis (EAE) was elicited in mice by means of proteolipid-peptide 
immunisation. Treatment, with anti-CD40-ligand monoclonal antibody, completely 
prevented the development of disease. 
Furthermore, administration of anti-CD40-ligand MAb, even after disease 
onset, shortly before maximum disability score was reached, led to dramatic disease 
reduction. 
The presence of Th-cells expressing CD40-ligand in brain tissue of multiple 
sclerosis patients and EAE animals, together with the functional evidence provided 
by successful experimental prevention and therapy in an animal model, indicates that 
blockade of CD40-CD40-ligand, essential for cognate cell-cell interactions, may be 
considered to be a method for interference in active multiple sclerosis. 
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Introduction 
Many activation signals, surface proteins and co-stimulatory factors are 
required for the optimal proliferation and differentiation of antigen specific B-cells. 
Binding of antigens to B-cell membrane bound Ig is followed by internalization and 
processing of the antigen. Subsequently the antigen is presented in context of MHC 
class II molecules to T helper (Th) cells. Recognition of this complex by the Th-cell 
receptor activates Th-cells to express CD40-ligand (Noelle et aI., 1992; Armitage et 
aI., 1992) and to produce and secrete cytokines. Binding of the CD40-ligand to its 
receptor CD40, which is present on all mature B-cells (Clark and L1ne, 1991), is 
required for the initiation of B-cell activation (Paulie et aI., 1989). Isolated Th-cell 
plasma membranes, which express CD40-ligand, can activate resting B-cells in vitro 
(Noelle et aI., 1991). The activation of resting B-cells by isolated Th-cell membranes 
can be blocked both by a soluble CD40-Ig fusion protein and by anti-CD40-ligand 
monoclonal antibody (Mab). In addition it was shown that CD40-CD40-ligand 
interactions are essential for thymus dependent humoral immunity (i.e. antibody 
production) ill vivo (Foy et aI., 1993; Eertwegh et aI., 1993). 
Although less well described, CD40-CD40-ligand interactions are thought to 
play a role activation of the monocytic lineage as well (Alderson et aI., 1993). 
Treatment of human monocytes with granulocyte macrophage colony-stimulating 
factor, interleukin-3 or interferon y resulted in the induction of CD40 mRNA and 
enhancement of cell surface CD40 protein expression. CD40 was found to mediate 
monocyte adhesion to cells transformed to express CD40-ligand. The CD40-ligand 
transfected cells provided a co-stimulatory signal for monocytes to produce tumor 
necrosis factOI'-a and interleukin-6 in the presence of granulocyte/macrophage 
colonYM stimulating factor or interleukinM 3 . 
Both B-cells and monocytes are considered to playa role in the pathogenesis 
of multiple sclerosis (MS). Active lesions in the central nervous system (CNS) of MS 
patients are characterized by mononuclear cell infiltrates. The infiltrating cells 
comprise T-cells, B-cells and macrophages (Traugott et aI., 1982). About 50% of the 
mononuclear cells in the perivascular lesions in the CNS of experimental 
autoimmune animals (EAE), an animal model considered to represent the effector 
phase of MS, are blood-borne monocytes/macrophages (Huitinga et aI., 1990) and 
microglial cells (Bauer et aI., 1994; De Simone et aI., 1995). In Lewis rats, in which 
EAE was induced either by adoptive spleen cell transfer or by active immunization 
with CNS white matter 11OmogenateJ the elimination of macrophages suppressed the 
development of EAE neurological signs significantly (Huitinga et aI., 1992). This 
suggests an important role for macrophages in EAE. 
Antibody producing B-cells and antibodies specific for a variety of putative 
CNS antigens like cerebellar soluble lectin (Zanetta et aI., 1990b), glycolipids (Endo 
et aI., 1984), myelin basic protein (Link et aI., 1990) (MBP), proteolipid protein 
(PLP) (Sun et aI., 1991) and myelin associated glycoprotein (Baig et al., 1991) have 
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been detected in both cerebrospinal fluid and sera of MS patients respectively. 
Recently, we have detected autoantigen specific B-cells in cerebeJJum and cerebrum 
tissue sections of MS patients as well (Gerritse et aI., 1994). Anti-MBP specific B-
cells were detected in CNS tissue sections of MS patients only and not in CNS tissue 
sections of patients with other neurological diseases nor in eNS tissue sections of 
healthy controls. However, it is not clear whether these antigen specific B-cells are 
activated by Th-cells in the demyelinated areas of the CNS or in peripheral localized 
lymphoid tissues. In order to investigate whether CD40-ligand bearing Th-cells are 
present in affected areas of MS patient CNS tissues, we have examined CNS tissue 
section on the presence of CD40-ligand bearing Th-cells using immunohistochemistry 
in the present study. 
In view of the above literature and our finding of CD40-ligand positive T-cells 
in human MS brain material, we investigated whether the interactions of T-cell 
activation markers and their ligands, such as CD40-ligand/CD40 might play a 
functional role in the initiation or development of the disease process in EAE. To 
this end the in vivo interaction between Tit-cell activation marker CD40-ligand and 
its receptor CD40 was blocked by administration of anti-CD40-ligand antibody prior 
to onset or during progression of EAE (fulminant disease). EAE mice were treated 
in several time- and dose-administration regimens with anti-CD40-ligand Mabs. The 
effect of anti-CD40-ligand Mab treatment on the course of the disease was 
monitored by evaluation of EAE clinical/disease characteristics (disability score), 
body weight reduction and by determination of serum anti-PLP peptide antibody 
responses by standard direct ELISA (Zegers et aI., 1991). 
Methods 
Histochemistry 
Human autopsy CNS tissues of MS (n= 12), normal controls and other 
neurological disease (OND) controls were obtained from the Multiple 
Sclerosis/Control Brain Bank (supported by the Foundation Friends MS Research), 
Coordinator Dr. R. Ravid, of the Netherlands Institute for Brain Research, 
Meibergdreef 33, 1105 AZ, Amsterdam. All histochemical analyses, of both human 
and mouse tissues, were performed on cryosections (8 micrometers) from snapfrozen 
material. In a pilot study selected CNS tissues of MS-patients (n=4) were used in 
which anti-MBP specific B-cells (putatively bearing CD40) were detected on a 
previous occasion (Gerritse et aI., 1994). 
CD40-ligand' bearing cells were detected immunohistochemically in human 
tissue using a CD40-Ig fusion protein as described in detail before (Van den 
Eertwegh et aI., 1993) and in the mouse with the monoclonal hamster antibody MRI 
(Noelle et aI., 1992; Van den Eertwegh et aI., 1993), directly labeled with alkaline 
phosphatase. Alkaline phosphatase was revealed, in blue, as described before (Van 
Rooijen et aI., 1989), briefly: 8 mg naphthol-AS-MX-phosphate (N-4875, Sigma, St. 
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Louis, USA) was dissolved in 400 1<1 OMF and added to 65 ml Tris-HCI buffer 
(O.1M, pH 8.5). Sixteen mg fast blue BB base (F-33?8, Sigma) was suspended in 400 
1'1 2N HCI. Sixteen mg NaN02 was dissolved in 4001'1 MQ water and added to the 
fast blue BB base solution. This solution was mixed for 1 min and added to the Tris-
HCI buffer. Sixteen mg levamisole was dissolved in 1 ml Tris-HCI buffer and added 
to the substrate solution. After 2 min incubation at 37'C in a waterbath the substrate 
solution was filtered to remove any precipitate. Slides were incubated vertically in 
coplin jars for 10-45 min at 37'C in a waterbath. C040 was revealed with a mouse 
anti-human C040 antibody (5012; a kind gift of Or. M de Boer, Pangenetics, 
Heemstede, Netherlands, Oe Boer et aI., 1993), followed by rabbit-anti-mouse-
horseradish peroxidase; RAMPO, P-260, OAKO, Denmark) and immunochemistry 
with 3-amino-9-ethylcarbazole (ABC, A-5754, Sigma) for a red color. Briefly: 26 mg 
AEC dissolved in 1.5 ml NN-dimethylformamide was added to 65 ml sodium-acetate 
buffer (0.05 M, pH 5.0), just before use 35 1<1 30% H,02 was added. Slides were 
incubated vertically in copJin jars for 8 minutes, reaction was ended by transferring 
the slides to PBS. C040 was revealed in a blue color after incubation with MAb 
5012 followed by horse-anti-mouse-biotin (Ve·etor, Burlingame, USA) and 
subsequent application of streptavidin-alkaline phosphatase (Gibco-BRL, 
Gaithersburg, USA; for alkaline phosphatase see above). Cells of the monocytic 
lineage (Eikelenboom, 1978; Frei et aI., 1987; Ulvestad et aI., 1994) were detected, 
in red, by acid-phosphatase staining (demonstrating endogenous enzyme activity in 
Iysosomes, Van Rooijen et aI., 1989). Briefly: 20 mg naphthol AS-BI phosphate (N-
2250, Sigma) was dissolved in 2 ml NN-dimethylformamide and mixed with 10 ml 
barbital buffer (O.15M pH 10) and 24 ml aqua dest. 1.6 ml hexazotized 
pararosaniline (Sigma) was mixed with 1.6 ml 4% NaNO, solution and added to the 
barbital-substrate solution. The solution was hrought to pH 5.0 with IN HCI or IN 
NaOH. Slides were incubated horizontally at 37'C for 30 minutes (Van Rooijen et 
aI., 1989). COllb (complement receptor 3, Frei et aI., 1987; Ulvestad et aI., 1994) 
was revealed after incubation with Leu-IS (Becton Dickinson, CA, USA) followed by 
RAMPO and ABC in red. B-cells were demonstrated as described before (gerritse 
et al., 1994) with mouse-anti-human IgG/lgM directly labeled with horseradish 
peroxidase and revealed with ABC in red. 
EAE induction and nnti-gp39 injection 
EAE was induced according to a standard protocol in three groups (n= 18) of 
female SJLlJ mice (age 12-15 weeks) by two subcutaneous injections of 75 ltg, 150 
Itg or 300l'g PLP-peptide in the abdominal flanks. The PLP-peptide being amino-
acid sequence 139-151 of rat PLP (Oautigny et aI., 1985). Peptide synthesis was 
performed using f-moc amino-acids with the 9500 Milligen synthesizer according to 
standard protocols. The standard EAB induction procedure using this peptide, 
results in the development of acute EAB, clinically and pathologically identical to 
EAE induced using whole CNS myelin or MBP (Tuohy et aI., 1989; Sobel et aI., 
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1990). The emulsion contained per 100 III: 25 I'g Mycobacteria mberc"losis (H37RA, 
Difco) in 50 1'1 FCA and 37.5 I'g, 75 I'g or 150 I'g peptide in 50 /11 PBS. On day a 
and 2, each mice was injected intravenously with 200 III Bordetella pertussis suspen-
sion (10.1010 /ml PBS). Mice were injected intraperitoneally with 125 I'g hamster 
anti-gp39 Mabs (Noelle et aI., 1992; Van den Eertwegh et aI., 1993) in 200 1'1 PBS 
on days [0, 2 and 4], [4, 6 and 8] or [7, 9 and 11]. Mice of the control groups 
received 125 I'g normal hamster antibodies (Serva, Feinbiochemica) in 200 1'1 PBS. 
The severity of BAB clinical signs was evaluated each day and graded according to 
discrete criteria: Disability scale (DAS) units; grade a = no clinical signs, grade I = 
tail weakness, grade 2 = mild paraparesis and ataxia of the hind legs, grade 3 = 
severe paraparesis or ataxia of the hind legs, grade 4 = moribund, grade 5 = death 
due to EAE. Blood samples were obtained on days 4, 9, 14, 21, 31 and 40 by tail 
vein puncture. Sera were screened in a direct ELISA on the presence of anti-PLP-
peptide antibodies. 
ELISA 
PVC round bottom microtiter plates (Falcon) were coated with PLP-peptide 
(10 I,g/ml in phosphate buffered saline (PBS), 25 III/well) overnight at 4°c' 
Subsequently plates were pre-incubated for 30 min at 2YC with gelatine (0.5 mg/ml 
PBS) to prevent non-specific antibody binding. The plates were washed five times 
with PBS-G (0.1 mg gelatine/ml PBS) and incubated for 60 min at 25°C with serum 
dilutions. The plates were washed (5x) with PBS-G and incubated for 1 hr at 2YC 
with alkaline phosphatase labelled rabbit anti-mouse Ig (Dakopatts, Denmark) in 
PBS-G. After the plates were washed (5x) with PBS-G, 50 1'1 of a para-nitrophenyl-
phosphate (Boehringer, Germany) solution (1 mg/ml 10 mM diethanol-amine, 1 mM 
MgCI" pH 9.8) was added to the wells. After incubation for 30 min at 25°C the 
absorption was determined at 405 nm. 
Results 
Detection of CD40-Iigand' TIl-cells 
As figure 1a shows, CD40-ligand' cells were detected in CNS tissue sections 
of MS patients (n= 12). Cells were shown to be of the Th phenotype by double 
staining for CD4 (data not shown). In control CNS-tissue sections of normal 
individuals (n=5) or of Alzheimer patients (n=5), no cells stained with CD40-Ig 
fusion protein were observed ( I b). Similar CD40-ligand bearing cells could he 
demonstrated in cryosections of EAE mice with either CD40-Ig fusion protein 
(crossreactivity of CD40-Ig and MR1 in mouse-immunochemiS!IY was shown before, 
Van den Eertwegh et aI., 1993) or the anti-CD40-ligand antibody MRI (Ie, day 12 
after induction of disease). CD40-ligand bearing cells were found in white matter 
lesions and not outside these lesions nor in control animals. 
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Detection of CD40 beadng cells 
In figure la-i serial sections of a representative perivascular infiltrate in a 
cryosection of MS-brain are shown. From figure Id it is clear that a majority of the 
infiltrating cells bears CD40. From our previous study on anti-MBP antibody 
production in MS brain (Gerritse et a!., 1994) we would have expected these cells to 
be CD40 bearing B-cells, however, only few cells (10-20%) were B-cells. Staining for 
either acid phosphatase (If-g) and CDllb (lh) showed that most CD40 bearing cells 
belonged to the monocytic lineage. Only very few of these cells were detected in 
control cerebrum tissue sections. 
Prevention of EAE by anti.CD40-ligand Mab 
Administration of PLP peptide resulted in a dose dependent (more intense 
with increase of peptide dose) induction of severe EAE. After EAE induction with 
75 I'g or 300l'g PLP-peptide (data of 150l'g not shown), control mice, or those 
receiving irrelevant hamster antibodies, showed a significant bodyweight reduction 
(25%-30%) from day eleven until day seventeen (figure 2, 3, upper panels, shaded 
bars), the first clinical signs of EAE becoming apparent on day eleven. 
Severe disease (most animals moribund Of dead) was induced with all peptide 
doses. The highest average DAS SCOfe of the control groups was 3.6 observed on 
days 16 - 23 (figure 3, middle panel) and a SCOfe of 2.3 was observed on days 15 -
22 (figure 2, middle panel) in animals in which EAE was induced with 300l'g or 75 
Ilg PLP peptide, respectively. Strikingly, no bodyweight reduction was observed in 
animals which were treated on days 0, 2 and 4 with 125 I'g anti-CD40-ligand Mab, 
irrespective of the peptide dose used for disease induction (figure 2, 3, upper panels, 
black bars). 
Even more dramatic, MRI treated animals showed only minimal or no 
clinical signs at both doses of PLP-peptide used for EAE induction (figure 2, 3, 
middle panels, note: no Of only very low black bars). Clinical signs in the anti-CD40-
ligand treated mice were only found when EAE was induced with the highest dose 
(300 /lg) PLP-peptide, and disappeared on day 31, whereas clinical signs of the 
control group remained severe (figure 3, middle panel). 
In control animals, anti-PLP-peptide serum antibody responses were observed 
from day 9 until day 40, with maximum responses on day 14 (titer = 1433) and 21 
(titer = 2710) after EAE induction with 75 I'g or 300l'g PLP-peptide respectively. 
In contrast, anti-PLP-peptide antibody responses in animals treated with CD40-
ligand Mabs on days 0, 2 and 4 were severely delayed and decreased, with highest 
levels on day 31 (titer = 571) and 40 (titer = 1034) after EAE induction with 751'g 
and 300l'g PLP-peptide respectively (figure 2, 3, lower panels). 
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Figure 1 
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Figure 1 (previous page) 
I" vivo evidence for involvement of CD40·CD40-ligand interactions in EAE and MS. 
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CD40-ligand positive cells No CD40-ligand positive CD40-ligand positive cells, 
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(plaque) in human MS- brain tissues from "normal" in mouse brain during EAE. 
brain. controls or other 
neurological disease 
(OND). Shown here is a 
representative section of 
Alzheimer-hrain. 
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Effect of anti-CD40-ligand treatment during disease. 
Treatment with anti-CD40-ligand Mabs around day 6 and day 9 after EAE 
induction with 150,tg PLP-peptide still resulted in blockade of disease by 80% and 
67% respectively as compared to the complete inhibition (100%) in animals treated 
with anti-CD40-ligand Mabs around day 2 (figure 4). Of the animals treated with 
anti-CD40-ligand none died due to EAE. In control animals the first EAE clinical 
signs (and death) were found already on day 11. 
Discussion 
This study provides evidence that CD40-ligand-CD40 interactions are involved 
in development of experimental allergic encephalomyelitis in mice and multiple 
sclerosis in man. Functionally, treatment of mice with antibodies against CD40-ligand 
both prevented development of disease (prophylaxis) and dramatically suppressed 
clinical signs when treatment was started after onset of disease (therapy). 
Histologically, cells expressing CD40 and CD40-ligand were found in the 
perivascular infiltrates in the CNS of both EAE-mice and MS-patients, but not in 
control tissues. Double staining procedures revealed that the majority of CD40-
expressing cells in human MS-brain were cells of the monocytic lineage, while a 
minority belonged to the B-cell subset. Finally, juxtaposition of CD40- and CD40-
ligand-expressing cells ill situ was demonstrated, indicative of ongoing cellular 
interactions. 
The interaction between CD40-ligand on activated CD4+ T-cells and CD40 
on B-cells has previously been shown to be indispensable for antibody responses 
against thymus dependent antigens. CD40 ligation by CD40-ligand induces B-cell 
proliferation, expression of several other activation markers, isotype switching, 
antibody production, as well as formation of germinal centers and B-cell memory 
(reviewed in: Durie et aI., 1994). However, recent data indicate that the CD40-
ligand-CD40 axis is involved not only in humoral immunity, but in development of 
some autoimmune diseases as well. For instance, anti-CD40-ligand treatment can 
prevent collagen-induced arthritis (Durie et aI., 1993) and lupus nephritis (Mohan et 
aI., 1995) in mice. These data prompted us to evaluate the functional role of CD40-
ligand-CD40 interactions in MS and in EAE as a model for MS. 
Figure 2 (next page) 
Prevention of EAR induced wilh low quautHy peptide, using nntl-CD40-ligand Mab. 
EAE was induced with 7514g PLP-peplide in female SJL/J mice (n=6) according to a standard 
procedure. Animals were treated with anti-gp39 Mabs on days 0, 2 and 4 (black bars). Control mice 
received normal hamster antibodies on the same days (shaded bars). The effect of anti-gp39 Mab 
treatment was monitored by determination of the body weight (upper panel) by evaluation of clinical 
signs (middle pallel) and by determination of serum anti-PLP-peptide antibody responses by standard 
direct ELISA (tower panet). 
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In view of earlier studies on antibody specificity of B-cells (putatively bearing 
CD40) in MS brain (Gerritse et aI., 1994) and considering the functional data 
obtained in this study, a role for the CD40-CD40-ligand axis in EAE and MS 
seemed apparent. Consequently, we evaluated whether both these molecules were 
expressed in EAE and MS. Cells expressing CD40-ligand could be found in 
perivascular infiltrates of CNS tissue of both EAE mice and MS patients, but not in 
control tissues. Frequencies of CD40M ligand expressing cells in these infiltrates were 
modest. This is in accordance with frequencies of CD40-ligand+ cells induced in the 
spleen by immunization of mice with thymus dependent antigen (TNP-KLH). In this 
system, approximately one CD40-ligand positive cell was found per 12 KLH-specific 
B-cells (Van den Eertwegh et al., 1993). In view of the above and the fact that this 
interaction is absolutely essential for antibody production it is evident that few T~ 
cells can very efficiently ligate with, and trigger, numerous CD40 bearing cells. 
Cells expressing CD40 were abundantly present in perivascular infiltrates of 
MS-brain. Using acid phosphatase and CDllb (CR3) as markers for 
monocytes/macrophages and microglia (Bauer et aI., 1994; Eikelenboom, 1978; Frei 
et aI., 1987; Ulvestad et aI., 1994), it was shown that CD40 expression was for the 
large majority restricted to cells of the monocytic lineage, while B-cells formed a 
minority of the CD40+ population. 
To functionally assess the role of CD40 and its ligand we blocked this cognate 
interaction ill vivo by intravenous administration of anti-CD40-ligand antibody. In the 
EAE-model in mice, treatment with anti-CD40-ligand MAb during disease onset 
(day 0-4) completely prevented development of disease. Indicating that CD40-ligand-
CD40 interactions play an important role in the induction phase of EAE. 
Development of antibody responses against the PLP-peptide used for immunization 
was delayed by anti-CD40-ligand treatment, but not completely blocked. This 
indicates that despite intact B-cell function at later time points after anti-CD40-
ligand treatment, EAE does not develop. Either B-cell responses are not crucial to 
disease induction (as discussed above relatively few B-cells were found in the 
infiltrates), or B-cells/antibodies become unable to induce disease after a critical 
susceptible period. 
FIgure 3 (previous page) 
Prevention of RAE induced nith high dose peptide, using Rnti-CD40·lIgand MRb. 
EAE was induced with 300 )~g PLP-peptide in female SJLjJ mice (n=6) according to a standard 
procedure. Animals were treated with anti·gp39 Mabs on days 0, 2 and 4 (black bars). Control mice 
received normal hamster antibodies on the same days (shaded bars). The effect of anti-gp39 Mab 
treatment was monitored by determination of the body weight (upper panel) by evaluation of clinical 
signs (middle panel) and by determination of serum anti-PLP-peptide antibody responses by standard 
direct ELISA (lower panel). 
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Figure 4 
Effect of delayed anU·gp39 treatment on FAE. 
EAE was induced with 150llg PLP-peptide in female SJLjJ mice (0=6) according 10 a standard 
procedure. Animals were treated with anti-gp39 Mabs on days [0, 2 and 4J, (4, 6 and 8] and [7.9 and 
11] (shaded bars). Control mice received normal hamster antibodies on the same days (black bars). 
TIIO cffect of antl-gp39 Mab treatment was monitored by evaluation of clinical signs. The cumulative 
DAS scores from day 12 ulltil day 28 of mice treated with gp39 on days 0, 2 and 4 was set at 100 % 
EAE suppression, Cumulative DAS scores from day 12 until day 28 of the other groups were related 
to this percentage. 
Importantly, delayed treatment with anti·CD40·ligand MAb, initiated shortly 
before maximum clinical disease score is reached, leads to ne3I·~total suppression of 
disease (figure 4). These results indicate that CD40·ligand·CD40 interactions are not 
only important in the induction phase but in the active phase of EAE as well, 
thereby providing a target for therapy as well as for prevention. As a consequence, 
this implicates that the development of this inflammatory disease of the CNS is 
dependent on continuous or repeated CD40-ligand·CD40 interactions (as shown for 
humoral responses against Hmodel" antigens; Van den Eertwegh et ai., 1993). 
What effector mechanisms are induced by CD40·CD40-ligand interactions in 
the CNS during EAE and MS? The immunocytochemical data discussed above 
clearly showed that the majority of CD40·bearing cells were macro phages or 
microglia. In addition, a small subpopulation of CD40+ cells belonged to the B·cell 
lineage. Consequently, CD40·ligand·induced functions of both macrophages/ 
microglia and B·cells should be considered.. With respect to B·cells, antibodies 
specific for or crossreactive with myelin components MS may be involved in the 
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process of demyelination in EAE, inflicting direct damage or acting through 
alternative mechanisms, like antibody dependent cellular cytotoxicity (ADCC). It has 
been shown that sera from guinea pigs with EAE can induce or enhance the 
breakdown of the myelin sheath, which surrounds the neuronal axons, in the eNS of 
syngeneic recipients (Bourdette et aI., 1986). In addition, intravenous injection of 
anti-myelin oligodendrocyte glycoprotein MAbs in Lewis rats with EAE resulted in 
augmentation of both clinical signs, inflammation and demyelination (Lassmann et 
aI., 1988). Willenborg and coworkers (1986), have also demonstrated a role of B-
cells in initiation of disease. We have previously found limited numbers of MBP 
specific plasma cells in the CNS of MS-patients and EAE-rhesus monkeys (Gerritse 
et aI., 1994). However, in view of the relatively limited (when related to the total 
number of infiltrating cells) number of CD40+ B-cells in lymphoid infiltrates of MS-
brain, the anti-PLP antibodies found even after anti-CD40-ligand treatment, and the 
convincing evidence that EAE can be adoptively transferred by T-cells, but not by B-
cells (Ben-Nun and Cohen, 1982; Swanborg, 1983), a role for B-cells in development 
of disease seems unlikely at present. 
This leaves macrophages/microglia (CDllb+, acid phosphatase containing 
cells: see figure ld-h) in perivascular infiltrates as the CD40-bearing population 
crucial to disease development. Consistent with this possibility, Huitinga et al. (1990) 
have elegantly demonstrated that macrophages are required for development of 
EAE in rats. What macrophage effector mechanisms contributing to inflammation 
and/or demyelination in the CNS may be activated trough CD40 triggering? 
Alderson et al. (1993) have shown that CD40 triggering of human monocytes 
induced tumoricidal activity, and in presence of appropriate cytokines, TNF-alpha, 
IL-6 and IL-8 was produced. In addition, Wagner et al. (1994) found IL-I after 
CD40 triggering, and production of IL-12 by human monocytes was reported by Shu 
et al. (1995). Finally, Tian et a!. (1995) demonstrated that murine splenic 
macrophages synergize with cytoldnes to enhance nitric oxide (NO) production. It is 
obvious that these compounds may directly contribute to inflammation and 
neurological dysfunction. In this respect it is of note that antibodies against IL-12 
prevent development of EAE in mice. It remains to be determined which of these 
compounds are actually produced ill vivo in response to CD40-CD40-ligand 
interactions, and what their relative contributions to disease development are. 
How does treatment with anti-CD40-ligand antibody prevent disease 
development and suppress established disease? As we discussed before (Foy et aI., 
1994), anti-CD40-ligand does not induce unresponsiveness by a direct cytotoxic effect 
on T-cells. This notion is supported by findings that anti-CD40-ligand treatment does 
not delete T-cells, nor does it affect their helper function. In addition, anti-CD40-
ligand treatment does not affect the frequencies of IL-2, IL-4 and IFN-gamma 
producing cells ill silll (Van den Eertwegh et al., 1993). Collectively, these 
observations and the current study suggest that amelioration of EAE by anti-CD40-
ligand treatment may result from direct blocking of interaction of CD40-ligand on 
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activated T-cells with CD40 on monocytes/macrophages and microglial cells. 
Alternatively, anti-CD40-ligand antibody may induces Th-cell unrespon-
siveness in EAE by interference with the CD40 related expression of co-stimulatory 
molecules on antigen presenting celis, resulting in impaired antigen presentation. 
Although speculative at this time, the results of other studies support this hypothesis 
in view of the fact that the blocking of interactions between B7 family members and 
their ligands ;n vivo induce a state of allo-specific T-cell unresponsiveness (Tan et 
aI., 1993). Therefore, receptors like CD40, of which the triggering was shown to 
regulate the expression of B7.1 and perhaps B7.2 (De Simone et aI., 1995; Tan et 
aI., 1993) might play an important role in controlling tolerance and immlmity. 
Although further details of the mechanism(s) of action are clearly needed, the 
co-localization of CD40-bearing macrophages/microglia and CD40-ligand-bearing 
cells in affected CNS tissue of patients suggests that CD40-CD40-ligand may play an 
important role in the immunopathology of multiple sclerosis. In analogy to the 
results obtained in EAE, blockade of CD40-ligand-CD40 interactions should be 
considered as a method to interfere in MS as well. Preventing CD40-ligand-CD40 
interactions is potentially useful in limiting duration, intensity and neurological 
damage of disease exacerbations. A significant advantage of CD40-ligand as a target 
for intervention is its transient expression restricted to activated CD4+ T-cells. This 
feature allows targeting of only those T-cells actively participating in the response, 
and not affecting the population of T-cells at large. 
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CHAPTER 4.1 
THE USE OF LACTOBACILLUS AS CARRIER 
FOR THE ORAL DELIVERY OF ANTIGENS 
Introduction 
Live transformed microorganisms can be appJied as antigen carrier for the 
oral delivery of antigens, provided that these organisms are able to carry the antigen 
to the proper sites of antigen presentation. The presentation of antigens to the 
immune system via the oral route may result in either the induction of an immune 
response or in immunological nonRresponsiveness. In other words, due to the oral 
delivery of antigens by microorganisms, the individual will be vaccinated, i.e. a 
cellular and/or humoral immune response wiH be developed upon a subsequent 
presentation of the same antigen, or the individual will be tolerized against the 
administered antigens. This chapter summarizes the basic understandings concerning 
oral vaccination and tolerization and describes the principles of the use of 
microorganisms as antigen delivery system. The use of Lactobacillus as a live antigen 
carrier device will be compared to other microorganisms as potential antigen 
carriers. 
The mucosal immune system 
The mucosal immune system compdses the lymphoid tissues which are 
associated with the gut (GALT, gut associated lymphoid tissues), the respiratory 
tract (BALT, bronchus associated lymphoid tissues) and several other organs with 
mucosal surfaces like the saHvary- and lacrimal gland and reproductive system. In 
general the mucosal immune system is the first protection system against 
environmental pathogens. The local mucosal immunity is relatively independently 
regulated from the systemic immunity. While the systemic immune response is 
characterized by antibodies of the IgM and IgG classes, the mucosal immune 
response is characterized by the production of IgA, which represents more than 60% 
of all antibody isotypes produced (Mestecky and McGhee, 1987). The IgA 
immunoglobulins are released along the mucosal surfaces and bind to foreign 
antigens. The exposure of an antigen at one mucosal site leads to immunological 
protection after a renewed exposure to the same antigen even when presentation 
occurs at a distant mucosal surface. Therefore it has been postulated that all 
mucosal surfaces form an integral specialized lymphoid system. 
The intestinal mucosal immune system spans a large surface area and 
comprises the Peyer's patches and lymphocytes in the lamina propria. An ingested 
antigen will only be presented to the intestinal mucosal immune system after it has 
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crossed the intestinal epithelial cells. Several methods of intestinal antigen uptake 
can be distinguished. I) A non-specific antigen uptake is possible via disrupted tight 
junctions between epithelial cells, this route of antigen uptake especially occurs in a 
damaged gut. II) Non-specific antigen uptake can occur at the tip of the microvilli 
on the epithelial cells due to endocytosis. III) Some epithelial cells, the microfold 
(M) cells, are especially adapted for IgA mediated transport of antigens from the 
intestinal lumen to the intestinal lymphoid cells. The M cells can facilitate the 
transport of both antigens in solution and particulate antigens. Antigen uptake of M-
cells does not result in degradation, but instead in delivery of intact antigen to 
lymphoid cells (Wolf and Bye, 1984). IV) Receptor mediated specific antigen uptake 
is possible, but for a limited number of antigens only, e.g. cholera toxin. 
Oral tolerance 
Ingested food antigens in healthy subjects usually do not evoke an immune 
response but achieve the opposite effect, i.e. the individual will become tolerant to 
the ingested antigens. The term oral tolerance refers to a state of systemic 
unresponsiveness to parenteral immunization which is induced by previous antigen 
feeding. Several mechanisms have been proposed to account for this peripheral 
unresponsiveness: clonal deletion (Jones et a\., 1990), clonal anergy (Whitacre et a\., 
1991) and specific suppression (Lider et a\., 1989). 
Oral tolerance for both 11lImoral and cellular immunity has been 
demonstrated in animals fed with several antigens (Kagnoff, 1978; Challacombe and 
Tomassi, 1980). Furthermore it has become clear from studies with experimental 
autoimmune diseases like collagen induced arthritis (Nagler-Anderson et a\., 1986), 
experimental autoimmune uveitis (Nussenblatt et a\., 1990) and experimental 
autoimmune encephalomyelitis (EAE) (Higgins and Weiner, 1988) that these 
experimental diseases could be prevented, delayed or decreased by feeding antigens 
prior to disease induction with the same antigen. These results support the idea that 
it might be possible to exploit oral tolerance in the treatment of human autoimmune 
diseases as well. 
Autoimmune phenomena are considered to play an important role in the 
pathogenesis of multiple sclerosis (MS). As a consequence, most MS therapies are 
based on the modification of the immune response, However, apart from 
pharmaceutical immune suppression of inflammation, most MS therapy trials 
reported until now were ineffective in the treatment of the disease, Therefore one of 
the most promising new approaches also for MS therapy might be the oral 
administration of autoantigens, in order to turn the anti-self (non-tolerance) state 
into a state of specific tolerance. 
From several experiments, in which antigen specific tolerance was induced 
after oral administration of autoantigens (reviewed in Weiner et aI., 1991), some of 
the conditions to achieve oral tolerance induction as a therapy for human 
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autoimmune diseases can be derived. Induction of tolerance has been shown to be 
dependent on I) the antigen dose, II) the duration of antigen administration (Strober 
et a!., 1981; Sjovall and Christensen, 1991) and III) the age of the individual (Van 
Hoogstraten et a!., 1991; Miller et a!., 1994). IV) Upon oral administration antigens 
are degraded to some extent when passing the gastfOM intestinal tract. Therefore, 
autoantigens need to be protected from degradation to be effective (Thompson and 
Staines, 1990). V) Large quantities of purified human autoantigens would be needed 
to satisfy the demand for therapy, once adequate regimens have been established. 
The use of microorganisms for oral tolerance induction 
Thus far in experimental protocols to induce oral tolerance, purified antigens 
were used which were orally administered in a pulse like fashion by feeding at 
regular intervals. An ideal therapy however should consist of a continuous 
production and presence of the autoantigen at the site of tolerance induction, i.e. 
the GALT. By using genetically transformed live microorganisms as antigen delivery 
system these demands could possibly be fulfilled. The oral administration and 
subsequent colonization of microorganisms-autoantigen constructs might realize the 
continuous presence of an autoantigen producing unit in the gastro-intestinal tract. 
This offers a number of advantages over traditional oral administration of 
autoantigens: I) no bulk purification of human proteins is necessary, II) autoantigens 
are released continuous and not in a pulse way manner, 1II) therapy call be 
restricted to a single or only few administrations of the autoantigen producing unit 
and iv) degradation during the passage of the gastrointestinal tract will be 
circumvented. 
Oml vaccination 
The administration of vaccines is generally used as a form of 
immunoprophylaxis. Vaccination wiB realize immunological protection even a long 
time before the organism is exposed to a infectious organism. The processes 
involved in the generation of the protective properties of the organism after 
infection are based on two components. The first component, the adaptive system, 
which include B-cells and T-cells, will replicate, differentiate and maturate only after 
stimulation with antigen. The second lInon~adaptivell component include factors like 
interferons and complement and cells like macrophages, monocytes and natural 
killer cells, which are involved in non-antigen specific processes. Since B-plasma and 
T-effector cells have a short lifespan, the generation of an immunological memory is 
a necessarily requirement to obtain a continuous protection. The duration of the 
protection obtained against infectious organisms is dependent on the nature of the 
antigen. Some vaccines will induce a live long protection while others will induce 
protection with a restricted duration. Furthermore, the duration of the protection is 
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dependent on the degree to which an infectious organism is able to change its 
antigens. 
To induce an immunological memory, the above mentioned adaptive and 
non-adaptive components of the immune system have to be stimulated by 
administration of the antigen of interest. The antigen can be administered in many 
way's but of all routes the oral route is the most convenient route of vaccination as 
compared to the more frequently used parenteral routes, especially in vaccination 
programs in which large numbers of subjects are involved. One of the advantages of 
an "oral" vaccine is that the administration needs not to be carried out by a trained 
medical staff. Furthermore the number of drop outs, those subjects who do not 
receive their booster injection, will be reduced since the booster vaccine can be 
provided, together with clear user instructions, simultaneously with the first 
administration. In addition, special equipment like sterile needles, disinfectants, 
autoclaves or repeating injectors are not necessary and concomitant risks on co-
infections due to the usage of this injection equipment are prevented. 
The use of microorganisms for oral vaccination 
A newly developed technique to deliver antigens to the immune system for 
vaccination purposes, is the use of microorganisms as antigen delivery vectors for 
immunizations. The underlying idea is that by using transformed microorganisms, 
which expose heterologous proteins, antigens will be delivered to the immune system 
in such a way that a protective response is triggered against the target pathogen. 
The strains of microorganisms used are usually genetically attenuated mutants of 
pathogenic bacteriae (the carrier) transformed to express a genetic construct (the 
vector) designed to obtain an adequate expression of antigens from other pathogens. 
Such carriers can then be used as a local antigen producer thereby circumventing 
expensive purification processes. It is to be expected that the right choice of carriers, 
vectors and antigens may lead to the desired protective immunity. 
Most work done so far involved the use of Sa/mollella thyphimtlriwn (Stabel 
et aI., 1991) and Sa/molle//a ellteridittls in animals and Sa/mollella typhi (Van de 
Verg et aI., 1990) in man. Attenuated Sa/molle//a typhi strains can serve as live oral 
vaccines to prevent typhoid fever. In an efficiency field trial carried out in 
Alexandria, Egypt, approximately 32.000 school children were randomized to receive 
orally three doses of the vaccine (10' organism) or placebo. During three years of 
surveillance a vaccine efficiency of 96% against culture confirmed typhoid fever was 
recorded (Wah dan et aI., 1982). Attenuated Sa/mollel/a strains have also been used 
as carrier for hepatitis B virus antigens. Other bacteria which are potentially useful 
as carrier include strains of Escherichia (Hale, 1990), Mycobacteria, Shigella, Vibrio 
cholerae and Yersinllia. However, most transformed microorganism used for oral 
immunization are recognized as pathogen and their use as antigen carrier may be 
limited. For this reason the use of a GRAS (Generally Recognized As Save) 
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organism, such as Lac/obacillus, as a safe antigen carrier for the delivery of foreign 
antigens in the gastrointestinal tract of animals and humans is to be preferred. 
Lactobacillus 
Lactobacillus represents a major genus of the lactic-acid bacteria, a diverse 
group of microorganisms, that produce lactic acid as the major end product of 
metabolism. Members of this genus are known, in the first place, for their 
widespread use in various food and agricultural fermentation processes (Chassy, 
1985; 1987) and secondly for ill supposed health promoting (probiotic) properties. 
This makes Lactobacillus a ve~1 attractive candidate for use as delivery system of 
antigens by oral administration. In addition, it has been demonstrated that oral 
administration of specific Lactobacillus strains is positively correlated with reduction 
of serum cholesterol levels (Tannock et a!., 1989), detoxification of potential 
carcinogens (Fernandez et a!., 1987; Gorbach et a!., 1990), stimulation of the host 
non-specific immunity (adjuvanticity; Bloksma et a!., 1979; Boersma et a!., 1994) and 
inhibition of the outgrowth of nicroorganisms causing infectious diseases (Perdigon 
et al., 1986c; 1988). However, the underlying mechanisms for the probiotic 
properties of Lactobacillus h"e not been explained satisfactory (Pauwels et al., 
1992). In addition, Lactobacillus can maintain a stable population in both animal and 
human gut (Perdigon et a!., 1986c; 1988; Chassy, 1985; 1987; Gorden and Golbach, 
1979; Kleeman and K1aenhammer, 1982), they possess a low intrinsic 
immunogenicity as compared to other microorganisms (Forrest, 1988; Carlsson and 
Bratthall, 1985) and Lactobacilli have mucosal adhesive properties (Lencner et a!., 
1987). 
Several genetic transformation procedures for expression of human proteins 
in Lactobacilli are available. It has become possible to transform virtually any 
Lactobacillus species with plasmid vectors. Lactobacillus casei, Lactobacillus 
plautamm, Lactobacillus pellloslIs, Lactobacillus aciriophillls, Lactobacillus /ennellt1l11l 
alld Lactobacillus brevis can be transformed routinely with plasmid vectors, making 
use of the electroporation technique (Posno et a!., 1991a; Pauwels et aI., 1992). 
Shuttle-vectors which replicate in both Escherichia coli and Lactobacillus and vectors 
which replicate in Lactobacillus only, have been constructed previously (Posno et a1., 
1990; 1991a). All Lactobacillus vectors appear to be structurally very stable. With 
regard to segregational instability it appears, that some Lactobacillus vectors are 
stable while others are not (Posno et a!., 1991b; Leer et a!., 1992). In addition, 
vectors have been constructed which allow directed insertion at a specific site in the 
chromosome, warranting stable maintenance and expression of the cloned gene. This 
technique also allows the replacement or a directed inactiva tion of a specific 
Lactobacillus gene (Leer et a!., 1993). 
These results indicate that Lactobacillus strains are potentially useful 
candidates to be employed as live antigen carriers/producers which can be used as 
102 
Lactobacillus as antigen canier 
vaccines or used to induce tolerance after oral administration. 
Lactobacillus as antigen carrier 
As was described in the preceding section the use of Lactobacillus as a live 
antigen carrier for oral administration offers a number of advantages as compared 
to the use of other microorganisms as antigen carrier or to traditional feeding of 
antigens. However, in order to establish the feasibility of the use of Lactobacillus as 
antigen carrier many questions have to be answered. Two prerequisites for the 
development of Lactobacillus as an oral antigen carrier system can be distinguished. 
A) The availability of gene-transfer and gene-expression systems for 
Lactobacillus for the introduction and efficient expression of homologous and 
heterologous proteins of interest. It is of prime importance to develop food grade 
(stable expression) vectors, since by definition food grade vectors may be applied for 
use in humans. Food-grade vectors are characterized by a nutritional selection 
system, homologous DNA and by the absence of an antibiotic resistance marker. As 
a consequence, the use of Lactobacilli which have been transformed with foodgrade 
vectors makes it possible to distinguish endogenous from experimental Lactobacilli 
upon analysis of gut content. Several experiments have already been performed 
concerning the development of food grade vectors. A number of genes involved in 
D-xylose catabolism (xyl-genes) in Lactobacillus pellloSlis were cloned and 
characterized (Lokman et a!., 1991). Sequences involved in (regulation) of 
expression of D-xylose catabolism encoding genes were identified. A Lactobacillus 
expression-vector was constructed by inserting a xyl-gene promoter and a xyl-gene 
terminator (separated by a multiple cloning site) in one of the Lactobacillus vectors 
previously constructed (Posno et a!., 1991b). Furthermore, expression of a 
heterologous model gene, i.e. Escherichia coli lacZ gene, in Lactobacillus was 
established and neutralizing epitopes from FMD virus fused to Escherichia coli lacZ 
were expressed making use of these vectors. 
B) Presentation of the appropriate genetically manipulated Lactobacillus to 
the immune system in such way that, dependent on the application, mucosal 
immunity as weU as a systemic memory response is generated or immunological 
tolerance is induced. Although much work already has been performed concerning 
the production of antigens by food grade vectors, it is unknown in what wayan 
orally administered Lactobacillus strain has to present the antigens to the immune 
system. There are several methods of antigen presentation possihle: 1) the antigen is 
expressed by the Lactobacilli and secreted in the gut, 2) the antigen is released from 
the cytoplasm of the Lactobacilli upon death and cytolysis in the gut, or 3) the 
antigen is expressed on the surface of the Lactobacilli and is presented by either live 
or dead organisms to the GALT. 
When using Lactobacillus as antigenic carrier of tolerogenic Of immunogenic 
fragments it is important to reveal the most efficient route of antigen presentation. 
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For this purpose transformed Lactobacillus strains with the above mentioned 
different antigen presentation systems have to be developed. 
In the next chapters we address a number of questions concerning the use of 
Lactobacillu .. "i as a new generation of vaccines for infectious diseases. We have 
determined the efficacy of Lactobacilli-antigen constructs to generate peripheral 
immunological memory after oral administration (chapter 4.2). In chapter 4.3, we 
have investigated the localization and routing through the immune system of 
Lactobacillus associated antigens which were orally administered. In addition, in 
chapter 4.4 we have investigated the possibility to enhance immunological non-
responsiveness, making use of oral administered Lactobacillus associated antigens. 
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CHAPTER 4.2 
ORAL ADMINISTRATION OF TNP·LACTOBACILLUS 
CONJUGATES IN MICE: A MODEL FOR EVALUATION OF 
MUCOSAL· AND SYSTEMIC IMMUNE RESPONSES AND 
MEMORY FORMATION ELICITED BY 
TRANSFORMED LACTOBACILLI 
K Gerritse, M Posno', MM Schellekens, WJA Boersma and E Claassen 
TNO Prevelltioll alld Health, Leidell, The Netherlallds 
'TNO Nllfritioll alld Food Research, Rijswijk, The Netherlallds 
Res Microbial 141:955-962, 1990 
Summary 
Safe live vectors systems are developed for oral delivery of antigens. For this 
we developed gene-transfer and expression systems in Lactobacillus species. Model 
systems were set up to evaluate immune responses. Orally administered 
trinitrophenylized Lactobacillus were examined for their ability to induce 
immunological memory formation via determination of specific antibody titers in 
serum. We demonstrate a direct correlation between the level of the systemic 
memory formation, as revealed by specific anti-TNP JgG serum antibodies, and the 
TNP substitution ratio of the Lactobacillus suspension used for oral priming. The 
specific IgG anti-TNP serum titers were comparable to or even higher than the titers 
of parental (i.p.) primed animals. These results demonstrate the feasibility of using 
orally administered antigen-Lactobacillus as a future approach to vaccination. 
Introduction 
Especially in vaccination programs in which large numbers of subjects are 
involved, the oral route of administration is very convenient as compared to the 
more frequently used parenteral routes. It has been shown that oral immunization 
can result in an adequate local expression of IgA responses in various mucosal 
tissues and secretions (Goldblum et aI., 1975; Mestecky, 1987; Nedrud et aI., 1987), 
the systemic antibody response, however, generally appears to be only moderate 
(even when high doses of antigens are applied). This may partly be due to digestical 
processing resulting in loss of immunogenic potential of the antigen. When a 
suboptimal amount of antigen reaches the mucosal immune system an adjuvans is 
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required to evoke or enhance the immune response. The efficiency of oral 
immunization may be improved by delivery of antigenic material to the mucosal 
surface by appropriate antigen carrier systems. It has been well documented that 
transformed microorganisms can be used as such carriers. However, most of the 
microorganisms currently used (e.g. E. coli, S. mlltalls, S. typili; Leclerc et a!', 1989; 
Chatfield et aI., 1989) are recognized as pathogens and their acceptibility for 
practical application may be limited. For this reason, the use of a GRAS (Generally 
Recognized As Safe) organism as a delivery vector is to be preferred. We have 
recently started to evaluate oral administration of lactobacilli expressing cloned 
foreign antigenic determinants as a means of antigen delivery to the gastrointestinal 
tract. The use of non-pathogenic Lactobacillus, a GRAS microorganism offers some 
major advantages. Lactobacillus is able to pass the tractus digestivus and, in some 
cases, is able to maintain a stable population in the gut (Savage, 1983) probably due 
to mucosal adhesive properties (Lencner et aI., 1987). Furthermore, Lactobacilllls 
strains have been shown to possess intrinsic adjuvans activity (Perdigon et a1., 
1986a), to activate peritoneal macrophages and mononuclear phagocytes (Perdigon, 
1986b,c). and they show a low intrinsic immunogenicity (Carlsson and Bratthall, 
1985) in comparison with other microorganisms e.g. Sa/mal/ella typili (Forrest, 1988). 
To develop a safe (non-pathogenic) live vector antigen delivery system we 
recently initiated investigations on: (1) development of gene-transfer and gene-
expression systems for the introduction and efficient expression of antigens in 
Lactobacillus species which are (natural) inhahitants of the gastrointestinal tract and 
(2) immunological evaluation and optimization of the immune responses (mucosal 
and systemic) that are generated through presentation of Lactobacilllls-associated 
antigens by the oral route. 
Material and methods 
Transformation procedure 
Lactobacillus cells were cultivated in MRS medium (Difco) in the presence of 
1 % (w/v) glycine (for cultivation of L.casei glycine was ommited). Electroporation of 
lactobacilli was carried out with the "Gene Pulser ControHer" from Bio-Rad. Briefly, 
1 J.'g plasmid DNA, cesiumchloride gradient purified, was added to 50/_d of a chilled 
suspension of (mid-log phase) Lactobacilllls cells (± lOW. mI") in 0.3 M sucrose, 5 
mM Na-phosphate pH 7.4 and 1 mM MgCI, in a 0.2 cm-gap disposable cuvet. 
Electroporation was carried out at 6250 V.cm-' with a parallel 200 ohm resistor and 
a capacitance of 25 J.'F. Following the pulse, the cell suspension was directly diluted 
with 450 J.'I MRS medium. Transformants were selected by plating the cell 
suspension on MRS-agar plates containing 10 J.'g.ml-' chloramphenicol. 
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Carrier/adjuvans properties of Lactobacillus 
After aerobic incubation at 37°C overnight the organisms were harvested by 
centrifugation at 3640 g for 15 min at room temperature and resuspended in PBS 
(lxlOlO CFU.ml"). Subsequently the suspension was heat killed for 30 min at 60'C, 
In order to obtain different TNPILactobacillus substitution ratios 1000, 500, 
50, 20, and 5 1'1 of a 2,4,6 trinitrophenyl sulfonic acid (TNBS) solution in PBS (20 
mg.ml" ) was added to 1 ml Lactobacillus suspension (53 mg.ml" PBS). The 
suspensions were incubated for 1 h at foom temperature in complete darkness, 
washed 3x and resuspended in 1 ml PBS. The Lactobacillils-TNP suspensions were 
coded according to the quantity of TNBS solution added (table 1). Prior to 
immunization the suspensions were diluted in 0.2 M NaHCO, (100 I'l.ml") for oral 
and in PBS (200 III.ml")for i.p. administration. Trinitrophenylated ovalbumin was 
used for the detection of anti-TNP antibodies in a direct ELISA. TNBS (100 mg) 
was added under gentle stirring to 100 mg ovalbumin in 10 ml borate buffer (0.1 M, 
pH 9.0). The solution was incubated in the dark for 2 h at room temperature, and 
dialysed against PBS. 
Immunization 
Lactobacillus-TNP conjugates were orally administered three times on 
alternating days to groups of four female mice (BALB/c 12-15 weeks Old). All oral 
administrations contained 500 I'g Lactobacillus, based on dry weight, suspended in 
500 1'1 0.2 M NaHCO,. Four weeks after the last oral administration, the mice were 
boosted i.p. with 500 I'g TNP-Lactobacilllls conjugate suspended in 250 III PBS. 
Control groups were both i.p. primed and boosted with the same TNP-Lactobacillus 
conjugates as the test groups. Three, five and seven day's after the last oral 
administration or i.p. prime injection and after the booster injection, blood samples 
of the mice were collected by bleeding of the tail vein. The sera were screened for 
anti-TNP and anti-Lactobacillus antibody (Ab) reactivity by a direct ELISA (table 1). 
Table 1 
Immunization scheme. 
PRIME 
Immunization route: oral oral oral oral oral ora) i.p. i.p. 
suspensions*: 1000 500 50 20 5 a 50 50 
no. of administrations: 3 3 3 3 3 1 1 
BOOST 
Immunization route: i.p. i.p. i.p. i.p. i.p. i.p. i.p. 
sllspensions*: 50 50 50 50 50 50 50 
no. of administrations: 1 1 1 1 1 1 
>Ie TNP-Lactobacillus ratio of the suspensions is indicated in "Materials and methods". 
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Direct ELISA 
Anti-TNP titers were determined in PVC microtiter plates coated with TNP-
ovalbumin (5 Ilg.ml" PBS, 50 "I/well) overnight at 4'C. Non occupied space was 
blocked with gelatine (5 mg.ml", 50 "I/well), 30 min at 25'C. After washing with 
gelatine in PBS (0.1 mg.ml") the plates were incubated for one hour at 25'C with 
dilutions of TNP-induced-antisera and pre-immune control sera. Then the plates 
were washed and incubated for 1 h at 25'C with either alkaline phosphatase labelled 
goat anti-mouse IgA, IgM or IgG (KPL, Inc., Gaithersburg, USA) and para-nitro-
phenyl phosphate (Boehringer, Mannheim, FRG) as the substrate. After 30 minutes 
the absorption was determined at 405 nm in a Titertek Multiskan (Flow, Irvine, 
Scotland). 
The anti-Lactobacillus serum titer was determined on preactivated 
polystyrene microtiterplates (NUNC). Plates were incubated 2 h at 56'C with 
glutaraldehyde (0.025% in Na,CO, 0.1 M, pH 9.0; lOOl'l/well; Baker, grade 25% in 
H,O). The plates were washed with gelatine (0.1 mg.ml" in PBS) and dried for 15 
min at 56'C. A suspension of Lactobacillus (10 Ilg.ml" Na,CO, (0.1 M, pH 9.0)) was 
added to the wells (100 III/well) and incubated overnight at 4'C. After incubation, 
the ELISA was performed exactly as was indicated for the TNP-ovalbumin coated 
microtiter plates. 
Results 
Gene~transfer system 
Most Lactobacillus strains have been shown to contain one or more plasmids 
(i.e. Nes, 1984; Vescovo et aI., 1981). We have isolated a 1.8 kb (cryptic) plasmid 
from L.p/alltamlll ATCC 8014 and subsequently introduced a chloramphenicol 
resistance gene into a unique restrictionsite of this plasmid. The resulting vector, 
designated pLP825 (table 2) was used to transform a number of Lactobacillus 
strains. 
Table 2 shows the results of electroporation experiments with representative 
strains of three indigenous Lactobacillus species of the intestinal microflora and, as a 
positive control, a L.casei strain which can be efficiently transformed following this 
technique by plasmid DNA (Chassy and Flickinger, 1987). L.acidophilus, 
L.fennelltulIl, L.brevis strains are transformed with pLP825 with about equal 
efficiency. Compared to the control strain, the efficiency of transformation is at least 
three orders of magnitude lower. Plasmid DNA analysis revealed that all 
transfonnants harboured an extra plasmid indistinguishable from pLP825 used 
originally for transformation (not shown). 
Serum antibody titers 
After immunization with Lactobacillus-TNP only in the Lp. primed animals a 
specific antibody response (IgM) was observed (figure 1). Nevertheless we recently 
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Table 2 
Transformation of Lactohacillus with plp825(1) by electroporation. 
Strain(') 
L.casei ATCC 393 
L.acidophilus NCK89 
L.fennellmm NCK127 
L. brevis VK3 
Transformation efficiency(3) 
10'_10' 
10'_103 
10' 
10' 
(1) The E.coli-Lactobacillus shuttle veClor pLP825 consists of pBR322, the emf gene of the 
Staphylococcus allreus plasmid pC194 and a 1.8 kb cryptic plasmid from L.plofllamm ATCC 8014 
(Posno et al., 1988). 
(2) The origin of L.acidophilus NCK89 and L.[ermellfllm NCK127 has been described before 
(Muriana and KJaenhammer, 1987; Barefoot and KJaenhammer, 1983). L.brevis VD was kindly 
provided by Dr. R. Havenaar (eIVO-TNO, Zeist, The Netherlands). 
(3) Expressed as the number of colony forming units per p.g DNA 
showed that oral priming resulted in specific anti-TNP responses as determined by 
detection of specific antibody forming cells in tissue sections (Gerritse et aI., 1991a). 
No specific anti-TNP and anti-Lactobacillus serum antibodies of the 19A isotype 
could be detected after both oral administration and i.p. booster (results not shown). 
Oral administration and subsequent i.p. booster injection resulted in a specific 
anti-TNP as well as a specific anti-Lactobacillus response, except for those animals 
which were immunized with the suspension with the lowest TNP/Lactobacillus ratio 
or with the non-conjugated hacteria suspension (figure 2). 
The majority of the antibodies specific for TNP and Lactobacillus are of the 
IgG isotype. The specific IgG and IgM responses of the orally primed and i.p. 
boosted animals (suspension 50) are of similar strenght as compared to the specific 
responses of the mice immunized twice i.p. with the same conjugate. In this 
experiment it is shown that the specific anti-TNP response is dependent on the 
Lactobacilll/s-TNP ratio of the suspension used for oral administration. The anti-
Lactobacillus responses, in all boosted mice, are of the same magnitude. 
Discussion 
A basic requirement for the introduction of foreign antigens in Lactobacillus 
is the availability of a reliable transformation protocol. Our results demonstrate that 
different Lactobacillus species can be stably and reproducibly transformed with the 
E.coli-Lactobacilllls shuttle-vector pLP825 by making use of the electroporation 
technique. Apparently, this replicon of L.p/all/antln is also functional in Lactobacilll/s 
species which occur in an entirely different ecological niche. The efficiency of 
110 
The sera of the mice were screened for specific anti-TNP and anti-Lactobacillus Ab's in a direct 
ELISA on a coating of ovalbumin-TNP and Lactobacillus respectively. Alkaline phosphatase labelled 
goat anti mouse IgM and IgG Ab's and para-nitro-phenylphosphate as substrate were used for 
detection, TIle resulls of 1:50 dilutions of sera collected on day seven after priming are shown, 
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Figure 2 
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TIle sera of the mice were screened for specific anti·TNP and anti-Lactobacilllls Ab's in a direct 
ELISA on a coating of ovalbumin-TNP and Lactobacillus respectively. Alkaline phosphatase labelled 
goat anti mouse IgM and IgG Ab's and para-nitro-phenylphosphate as substrate were used for 
detection. TIle results of 1:50 dilutions of sera collected on day seven after Lp. booster injection are 
shown. 
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transformation is strain-dependent and may vary from a few transfonnants to up to 
more than 10' transformants per I-'g DNA (table 2). This implies that shotgun 
cloning in Lactobacillus, at least in some strains, has come within reach now. To 
date relatively little is known of (heterologous) gene in expression in Lactobacillus. 
Therefore, our current molecular biological research is directed to the generation of 
fundamental insights in gene expression in Lactobacillus and to the construction of 
different Lactobacillus expression systems for the (over)production of homologous 
and heterologous proteins. 
The present study demonstrates that orally administered Lactobacillus-TNP 
evoke a specific anti-TNP antibody response in serum, as could be concluded from 
the IgG serum titers after booster injection. There was a direct relation between the 
anti-TNP antibody titers and the Lactobacilllls-TNP substitution ratio of the orally 
administered Lactobacillus. However, a minimal TNP load on the bacterial 
membrane is essential, otherwise memOlY formation fails to occur, as could be 
revealed from the serum antibody titers of the animals which were immunized with 
the suspension with the lowest TNP/Lactobacillus ratio. 
No detectable specific IgA antibodies were demonstrated in the sera both 
after prime and booster injection. The majority of the 19A precursor cells are 
derived from Peyer's patches (Craig and Cebra, 1971, Husband and Gowens, 1978). 
After stimulation they migrate into the circulation and develop into cells with 
cytoplasmic IgA (Rollx et a!., 1981). From the circulation these cells distribute over 
the mucosal tissues with a preference for the organ in which they were induced 
(Pierce and Cray, 1982). Restimulation of these cells by Lp imunization is not likely 
to occur. That IgA antibodies were not detected in the sera could also be due to the 
use of a heat killed Lactobacillus suspension. The underlying mechanisms which 
causes the differences in immune responses between replicating and non-replicating 
antigens upon oral administration are not yet fully understood (Wold et a!., 1989). 
Usually non-replicating (dead) antigens, like food-antigens, do not induce a specific 
IgA response. This was confirmed for Lactobacilli as carriers. The presence of TNP-
specific antibody producing cells was demonstrated in the spleen and mesentherial 
lymph nodes, the latter in limited numbers only, on day 5 and 7 after the last oral 
administration. However, no antibodies were found in the sera. The anti-
Lactobacillus responses in all immunized mice were of the same magnitude since all 
animals were immunized with the same dose of Lactobacillus. 
It is surprising and important to notice that oral administration of hapten-
Lactobacillus conjugates led to a level of immunological memory formation which is 
of similar magnitude to the level of memory formation in i.p. immunized mice. 
Although it remains uncertain whether the immunological memory formation is due 
to the adjuvans capacities Of the vehicle properties of Lactobacillus, the results of 
this study open new possibilities to use the non pathogenic Lactobacillus as a 
potential vaccine carrier. Experiments with transformed Lactobaci/(lis are in 
progress. 
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CHAPTER 4.3 
MUCOSAL IMMUNE RESPONSES AND SYSTEMIC 
IMMUNOLOGICAL MEMORY AFTER ORAL 
ADMINISTRATION OF TRINITROPHENYL 
LACTOBACILLUS CONJUGATES IN MICE 
K Gerritse, M Posno·, MJ Fasbender, MM Schellekens, 
WJA Boersma and E Claassen 
TNO Prevelltioll alld Healtlt, Leidell, Tlte Netlter/allds 
"TNO Nlltritioll alld Food Researclt, Rijswijk, The Netlterlallds 
Lymphatic Tissues and ill vivo Immune Responses 84:497-504, 1991 
Summary 
Lactobacillus can be used to deliver antigens via the oral route to the immune 
system to generate a humoral immune response to antigens which are associated to 
the bacterial membrane. This chapter describes the ronting of Lactobacillus associ-
ated antigens and the ill sim localization of antigen specific AFCs in lymphoid 
organs, after both oral administration and intraperitoneal injection of a Lac/ohaemus 
associated model antigen, trinitrophenyl. The data discussed here show that at least 
a part of the TNP-Lactobacillus, is transported directly to the mesenteric lymph 
nodes (MLN), as could be concluded from the presence of antigen-complexes in 
MLN tissue sections. 
Introduction 
The oral route is a very convenient route of vaccination in comparison with 
the more frequently used parenteral routes, especially in vaccination programs in 
which large numhers of subjects are involved. In addition, the activation of the 
mucosal immune system as well as systemic responses can be obtained by oral 
application of antigens. Although this sometimes results in an adequate local 
expression of immunoglobulin A (IgA) responses in various mucosal tissues and 
secretions (Mestecky, 1978), the oral administration is generally very inefficient, 
requiring large quantities of immunogen and yielding only modest systemic antibody 
responses. With regard to numerous pathogens, a local response only is not 
sufficient and a systemic response obligatory. 
Owing to a digestive processing, many antigens loose their immunogenic 
potential. A suboptimal amount of antigen reaches the mucosal immune system and, 
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therefore, requires an adjuvant to evoke or enhance the immune response. 
Transformed microorganisms can be used as antigen carriers, but most of these 
microorganisms (e_g., Escherichia coli, Streptococcus Inutalls, Sa/mollel/a typM; 
(Leclerc et al., 1989» are generally recognized as pathogens and are not acceptable 
for general application. In this respect, the use of a GRAS (Generally Recognized as 
Safe) organism like Lactobacillus may be preferred. 
The use of Lactobacillus as a vector antigen delivery system has several other 
potential advantages over other microorganisms besides the above mentioned GRAS 
status, Lactobacillus, in mammals, is able to pass the digestive tract and colonize in 
the gut. In addition, adjuvant properties of Lactobacillus have been described 
(Perdig6n et aI., 1986c). As for many other microorganisms, it is possible to produce 
transformations of Lactobacillus with foreign deoxyribonucleic acid (DNA). Strains 
of Lactobacillus which produce a foreign antigen epitope, which is expressed on the 
membrane surface or is secreted intra~ or extrace]]u]arly, can be constructed. 
Considering the findings mentioned above, we recently initiated investigations 
on: (a) development of gene-transfer and gene-expression systems for the 
introduction and efficient expression of antigens in Lactobacillus species which are 
(natural) inhabitants of the gastrointestinal tract, and (b) immunological evaluation 
and optimization of the immune responses (mucosal and systemic) that are 
generated through presentation of Lactobacillus-associated antigens by the oral 
route. 
The aim of the work presented here was a comparative study on the effects 
of Lactobacillus administered by the oral or peritoneal route on the generation of 
the systemic response. To evaluate this a small llapten, trinitrophenyl (TNP), 
coupled to Lactobacillus was used for oral immunization purposes, serum titers were 
determined, and lymphoid tissues were screened for specitJc antibody forming cells 
(AFCs). 
Although life antigen carriers are more immunogenic at mucosal surfaces 
than nonreplicating antigen carriers (Lycke and Holmgren, 1986), most live antigen 
carriers have an undesirable potentiation of an immune response to a large number 
of bystander antigens found in the gastrointestinal tract. For this reason, the 
Lactobacillus microorganisms were heat killed prior to trinitrophenylization. 
Furthermore, B10ksma et al. (1979) revealed that viable Lactobacillus 
microorganisms stimulate exclusively delayed hypersensitivity, whereas heat-killed 
bacteria had an adjuvant effect on antibody formation. The potential use of 
Lactobacillus as a antigen carrier system will be discussed. 
Material and methods 
Cultivation of Lactobacillus 
Lactobacillus acidophilus (strain NCK89) was grown on Man Rogosa Sharp 
(MRS) broth (Difco, Detroit, Michigan, USA). After aerobic incubation at 37°C 
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overnight, the organisms were harvested by centrifugation at 3640 g for 15 min at 
room temperature and resuspended in phosphate-buffered saline (PBS) (lx101O 
CFU.ml-'). Subsequently the suspension was heated for 30 min at 60°C, 
Conjugation 
In order to obtain TNP-Lactobacillus conjugate, 501'1 of a 2,4,6-trinitrophenyl 
sulphonic acid (TNBS) solution (20 mg.ml-' PBS) was added to 1 ml Lactobacillus 
suspension (53 mg.ml-' PBS). The suspension was incubated for 1 hr at room 
temperature in the dark, washed, and resuspended in 1 ml PBS. The TNP-alkaline 
phosphatase (TNP-AP) conjugates were obtained essentially according to the 
method of Claassen and Van Rooijen (1984). 
Trinitrophenylated ovalbumin was used for the detection of anti-TNP 
antibodies in a direct enzyme-linked immunosorbent assay (ELISA). The TNBS (100 
mg) was added under gentle stirring to 100 mg ovalbumin in 10 ml borate buffer 
(0.1 M, pH 9). The solution was incubated in the dark for 2 hr at room temperature, 
and dialyzed against PBS. 
Immunization 
Lactobacilllls-TNP conjugates were orally administered three times on 
a Iternating days to groups of female mice (Balb/c 12-15 weeks old). Each oral 
administration contained 500 IIg Lactobacillus suspended in 500 III 0.2 M NaHCO, 
to neutralize hydrochloric acid in the stomach and reduce degradation of the antigen 
determinants to a minimum (Black et aI., 1983). Four weeks after the last 
administration, the mice were boosted orally three times on alternating days. Control 
groups were both i.p. primed and boosted with 500Jtg TNP-Lactobacilllls conjugates 
suspended in 250 1'1 PBS. The mice were sacrificed 3, 5, 7 and 21 days after the last 
oral administration or i.p. prime injection and five day's after the last booster 
administration or booster injection. Blood samples of the mice were cal1eeted by 
heart puncture. The sera were screened for antiRTNP and antiRLaclobacillus 
antibody (Ab) reactivity. The spleen (SP) and mesenteric lymph nodes (MLNs) were 
removed and stored in liquid nitrogen. Tissue sections of the organs were screened 
for anti-TNP specific AFCs and antigen trapping. 
Direct ELISA 
Polyvinyl chloride (PVC) microtiter plates (Titertek, Flow Laboratories, 
IIvine, Scotland) were coated with TNP-ovalbumin (5 IIg.ml-' PBS, 50 III/well). To 
block nonspecific binding a second coating of gelatine (5 mg.ml-', 50 III/well) was 
applied. The plates were incubated for 1 hr at 25°C with dilutions of TNP-induced 
antisera and preimmunization sera to correct the TNpMinduced antisera for 
background reactivity. Sera dilutions were added to three separate plates. The plates 
were washed and separately incubated with either alkaline phosphatase-labelled 
goat-antimouse IgA, IgM or IgG (H + L) (KPL, Inc., Gaithersburg, Maryland, USA) 
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1:2000 in PBS. After washing 50 1'1 para-nitrophenylphosphate (Boehringer, 
Mannheim, West Germany) solution (1 mg.ml·!) in 10 mM diet hanoi amine (1 mM 
MgCI" pH 9.8) was added to each well. Alter 30 min, the absorption at 405 nm was 
determined. 
The anti-Lactobacillus serum titer was determined on glutaraldehyde-
preactivated polystyrene microtiterplates (NUNC, GIBCO Europe, Breda, The 
Netherlands). The ELISA was performed as was indicated for the TNP-ovalbumin 
coated microtiter plates. 
Tissue preparation and immunocytochemical staining 
Mice were sacrificed by CO2 euthanasia, SP and MLNs were removed and 
snap frozen in liquid nitrogen. Eight micrometer cryostat tissue sections were fixed 
for 10 min in acetone containing 0.02 % (v/v) hydrogen peroxidase. For 
determination of the antigen specificity of the APCs in MLNs or SP, tissue sections 
were incubated overnight with TNP-AP dilutions in 0.1 % bovine sera albumin 
(BSA) in PBS (w/v). The AP activity was revealed according to the method of 
Burstone (1958) with some modifications (Claassen et aI., 1986d). 
Trapped Lactobacillus conjugate was detected in a two-step staining 
procedure. Slides were incubated overnight at 4°C with purified rabbit anti-
Lactobacillus Abs (2 mg.ml"!) diluted 1/15 to 1/50 in a solution of BSA (1 mg.ml"! 
PBS). Alter washing, the slides were incubated for 60 min at RT with goat-antirabbit 
IgG-horseradish peroxidase (HRP) conjugate diluted 1/100 in a solution of BSA (1 
mg.ml"! PBS) and normal mice sera (1% v/v). The HRP activity was revealed as 
described previously (Claassen et aI., 1986). 
Results 
ELISA analysis of the sera antibody titers 
In both oral- and intraperitoneal primed animals, a specific anti-TNP 
antibody response (IgM) was observed with a peak level on day 7 after prime. Only 
in the intraperitoneal primed mice, a low IgM anti-Lactobacillus response was 
detected (figure 1). No specific anti-TNP and anti-Lactobacillus serum antibodies of 
the IgA or IgG isotype could be detected after both oral or Lp. prime. In both 
groups, the booster administration Of injection resulted in a specific anti-TNP as well 
as a low specific anti-Lactobacillus response (figure 2). Immunoglobulin G is the 
prevailing isotype of the anti-TNP and anti-Lactobacillus antibodies after boost in 
both groups. In the oral boosted animals, also a significant anti-TNP IgA response 
was detected. The anti-TNP IgG response of the orally primed and boosted mice is 
of similar strength as compared to the specific anti-TNP IgG response of the 
animals immunized twice i.p. 
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Figure 1 
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Sera of the mice were screened for specific anti-TNP and anti-Lactobacillus Abs in a direct ELISA 
on a coating of ovalbumin-TNP and Lactobacillus, respectively. Alkaline phosphatase-labelled goat-
anti mouse JgA. JgM and IgO Abs and para-nitrophenylphosphate as substrate were used for 
detection. The results are shown of 1:50 dilutions of sera collected on days 3, 5, 7, and 21 after 
prime. 
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Figure 2 
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Analysis of serum anti-TNP and anti-Lactobacillus antibodies in ELISA The assay conditions arc as 
indicated for figure 1. The results are shown of 1:50 dilutions of sera collected on day 5 after booster 
injection or last booster administration. 
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Figure 3 
MLNs and SP of the animals, fed with a suspension of TNP-Lactobacillus conjugate, were removed 
on day 5 after the last oral prime administration. Tissue sections of mesentherial lymph nodes (a) 
and spleen (b) were stained with TNP-AP conjugate. 
Table 1 
Time: Immunization: oral i.p. oral Lp. 
(days) Tissue: MLN MLN SP SP 
3 0 0 3.4 1.7 
5 1.4 0 7.9 6.2 
7 1.2 0 3.1 5.1 
21 0.4 0 2.0 2.1 
Number of specific anti-TNP antibody-forming cells in MLNs and SP tissue sections after oral or 1.1" 
priming. The number of AFO was calculated per square mm! on day 3, 5, 7 and 21 after 
immunizHtion, Cells were detected by TNP-AP staining. 
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Immunocytochemical Detection of TNP.Specific AFCs 
In the spleens of both the oral- and intraperitoneal-immunized mice, specific 
anti·TNP antibody·forming cells were detected on all sample day's (figure 3). The 
number of AFCs in the spleen sections is of the same magnitude in both groups 
(table 1). Specific AFCs in the MLNs are only observed in the oral·primed 
animals (figure 3). The greatest number of AFCs were found in the tissue sections 
of the MLNs removed on day 5 after the last oral administration. Antigen trapping 
in immune complexes was observed in MLN tissue sections of the oral immunized 
animals by staining with TNp·AP (see figure 3). The antigen trapping was verified 
by staining alternating tissue sections with anti·Lactabacilllls antibodies (results not 
shown). The immune complexes were detected in the lymphoid follicles; this 
observation is in accordance with the normal localization of immune complexes as 
reviewed by Van Rooijen et al. (1989). 
Discussion 
In a previous study we demonstrated that orally administered TNP· 
Lactobacillus conjugates evoke a specific anti·TNP IgG antibody response in serum 
after an i.p. booster injection (Gerritse et aI., 1990b). We now demonstrate that oral 
priming followed by an oral booster administration also results in a specific anti-TNP 
response, as could be revealed from the serum IgG antibody titers. This response 
was of the same magnitude as the antibody response in serum of the animals 
immunized twice i.p. This implies that an anti·TNP response is equally effective 
elicited by oral administration of TNP·Lactabacilllls conjugates as by 
Lp.immunization. In addition, the enumeration of the antiRTNP AFCs in tissue 
sections of the spleen led to similar results. 
To get similar levels of serum antibody responses, it is necessarily to 
administrate orally three times the Lactobacillus conjugate. Oral administration of 
the TNpRLactobacillus conjugate only once or twice is not sufficient to evoke a 
specific response (results not shown). This could be explained in two ways. One 
possibility is that only a small part of the total amount of TNP-Lactobacilllls reaches 
the mucosal epithelium and is only partly internalized by either the epithelium cells 
or the specialized M cells, whereas the greater part passes the digestive tract. 
Another possibility is that when antigens enter the mucosa, they mainly stimulate 
IgA precursor lymphocytes owing to the fact that the greatest population of B cells 
in the GALT are IgA lymphocytes. For this reason, it is not surprising that there is a 
larger amount of antigen needed to stimulate the relatively small population of non-
IgA lymphocytes. 
Only in the sera of the orally boosted mice was a specific IgA response 
observed. In previous experiments, no IgA response was observed after oral priming 
subsequently followed by an i.p. booster injection, suggesting that IgA-producing 
lymphocytes can only be restimulated via the oral route. 
121 
Chapler4.3'-------------------------
The occurrence of an IgA response could be explained in two ways. The 
majority of the IgA precursor cells are derived from Peyer's patches (Craig et aI., 
1971). After these cells are stimulated for the first time they migrate via the MLNs 
and thoracic duct into the circulation. Finally, they return to the mucosal tissues with 
a preference for the organ they were initially stimulated by (Pierce et aI., 1982). 
After restimulation, the greater part of the Abs produced will be excreted as 
secretory IgA in the intestinal lumen, whereas a small amount will be released as 
monomeric IgA to the circulation. Alternatively, it is possible that a part of the 
precursor IgA cells do not return to the mucosal lymphoid tissues after the first 
stimulation but remain in the MLNs. Since trapped TNP-Lac/Obaci/lus could be 
detected in the MLNs after oral immunization, restimulation might occur. 
Determination of the isotype of the specific AFCs in the MLN which occur during 
the time coarse between prime and boost could help to clarify this issue. 
In both groups, low IgM and IgG and no specific IgA anti-Laclobacillus 
responses were measured after boost. This observation confirms the low intrinsic 
antigen properties reported by other investigators (Carlsson and Bratthall, 1985). 
The low responses could be due to the use of a heat-killed Laciobacilllls as carrier. 
Usually, life antigens induce better immune responses than non replicating antigens 
(Fuhrman and Cebra, 1981). 
When antigens are internalized in the mucosal tissue it is believed that 
antigen is processed by antigen-presenting cells and subsequently presented to T 
lymphocytes or B lymphocytes in the lamina propria or Peyer's patches, respectively. 
In this study, it has been shown that at least a part of the TNP-Lactobacilllls, 
whether or not processed, is transported directly to the MLNs, as could be 
concluded by the presence of antigen complexes after staining with TNP-AP and 
anti-Laclobacillus in alternating MLN tissue sections. 
The low intrinsic antigenic properties of the Lactobacillus together with the 
observation that oral prime and booster administrations led to a comparable specific 
antibody response obtained after i.p. immunization suggests the possible usage of the 
Lactobacillus as an antigen carrier for oral immunization purposes. 
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CHAPTER 4.4 
LACTOBACILLUS AS A VECTOR FOR ORAL DELIVERY OF 
ANTIGENS: THE ROLE OF INTRINSIC ADJUVANTICITY 
IN MODULATION OF IMMUNE RESPONSES 
K Gerritse, K Maassen, R Leer*, D Heemskerk, 
WJA Boersma and E Claassen 
TNO Prevention and Health, Leiden, 11/e Netherlands 
'TNO Nutrition and Food Research, Rijswijk, 111e Netherlands 
Submitted for publication 
Summary 
The influence of the adjuvant activity of Lactobacillus strains on the activation 
or tolerization of the immune system was investigated. Lactobacillus plall/anlln 80, 
transformed to produce Escherichia coli fi~galactosidaseJ were orally administered to 
BALBlc mice, prior to intraperitoneal challenge with purified Jl-galactosidase. In 
animals fed with Jl-galactosidase producing Lactobacillus plantan/III 80 a suppression 
(up to 64%) of the anti Jl-galactosidase serum responses was observed after 
subsequent antigen injection. The data presented in this study show that oral 
administration of an antigen by Lactobacillus pla1lfanOl1 80, a strain with relatively 
low adjuvant properties can lead to the induction of a state of peripheral tolerance. 
The influence of oral administration of a Lactobacillus strain, wHh relative 
high adjuvant activity, mixed with antigen, on an immune response induction with 
development experimental autoimmune encephalomyelitis (EAE) in mice as a read 
out system was also investigated. A suspension of Lactobacillus casei ATCC393 and 
antigen was administered orally, prior to disease induction with the same antigen. 
The simultaneous oral administration of Lactobacillus casei ATCC393 and antigen 
resulted in a significant enhancement of the immune response. 
The results of this study indicate' that dependent on strain specific 
adjuvanticity Lactobacillus are potential candidates for the oral delivery of immune 
potentiating signals as well as for the induction of peripheral immunOlogical non-
responsiveness against putative autoantigens in human autoimmune diseases. 
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Introduction 
Oral administration of antigens may lead to a systemic antigen specific IgG 
antibody response, without a significant IgA response (Gerritse et aI., 1990b; 1991; 
Peri et aI., 1982). However, dependent on specific conditions, oral administration of 
antigens can either induce a relative state of specific immunological non-
responsiveness to a subsequent parental challenge with the same antigen (Vaz et aI., 
1977; Miller and Hanson, 1979; Thompson and Staines, 1990; Brod et aI., 1991) or 
may lead to the production of antigen specific secretory JgA antibodies at the 
intestinal mucosa and other distant mucosal sites (i.e. respiratory and genital tract). 
It is generally assumed that the presentation and processing of tolerance 
inducing and immunogenic proteins are the same. This suggests that there are 
certain additional requirements/conditions which determine, whether the immune 
system will be stimulated Of will reach a certain state of tolerance. Experiments 
performed by Melamed and Friedman (1993) showed that a single intra-gastric 
delivery of ovalbumin induced a transient form of tolerance. Pulsed oral 
administration of ovalbumin, one single administration per day, for 14 days was not 
able to induce tolerance in mice. CBA and SWR/J mice, aged 2-3 months, were only 
tolerized, when antigen was administered semi-continuous, i.e. throughout the day by 
voluntary ingestion (Stokes et aI., 1983). In addition, it was demonstrated that the 
semi-continuous oral administration of small amounts of antigen is an effective 
condition for the induction of tolerance (Saklayen et aI., 1984; Heppell and Kilshaw, 
1982). Genetically modified microorganisms can be used for the continuous 
production of antigens. Genetically modifjed microorganisms which colonize the 
gastrointestinal tract after a single or perhaps a few oral administrations, may 
effectively fulfil the requirements for an oral tolerance inducing delivery system. 
It has been shown that Lactobacillus can maintain a stable population in both 
animal and human gut (Savage, 1977; Pouwels and Leer, 1993; Chassy, 1987; 
Perdigon et aI., 1988) and lactobacilli have mucosal adhesive properties (Lencner et 
al., 1987). In previous studies we have shown oral administered Lactobacillus to be 
very efficient as antigen presenting vehicles (Gerritse et aI., 1990b; 1991a). 
Furthermore, gene transfer and expression systems for an efficient production of 
foreign antigens by a variety of Lactobacillus species have been developed recently 
(Posno et aI., 1991a; Pauwels et aI., 1992). In addition, Lactobacillus exhibit a low 
intrinsic immunogenicity as compared to other microorganisms (Carlsson and 
BraUhall, 1985) and the presence of Lactobacillus in the gastro-intestinal tract can 
inhibit outgrowth of microorganisms causing infectious diseases (Perdigon et at, 
1986c; 1988). Taking together, these data indicate that Laclobacillus might be a 
convenient microorganism to be used as antigen carrier and producer 
simultaneously, for delivery of antigens to the immune system by the oral route. 
In this paper we describe two types of experiments to study the effects of oral 
administration of antigens on the immune system. For this purpose we used two 
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Lactobacillus strains, which differ in their adjuvant properties. First, we have studied 
the effects on the immune system of oral antigen delivelY and presentation using a 
Lactobacillus strain with relatively low adjuvant properties, in order to induce 
immunological tolerance. To this end, low levels of ll-galactosidase producing 
Lactobacillus pialltalll/ll 80 (LP80), were administered orally to mice. Serum anti-ll-
galactosidase antibody responses were determined after intraperitoneal challenge 
injections with J3-galactosidase. Subsequently, immune reactive or tolerant spleen 
ceJls were transferred to naive recipient mice and serum anti-fi-galactosidase 
antibody responses were determined after [I-galactosidase booster injection. The 
effects oral administration of antigen and a Lactobacillus strain with high adjuvant 
properties, Lactobacillus case; (L.easei), was studied in mice using an immune 
disease induction model. To this end EAE was induced in mice with an 
encephalitogenic proteolipid protein (PLP) peptide. Induction with PLP-epitope 
residues 139-151 results in the development of acute EAE, which is clinically and 
pathologically identical to EAE induced hy sensitization with whole CNS myelin or 
with MBP (Tuohy et aI., 1989; Sobel et aI., 1990). A suspension of L.casei, and the 
synthetically produced PLP T-cell epitope (Tuohy et aI., 1989) were simultaneously 
administered orally to mice. Subsequently, EAE was induced by immunization with 
PLP-peptide in adjuvant. The effects of the simultaneous oral delivery of the PLP-
peptide and high adjuvant strain L.easei on the course of disease, were monitored by 
evaluation of clinical characteristics. 
Material and methods 
Construction of LP80 producing E.coli n-galactosidase 
The Lactobacillus expression vector pLPCR2 (Forrest, 1988) was obtained by 
inserting the promoter of the xylR gene and the terminator of the xylB gene of 
Lactobacillus pel/tos/IS (separated by a multiple cloning site) in the Escherichia coli -
Lactobacillus shuttle-vector pLP3537 (Carlsson and Bratthall, 1988; Forrest, 1988). 
To construct pCBH72, the promoter of the .')'IR gene in pLPCR2 (Pouwels et aI., 
1992) was replaced by a fragment comprising the promoter of the conjugated bile 
acid hydrolase gene of Lactobacillus pialltanllll 80 (LP80) (Christiaens et aI., 1992) 
and the E.eoli IneZ gene was inserted into the multicloning site. 
LP80 was cultivated and transformed by electroporation as described 
previously (Christiaens et aI., 1992). LP80 transfonnants were selected on solid MRS 
medium supplemented with 10 flg/ml e.)'thromycin. ll-Galactosidase production was 
confirmed in the lysate of LP80 transfonm1llts by standard gel electrophoresis, 
immunological techniques and protein staining. /3-Galactosidase producing and non 
ll-galactosidase producing LP are designated LP80' and LP80- respectively. 
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Antigen administration by LP80+ and immunization 
Six groups of female BALBlc mice (10-12 weeks) received orally 0.05 (I), 0.1 
(II), 0.5 (III) and 1 (IV) mg dry weight LP80" I mg dry weight LP80- (V) or PBS 
(VI) only. The fj·galactosidase expression levels in LP80+ were approximately 1-2% 
of total protein contents. The estimated gastrointestinal passage time is about two 
days. To mimic a continuous delivery of antigens during a period of ten days, 
Lactobacillus administrations (500 fll) were repeated five times with a two day 
interval. At days 3 and 31 after the last oral administration all mice were boosted 
(booster injection I and II) i.p. with 8 fig fl·galactosidase in 200 III PBS (table 1). 
The amount of antigen (8 I'g) used for booster injection was a low dose of Jl-
galactosidase which is just sufficient to mount an anti~J3~galactosidase serum Ig 
response after an i.p. booster injection in low dose fi-galactosidase primed mice 
(data not shown). Serum anti-fi"galactosidase responses were determined in a direct 
ELISA. 
Transfer of spleen cells 
Mice were sacrificed by CO2 euthanasia and the spleens were removed. 
Erythrocytes were removed by standard ammoniumchloride treatment (Mishell et 
ai., 1980). Cells of individual spleens (500 fll) were injected i.v. in naive, 5 Gy 
irradiated, recipient female BALB/c mice (10-12 weeks old). Two days after cell 
transfer mice were boosted (III) by i.p. injection with 8 fig {i-galactosidase in 200 III 
PBS (table I). The sera were screened for anti·{i-galactosidase antibody reactivity in 
a direct ELISA. 
ELISA 
PVC microtiter plates were coated with {i·galactosidase (5 Itg.ml-', 50"l/well) 
overnight at 4°C. Subsequently free sites were blocked for 30 min at 2YC with 
gelatin (0.5 mg.ml-' PBS, 50/t1/well) to prevent non-specific antibody binding. After 
washing (5x) with PBS-G (0.1 mg gelatine/ml PBS) the plates were incubated for 60 
min at 25°C with dilutions of immune sera. The plates were washed (5x) with PBS-G 
and incubated with alkaline-phosphatase labelled goat anti-mouse Igtotal (i.e. IgG, 
IgM, IgA)(KPL, Inc., Gaithersburg, USA) for 60 min at 25°C. The plates were 
washed (5x) with PBS-G and incubated with paranitrophenyl phosphate (1 mg.ml·' 
10 mM dietanolamine, I 111M MgCI" pH 9.8) as enzyme substrate. After incubation 
for 30 min at 25°C the absorption was determined at 405 '1m. 
Peptide synthesis, purification and characterization 
The synthesis of the PLP-peptide was carried out with 9-
f1uororenylmethoxycarbonyl (f-moc) protected aminoacids, following the solid phase 
synthesis method (Merrifield, 1963) 011 an automated Milligen 9050 Continuous Flow 
Synthesizer (Millipore Co., Bedford, MA, USA). The PLP-peptide is a 13-mer 
aminoacid sequence analogue to residue numbers 139·151 of rat PLP (Dautignyet 
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Administration and immunization scheme 
booster I 
oral 
Administrations 
booster II booster Ill' 
_t~t~1 ~t~t~t~ ______________ _LI/\~I~I __ 
0246 8 11 41 V 02 
Days r 
transfer 
Table 1 
Administration and inuuunlzution lime schedule. 
Different doses of ,1-galaclosidase producing transformed Lactobacillus plalltamfJI 80 (LP80+) were 
administered to four groups of mice (A: 0.05 mg; B: 0,1 lUg; C: 0.5 mg; D: I O1g). Non-transformed 
Lactobacillus plantamm 80 (LP80-)(E: 1 mg) and PBS (F) only were administered to control groups, 
Subsequently mice were boosted twice (I, II) i.p. with /J-galaclosidase. Individual spleen cell 
suspensions were transferred to naive recipient mice. Recipient mice were boosted (III) with p. 
galactosidase two days after transfer. 
aI., 1985) sequence: NH2-His-Cys-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe-
COOH. Side-chains were protected: aspargine: 2,4,6-trimethoxybenzyl; histidine and 
cysteine: trityl; lysine: tertiar-butoxycarbonyl. Peptide cleavage and side-chain 
deprotection of the completed peptide were performed by trifluoracid treatment as 
presented earlier (Van Denderen et aI., 1987). Peptide purification was performed 
according to the method as was described by Shively (1986). Aminoacid composition 
of the synthetic peptide was confirmed by HPLC analysis according to the method of 
Janssen et a!. (1986). 
Oral administration of PLP-peptide and Lactobacillus casei ATCC393 
Female SJUj mice (12-15 weeks old, 8 mice per group) were pre-treated by 
oral administration of L.casei and PLP-peptide (group E and F), PLP peptide 
(group B and C), L.casei (group D) or PBS only (group A). To mimic a continuous 
delivery of antigens during a period of ten days, administration of suspensions or 
solutions (500 I" per administration) were repeated five times with a two day 
interval. PLP-peptide was administered in two amounts: 100l'g (group B and E) and 
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500 I'g (group C and F). L.easei suspensions, administered to mice of group D, E 
and F, contained 5.108 colony forming units. EAE induction was performed three 
days after the last oral administration. 
EAE induction 
EAE induction was performed by subcutaneolls injection at two sites in the 
abdominal flanks, with 150l'g PLP-pepticte emulsified in Freunds complete adjuvant 
(FCA)(100 Iii/injection). The emulsion contained per 100 /Ii: 25 I'g Mycobaeleria 
Illberell/osis (H37RA, Difco) in 501'1 FCA and 75 I'g peptide in 50 1'1 PBS. In 
addition each mouse was injected intravenously, on day 0 and 2, with 200,,1 
Bordelella perlllssis suspension (10.1010 in 1 ml PBS). The severity of EAE clinical 
signs was evaluated each day according to following criteria: Disability scale (DAS) 
grade 0 = no clinical signs, grade I = tail weakness, grade 2 = mild paraparesis and 
ataxia of the hind legs, grade 3 = severe paraparesis or ataxia of the hind legs, 
grade 4 = moribund, grade 5 = dead due to EAE. 
Results 
Oral antigen delivery 
A significant reduction in the anti-iJ"gaiactosklase sera responses was 
measured after the second booster injection in aU groups of mice pre-treated with p-
galactosidase producing Lactobacilli (figure 1). After booster injection I (for 
administration and immunization schedule see table 1) low anti-Ii-galactosidase Ig-
total serum responses were observed on all sample days (absorbance < 0.1 at 1/200 
serum dilutions). The anti-f3-galactosidase serum responses of the mice pre-treated 
with Ii-galactosidase producing Loctobacilli (groups I, II, III, and IV) did not differ 
significantly from the responses of the control groups (V and VI) (data not shown). 
After booster injection II the highest anti-Ii-galactosidase serum antibody responses 
were measured on day 8 (tlgure 1). The anti-p~galactosidase antibody responses 
(1/800 serum dilutions), of the animals which received 50, 100, 500 and IO00l'g 
transformed LP80' orally, were reduced with 64%, 51 %, 27% and 39% respectively 
as compared to the anti-p-galactosidase response measured in control animals. 
Post-transfer nnti-p-gnlactosidnse serum antibody responses 
A reduction of the anti-p-galactosidase responses was obseJVed after a 
subsequent booster injection (III) with Ii-galactosidase in three out of four test 
groups which received spleen cells of donor mice pre-treated with oral 
administrations of LP80+. The anti-p-galactosidase responses were most reduced in 
sera from mice, which received the spleen cells of donor mice orally pre-treated with 
a low dose of Ii-galactosidase producing LP80' (0.1 mg)(figure 2). The highest anti-
p-galactosidase responses were observed in mice which received spleen cells of 0.5 
mg Ii-galactosidase producing LP80' pre-treated donor mice. These latter animals 
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The anti fJ-galactosidasc serum antibody responses on day 0, 5, 8 and 14 after {J-galactosidase booster 
IT injection (table 1) were measured in a direct ELISA (see: Material and Methods). The results are 
exprcssed as the average absorbance at 405 nm of serum dilutions (11800) of three mice per group. 
The animals of the four lest groups orally received 50(1). 100(11), 500(111) and 1000 pg LP80+(IV) 
Lactobacillus plantanml respectively, prior to boosler fJ-galactosidasc Injections. The animals of the 
control groups received nOll transformed Lactobacillus plontamm (neg., V) or PBS (IV) only prior to 
booster /J-galaclosidase injections. 
showed the lowest reduction (27%) in anti'll-galactosidase antibody responses after 
booster injection II. In contrast to the other three groups, the anti-fl-galactosidase 
responses of this group of donor mice were not reduced as compared to the 
responses of both control groups of mice. 
Role of adjuvanticity of Lactobacillus case; on EAE induction 
Oral administration of Lac/obacillus casei only, prior to EAE induction (group 
D), resulted in EAE enhancement, as compared to the course of disease of animals 
which were not pre-treated with Lactobacillus casei (A, Band C) (administration 
and EAE induction schedule; see table 2). 
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The anti fJ-galactosidase serum antibody responsc.s on day 8 after post transfer j3-galaclOsidase 
booster injection (III) (table 1) were measured in a direct ELISA (see: Material and Methods). The 
resulls arc expressed as the average relative liters. The average liter of the control recipient animals 
which received the spleen cells of the PBS pre-treated donor animals was set at 100%. Standard 
deviations of the average relative Iilers are indicated. 
Animals which were pre-treated with PBS only (group A) followed by EAE 
induction developed a moderate form of EAE, with the highest average OAS score 
(1.38) at day 31. The peak levels of the OAS scores of animals of groups B (1.63) 
and C (1.75), which were pre-treated by oral administration of different doses of 100 
and 500 f.'g PLP-peptide prior to EAE induction, were reached on day 34 and 32 
respectively. During the entire course of the disease, the average DAS scores of the 
animals of groups B (lOO'lg) and C (lOOOllg) were higher as compared to the 
average OAS scores of the animals of group A. The oral administration of PLP-
peptide simultaneously with Lactobacillus casei (groups E (100 I'g) and F (5001Ig)) 
resulted in a synergistic enhancement of EAE (E and F vs 0). Peak levels of 
average OAS scores of the animals of group E (3.14) and F (3.38) were higher and 
were reached earlier as compared to groups B (1.63) and C (1.75), which received 
the same amount of peptide but no Lactobacillus casei (table 2). 
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Table 2 
Oral administration and EAE induction. 
Group code: A B C 0 E F 
Oral administration 
Solvent (5001'1): PBS PBS PBS PBS PBS PBS 
PLP-peptide (I'g): 0 100 500 0 100 500 
Dose Lactobacillus (CFU): 0 0 0 5.10' 5.10' 5.10' 
Number of administrations: 5 5 5 5 5 5 
EAE induction 
PLP-peptlde (j<g): 150 150 150 150 150 150 
Maximum OAS levels: 1.38 1.63 1.75 2.71 3.14 3.38 
Maximum levels on day: 31 34 32 32 29 30 
DisclIssion 
In this study we show that oral administration of fl-galactosidase producing 
Lactobacilli, with low adjuvant properties, induces a state of peripheral immune 
suppression. This state of peripheral immune suppression, which is reflected by a 
reduced anti-fi-galactosidase antibody response after a subsequent booster injection 
with ,B-galactosidase, is also significant after adoptive transfer of the spleen cells to 
naive recipient mice. Furthermore, the oral administration of Lactobacilli with high 
adjuvant properties, together with EAE inducing peptides, reslIlts in stimulation of 
the immune system as monitored by EAE disease enhancement. 
The oral delivery of the intact protein fl-galactosidase by LP80', prior to Lp. 
booster I and II injections with fl-galactosidase, induces a reduction in anti-fl-
galactosidase responsiveness. This may be interpreted as (incomplete) tolerance 
induction. The average anti-fi-galactosidase antibody response in animals which 
received 50 JIg transformed LP80' was reduced 64% after the second booster fl-
galactosidase injection, as compared to animals not receiving tolerance inductive 
pretreatment. The average anti-fl-galactosidase antibody responses were reduced 
52%, 27% and 39% in the animals which received orally IOOl'g, 500 I'g and lOOOl'g 
of transformed LP80+ respectively, after the second booster p-galactosidase injection. 
The obselvation that small amounts of orally administered antigen were more 
efficient in inducing non-responsiveness as compared to large amounts of oral 
Figure 3 (next page) 
Oml udmlnlstrlltlon of It synthetic epUupe mildly enlHlllccs EAE Inducllon. 
After oral administrations and EAE induction, the severity of clinical signs was evaluated every day. 
The results of the mice of group A, Band C are expressed as average DAS units per day, in the 
upper, middle and lower panel respectively. Oral administrations were performed 011 day 0, 2, 4, 6 
and 8 (arrows). EAE was induced on day 1O(t). 
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administered antigen suggests that there exists a low zone tolerance for f3-
galactosidase. In the present experiments only a state of incomplete low zone 
tolerance was observed. This mi:sht be explained by differences in antigen processing 
of intact Lactobacilli with intracdlular jJ-galactosidase and processing of free soluble 
jJ-galactosidase derived from Lactobacilli degraded in the gastro intestinal tract 
which may lead to differences in the induction of immunological unresponsiveness. 
Stokes et al. (1983) have suggested that oral immunization, i.e. the 
development of an antibody response, requires a fast antigen uptake by the 
intestinal epithelium, whereas oral tolerance requires a gradual antigen delivery. The 
transformed Lactohacillus plalllamm strain used in our experiments produces fl-
galactosidase in the cytoplasm. The antigen is most likely released from the 
cytoplasm upon death and cytolysis of the strain in the gastrointestinal tract. Possibly 
presentation of the antigen by the LP80+ in our experiment may lead to a relatively 
fast antigen uptake and therefore might be a reason for the observed incomplete 
tolerance as well. However, various other methods of antigen delivery (presentation) 
by micro·organisms can be envisaged to realize a differential uptake of antigen: a) 
the antigen expressed by Lactobacillus and subsequently secreted in the 
gastrointestinal tract and b) the antigen is expressed on the surface of the 
Lactobacillus and is presented either by live or dead organisms to the gut associated 
lymphoid tissues. Experimental evaluation of these modes of antigen presentation by 
orally administered transformed microorganisms for induction of peripheral 
tolerance is presently investigated. 
Another factor which may influence the completion of tolerance induction is 
the age (12-15 weeks) of the animals. Faria et al. (1993) showed that B6D2F" 
C3H/I-IeJ and NJ mice were highly susceptible to induction of oral tolerance against 
ovalbumin at 8 weeks of age. In contrast, no oral tolerance induction was observed 
in NJ mice and only a partial tolerance was induced in the B6D2F, and C3H/I-IeJ 
mice, which were 24 weeks old. Also in C57BI/6J mice, age has been shown a 
limiting factor for oral tolerance induction as well (Rios et aI., 1988). These results 
suggest that, dependent on genetic background, there is a certain time window in the 
ontogeny in which the mice are most susceptible to induction of oral tolerance. The 
period in which the mice are most susceptible to oral tolerance induction in general 
is found shortly after immunological maturation (Hanson, 1981). Possibly oral 
administration of LP80' to younger mice (8-10 weeks), instead of to young adult 
mice (12-15 weeks) as in our experiment, might improve tolerance induction. 
Figure 4 (next page) 
Oral Rdll1inlstmtiolls of Laclobuciflus case; synergistically enhllnccs EAE rcsponsi\-'eness. 
After oral admhlistrations and EAE induction, the severity of clinical signs was evaluated every day. 
The results of the mice of group 0, E and F arc expressed as average DAS units per day, in the 
upper, middle and lower panel respectively. Oral administrations were performed on day OJ 2, 4, 6 
and 8 (arrows). EAE was induced on day 10(*). 
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We have investigated the effect of oral administration of EAE inductive 
peptide with and without high adjuvant L.casei on EAE induction. It was shown that 
oral administration of low doses of 100 I'g and sao I'g peptide, prior to disease 
induction, did not induce tolerance for EAE (group B and C). At least two reasons 
might explain why tolerance induction was not accomplished in these mice: a) the 
high doses of antigen used for oral pre-treatment and b) the choice of an 
encephalitogenic PLP-epitope. It may he assumed that the amount of PLP-peptide 
which we have used for oral administration is still too large to be efficient for low 
zone tolerance induction. In the experiments using LP80+ only the smallest amounts 
of fl-galactosidase producing LP80+ were efficient in tolerance induction. These mice 
received an estimated amount of 0.1 Ilg p'galactosidase, which is at least a factor 
1000 less as compared to the lowest amount of PLP-peptide administered to the 
SJL/j mice. Furthermore, taking the molecular weight of both fl-galactosidase and 
PLP-peptide in consideration, the amount of fl-galactosidase may be reduced with 
another factor 200 as compared to the amount of PLP-peptide used for pre-
treatment. The choice of the encephalitogenic PLP epitope for oral administration 
may be due to the failure to induce tolerance as well. Both in Lewis rat and SJL/j 
mice a number of peptides have been described which can induce oral tolerance 
against EAE induction. These include the non-encephalitogenic tolerizing 
decapeptide from MBP (Higgins and Weiner, 1988) and a variety of other MBP 
sequences (Avrilionis and Boggs, 1991; Naiki et aI., 1991; Su and Sriram, 1991; 
Weiner et aI., 1992). In subsequent studies, the synergistic effects of oral 
administration of tolerizing epitopes on EAE will be studied. 
Oral administration L.case; (group E and F) prior to EAE induction resulted 
in a considerable EAE enhancement (figure 4) as compared to the course of disease 
of animals which were not orally pretreated with L.case; (figure 3). The severity of 
clinical signs was even enhanced when L.casei was orally administered without 
peptide (group D vs A). Therefore the enhancement of disease is most likely due to 
the high adjuvant properties of this Lactobacillus strain. Some Lactobacillus strains 
can exert non-specific immunostirnulatory effects (Bloksma et aI., 
1979)(adjuvanticity) which seems mainly due to wall components of the bacteria 
(Kato et aI., 1984; Yokokura et aI., 1986). However Lactobacillus do not produce 
LPS and the mechanism (component) of adjuvant activity of Lactobacillus is still 
unknown (Claassen et aI., 1994). The adjuvant properties of Lactobacillus may 
influence whether the immune system is activated or tolerized, upon oral delivery of 
Lactobacillus and antigens. In general, immune responses are enhanced by adjuvant 
(Claassen and Boersma, 1992). On one hand, Goverman et al. (1993) showed that 
spontaneous experimental autoimmune encephalomyelitis (EAE), can only develop 
in myelin basic protein (MBP) specific T-cell receptor transgenic mice when the 
animals were housed in a non-sterile facility and not when they were kept under 
specific pathogen free conditions. These findings suggest that the presence of 
specific bacteria in the gastro-intestinal tract contributes to the activation of the 
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immune system of EAE animals. On the other hand it has also been shown that 
colonization of the gastro-intestinal tract by Jipopolysacharide (LPS) producing 
micro-organisms is one of the requirements for oral tolerization (Wannemuhler et 
aI., 1982). Oral tolerance to MBP is enhanced by the oral administration of LPS, 
possibly through the production of specific cytokines, i.e. TOF-Ii and IIA (Khoury et 
aI., 1992). Furthermore it was shown that certain bacteria, i.e. Bordelella pertussis 
and Mycobacterillm IIIberculosis can playa beneficial role in the induction of T cell 
mediated suppression (Lehmann and Ben-Null, 1992). 
In conclusion, this study shows that partial induction of peripheral tolerance 
in young adult mice, can be established after the oral administration of fJ-
galactosidase producing Lactobacilllls LP80+ with low adjuvant properties. In 
contrast, the use of L.ease; with high adjuvant properties, mixed together with 
soluble antigen, resulted in enhancement of the immune response. The results of this 
study indicate that Lactobacillus are potential candidates for the delivery of immune 
stimulating signals as well as for the induction of peripheral tolerance against 
putative autoantigens in human autoimmune diseases. 
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CHAPTER 5 
GENERAL DISCUSSION 
Introduction 
Multiple sclerosis (MS) presents itself as an inflammatory autoimmune 
disease which is restricted to the central nervous system (CNS). In the inflammatory 
reaction mononuclear cells, antigen presenting cells (APC), B·cells and regulatory 
and effector T-cells are involved. Animal studies revealed that also other cells may 
be involved in the immune response. MHC class II expression has been 
demonstrated on meningeal cells, perivascular cells, astrocytes and microglia cells 
(Hickey and Kimura, 1988; Vass and Lassmann, 1990). Furthermore, astrocytes and 
glial cells have been shown to produce cytokines (Robbins et al., 1987). 
Despite intensive scientific and clinical research on MS, the etiology and 
pathogenesis is still unknown. Several hypotheses on the etiology of MS have been 
postulated; MS may be induced by an infectious organism, an autoantigen Of an 
antigen mimicking a self-component. However until now no single infectious 
organism, autoantigen or antigen has been linked to the disease. The IIconsensusll 
hypothesis on the etiology of MS is that a combination of environmental factors in a 
genetically susceptible subject may lead to the induction of an autoimmune response. 
Based on the premise that MS is mediated by an aberrant immune response 
most approaches to prevent MS, which were developed so far, are related to 
intervention or enhancement of certain immunological processes. This chapter will 
discuss the relevance of the experiments described in this thesis in relation to recent 
developments concerning inununo-intervention in MS. 
B-cell specificity 
In most MS patients an elevated level of intrathecally synthesized 
immunoglobulins in the cerebrospinal fluid (CSF) is observed (Walsh and 
Tourtelotte, 1983). These antibodies show a polycional banding pattern when 
separated by isoelectric focusing, indicating an antibody response based on a limited 
. number of specificities. Some of the polyclonal antibodies are directed against CNS 
autoantigens, however the majority of the antibody specificities still remain obscure. 
It has been suggested that a part of the antibodies are directed against idiotypes of 
the autoantigen antibodies. According to the network theory of Jerne (1975) it is 
conceivable that anti-idiotype antibodies Illay down regulate the autoantibody 
response without undesirable side effects. Down regulation of the autoantibody 
response based on the production of anti-idiotypic antibodies may contribute to 
therapy of MS. Whether this anti-idiotype antibody based method can be applied to 
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decrease autoantibody levels remains to be investigated. 
Antibodies against a variety of CNS antigens have been detected also in sera 
of MS patients. However, antibodies directed against CNS antigens have been 
detected in the CSF and sera of healthy subjects as well. In most studies 
autoantibody levels in sera and CSF of MS patients were increased as compared to 
the autoantibody levels in healthy subjects. In chapter 2 we have shown that the 
majority of the APes detected in brain tissue sections was directed against MBP. 
Furthermore we have shown that the presence of MBP specific antibody forming 
cells in CNS tissue sections is specific for MS patients. Anti-myelin basic protein 
(MBP) antibody forming cells (AFCs) were not detected in CNS tissue sections of 
healthy subjects nor in CNS tissue sections of patients with other neurological 
diseases. This finding indicate that the antibody response to myelin basic protein is 
important in MS immunopathology. This was confirmed in a study performed 
recently by Warren et al. (1994). In a panel of 116 chronic progressive MS patient it 
was shown that 111 had anti-MBP titers in the cerebrospinal fluid, while 173 of 180 
relapsing MS patients had anti-MBP antibody in the CSF. Although these findings 
are highly suggestive for an important role of MBP as antigen it can not be 
concluded that MBP is the primary target antigen. One of the problems in 
identifying the target antigen in autoimmune diseases in general is the occurrence of 
antigen diversification of B-cell responses to other antigens, after a primary immune 
response which triggered the disease. 
Bocell activation 
The development of an autoantibody response in MS is generally explained as 
a secondary phenomenon due to the release of autoantigens to the circulation. 
Autoantigens have been detected in serum and urine of MS-patients (Whitaker, 
1977; 1987). Autoantigens in the circulation will eventually arrive in the peripheral 
immunological tissues and will be presented to B-cells. Guided by autoantigen 
specific T-cells these cells will proliferate and differentiate. Subsequently, the 
autoantigen specific APCs will reach the blood brain barrier due to normal immune-
surveillance and in case of local expression of adherence molecules, the autoantigen 
specific APCs will enter the CNS tissues. On the other hand it can not be excluded 
that the B-cell response is not lIautoantigen drivenll as is described above, but that an 
additional "defectivell control mechanism, e.g. the neuro-endocrine system, is due to 
the increased number of autoreactive B-cells in MS patient sera and CSF. 
In addition, a damaged blood brain barrier will facilitate a non-antigen 
specific entrance of B-cells into the eNS tissues. Due to presence of autoantigens 
especially the autoantigen reactive B-cells will be activated. In chapter 3 we have 
demonstrated that gp39 positive T-cells are localized in the same affected region of 
the CNS tissues as the APCs specific for MBP. This observation indicate that anti-
MBP AFCs may be activated locally. Although the observed autoantibody response 
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in MS patients is generally explained as a secondary phenomenon, it should be 
emphasized that "secondaryl1 autoantibodies may contribute to immune mediated 
demyelination as well. 
lt can not be excluded however, that the autoreactive B-cel1 response in MS 
is playing a primary role in the pathogenesis. Non-antigen specific homing of 
lymphocytes to the CNS tissues takes place even in healthy, normal unaffected brain. 
Adhesion molecules expressed by immune-competent cells are candidates to guide 
the cells through the blood brain barrier and subsequently into the CNS. Several 
families of adhesion molecules are expressed on the surface of lymphocytes, having 
respective ligands (addressins) on endothelial cells of the blood brain barrier 
(Springer et aI., 1987). The interaction of the lymphocyte adhesion molecules with 
their respective ligands not only facilitates the binding of lymphocytes to the 
endothelial cells but also leads to certain changes in the blood brain barrier which 
seems to be essential for the regulation of migration of the lymphocytes (Akiyama et 
aI., 1989). This indicates that B·cells may enter the CNS even before the blood brain 
barrier is damaged and therefore could playa role even in the initial events leading 
to demyelination. 
Bocell functions 
Studies with EAE animals suggest an important role for autoantibodies and 
autoantibody forming cells in the process of demyelination. Antibody deficient rats 
fail to develop clinical or histological evidence of EAE, when sensitized with either 
whole spinal cord homogenate or purified myelin basic protein (Willenborg and 
Prowse, 1983). Intravenous injection of monoclonal antibodies against myelin 
oligodendrocyte glycoprotein in EAE in Lewis rats resulted in augmentation of both 
clinical signs, inflammation and demyelination (Lassmann et aI., 1988). Furthermore, 
in the presence of anti-myelin oligodendrocyte glycoprotein (MaG) monoclonal 
antibodies 10-100 times less encephalitogenic T-cells are needed to induce EAE by 
passive transfer (Linington et aI., 1988). The autoantibodies and autoantibody 
producing B-cells may be pathologically involved in demyelination in several ways. I) 
Autoantibodies directed against myelin components may be active in demyelination 
by complement mediated breakdown (Kerlero de Rosbo et aI., 1990; Bradbury et al., 
1984). Although, decomplementation of anti-MaG treated EAE animals only 
partially reduced clinical signs of the disease (Linington et aI., 1990). II) 
Autoantibodies IIlay be involved in demyelination by opsonization for macrophage 
attack (Williams et aI., 1980; Ozawa et aI., 1989). III) B·cells may be involved in 
demyelination by their antigen presenting capacity (Lanzavecchia, 1987). The 
membrane bound antibodies on B-cells may sequester and concentrate autoantigens 
which are present even in very low concentrations. The autoantigens then will be 
processed and presented in context of MHC class II to T-cells. This indicates that 
the presence of autoantibodies may focus the immune response to specific targets, 
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thereby inducing a very selective tissue destruction. It also indicates that the T-cell 
repertoire indirectly is affected by the B-cell repertoire. IV) Furthermore it was 
demonstrated that CNS derived immunoglobulins from MS patients are involved in 
the activation of a myelin associated protease acting on MBP (Kerlero de Rosbo 
and Bernard, 1989). 
Therapeutic approaches 
EAE animal studies indicate that autoantigen directed B-cells are directly 
related to the immunopathology of the disease. In addition, we have detected 
autoantigen specific B-cells in the CNS of MS-patients only (chapter 2). 
Furthermore, activation marker gp39 positive T-cells were detected (chapter 3) in 
affected areas of CNS tissues of MS-patients which indicates that at least a part of 
the autoreactive B-cells in MS will be activated in the CNS. These findings would 
strongly support the clinical use of immunosuppressive and immuDOInodulating 
therapies to reduce the levels of such putative pathogenic auto-antibodies. Therapy 
could be directed at the specific B-cells responsible for the production of 
autoantibodies as well as to the helper T-cells which are necessary for the B-cell 
activation. In both CSF and sera of MS patients antibodies directed against a variety 
of putative CNS antigens were detected (Zanella et aI., 1990a, 1990b; Endo et aI., 
1984; Hirsch and Parks, 1976; Link et aI., 1990; Sun et aI., 1991; Baig et aI., 1991; 
Henneberg et aI., 1991). From this it can be concluded that analysis of sera, CSF 
and immunoglobulins extracted from the brain of MS patients has failed to identify a 
single disease specific autoantibody population, which is directed against a CNS 
autoantigen. Therefore methods for the selective elimination of autoantigen specific 
B-cells will not be helpful in MS until the major primary target antigen is identified. 
In view of the heterogenous antibody specificity only therapeutical methods with a 
broad-spectrum (aspecific) character like immunosuppressive drugs can be applied. 
However, in general immunosuppressive drugs do not cross the blood brain barrier. 
Therefore these drugs are not effective against Band T-cells within the CNS. On the 
other hand if cells which are responsible for the antibody formation continuously 
enter the CNS, it may be possible to suppress the antibody production in the CNS 
indirectly by manipulating the cells of the peripheral immune system. In view of this, 
the effect of plasmapheresis on the local CNS autoantibody levels and as a 
consequence on the development of disease, has to be evaluated. 
If vascular addressins play an important role in lymphocyte traffic between 
blood circulation and the CNS compartment in MS, they may be considered to be 
important in CNS specific anti-inflammation therapy development. A high level of 
expression of vascular addressins was detected in venules in the proximity of lesions 
in the CNS of MS-patients (Raine et aI., 1990). Therefore the administration of 
soluble factors which inhibit the expression of adhesion molecules or block the 
adhesion molecules is a promising approach to interfere in the blood brain barrier 
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traffic in MS. Yednock et al. (1992) already showed that the administration of 
antibodies directed against integrin a4jJ 1 prevented the accumulation of lymphocytes 
in the eNS and inhibited the development of experimental autoimmune 
encephalomyelitis (EAE). 
EAE is transferred by autoantigen reactive T-eells to naive recipients. MBP 
reactive T-cell lines induce demyelination when added to myelinated CNS cultures 
(Lyman et aI., 1988). Other T-eells can exert an antigen specific cytotoxicity against 
antigen presenting cells like astrocytes and cerebral endothelial cells (Sun and 
Wekerle, 1986; Risau et aI., 1990). Although as yet the definite proof lacks that cell 
mediated activity is the crucial pathological event in man as well, the findings in the 
EAE animal model and the ill vitro experiments with human T-eells, strongly support 
the idea that MS is a T-cell mediated disease. As a consequence experimental MS 
therapy developed safar, was focused on the reduction or modulation of the cell 
mediated activity. Broad range effective agents, like cytokines, anti-cytokine 
antibodies, soluble cytokine receptors, anti-lymphocyte surface antigen antibodies 
and immunotoxins have been used to reduce T-cell (mediated) autoimmune 
responses in MS. However, as with the modulation of the antibody mediated activity 
it is not clear in what way the modulation of peripheral T-cell activity influences the 
local CNS T-cell activity. Until now it was shown that the systemic administration of 
these broad range agents has a relatively low effect on the development of the 
disease. In addition, it is not clear which subset(s) of T-eells are pathologically most 
important and which antigens are the target antigens. Therefore broad range 
immunosuppression seems to be the only way to modulate T~cell mediated activity in 
MS. Many immunosuppressive drug have anti-inflammatory effects as well and the 
use of this kind of drugs would eliminate the need to identify the target antigen(s). 
On the other hand, the use of anti-inflammatory drugs affects all inflammatory 
responses, also those responses which are necessary for the normal body defense 
mechanisms. Furthermore, if one supposes a viral ethiology of MS, an appropriate 
inflammatory immune response is essential to prevent further spreading of the virus 
(development of the disease). 
A more specific immune intervention can be obtained by blocking the 
APCrr -cell interaction. This can be achieved by administration of agents which 
target on either the MHC products or by agents which target on the T-cell receptor 
(TCR), such that encephalitogenic T-cells can not be triggered. A strain dependent 
limited VjJ gene usage by cells specific for MBP has been identified in both rats and 
mice. EAE can be prevented by pretreatment with monoclonal antibodies directed 
against the VjJ8 coded TCR chain. Furthermore EAE remission is correlated with 
the development an anti- VjJ8.2 antibody response. Also direct immunization with a 
VjJ8.2 peptide, representing the antibody epitope, resulted in prevention of disease 
induction (Hashim et aI., 1992). Data have been presented that class I CDS+ T-cells, 
reactive with the TCR pep tides, are responsible for the protection against EAE 
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disease induction (Offner et aI., 1991). On the other hand it was shown that CD4 t 
T-cells secrete the inhibitory TGF-p and IL-4 cytokines upon exposure to a VPS 
peptide (Karpus et aI., 1992). Furthermore, it was shown that TCR gene VP17 was 
predominantly used by human T -cells reactive with MBP fragment 84-102 
(Wucherpfennig et aI., 1990). However, with some exceptions, the Vp usage will vary 
between individuals (Ben-Nun et aI., 1991), this makes the identification of a 
consensus target molecule, which can be used to block the TCR in more than one 
subject, very difficult. Therefore, the TCR blockade therapy seems to be useful in 
individual patients only, presuming that the administration of these peptides in 
human can reduce the activity of autoreactive T-cells. The usage of peptide mixtures 
could make the TCR-blockade therapy even more widely applicable. 
An alternative way of blocking cellular interactions and as a consequence the 
activation of cells is the use of antibodies. In chapter 3 it was demonstrated that the 
administration of anti-gp39 monoclonal antibodies, prevented the development of 
EAE. Even the administration of anti-gp39 after disease onset, shortly before 
maximum disability score was reached, lead to dramatic disease reduction. These 
results indicate that gp39-CD40 interactions are required to maintain EAE. 
However, it is unknown through which mechanism gp39 and CD40 are involved in 
the maintenance of the disease. Several possible mechanisms can be distinguished. I) 
As was discussed before (see B-cell function) autoantibodies produced by CD40 
positive B-cells, may be involved in the process of demyelination in many ways. II) 
Macrophages expressing CD40 may be activated by gp39 t T-cells as well. 
Macrophages can be involved in demyelination by the production of cytotoxic and/or 
inflammatory cytokines and cytotoxic oxygen radicals. III) The gp39t T-cells may be 
involved in pathology of the disease due to the production of a variety of 
inflammatory cytokines. In chapter 3 we have shown that gp39 t T-cells are present in 
CNS tissue sections of MS patients. This finding indicate that gp39/CD40 
interactions are possibly involved in MS immunopathology. Therefore, in analogy to 
the results obtained in EAE, the blockade of cognate gp39-CD40 interactions might 
be considered to induce a long term antigen specific suppression in MS 
demyelination as well. However, since the gp39 membrane marker is expressed on 
all activated T-cells, anti-gp39 treatment may be considered to be a therapeutic 
method with a limited specificity only. An alternative approach to induce long term 
antigen specific suppression is the induction of oral tolerance. 
Tolerance induction 
In normal healthy subjects food antigens normally do not provoke an 
immunological reaction. This implicates that feeding of autoantigens to humans, 
under certain conditions, may be expected to induce a state of antigen specific 
tolerance, as they do in animals. Therefore, the most promising nOllatoxic, immuno~ 
specific therapy is tolerance induction by oral administration of autoantigens. 
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However, an essential requirement for this kind of therapy is the identification of 
the autoantigen(s). In EAE animals, the oral administration of MBP, prior to disease 
induction and subsequent suppression of disease in treated animals induced an 
increased local production of the inhibitory cytokine TGF-p (Khoury et aI., 1992). 
Under certain conditions, oral tolerance to MBP may be mediated by clonal 
deletion, rather than by active suppression due to the action of cytokines. After oral 
administration most antigens are processed first by intestinal enzymes and secondly 
by intestinal epithelial antigen-presenting cells, which will probably present the 
tolerogenic epitopes to intraepithelial lymphocytes. The activated or tolerized 
lymphocytes migrate via the mesentherial lymph nodes and thoracic duct to the 
spleen where they may mediate induction of anergy (Whitacre et aI., 1989; 1990). 
Although the induction of oral tolerance in animals is most promising and is 
considered as a possible method for MS-therapy as well, oral tolerance induction 
therapy has still some disadvantages. Oral administration of autoantigens may 
enhance an already established systemic immune response (Hanson et aI., 1979). 
Dependent on dose of antigen, administration regimen, delivery system and adjuvant 
properties of the delive,y system it is possible to induce a systemic immunological 
memory formation, following the same route as is used for tolerance induction 
(chapter 4.3). This indicates that secondary conditions will to a large extent 
determine the outcome of tolerance induction protocols. As was shown in chapter 
4.4, the oral administration of PLP synthetic epitopes together with Lactobacillus 
casei prior to EAE induction in naive SJUJ mice resulted even in a significant 
enhancement of the immune response. 
Antigens may exhibit inductive as well as tolerogenic epilopes. Therefor an 
alternative approach to reduce the possibility of disease exacerbations after oral 
administration of autoantigens is the use of selected tolerogenic synthetic peptides 
fragments, which are not autoimmunogenic by itself. Both in Lewis rat and SJL/J 
mouse EAE models a number of peptides, related to myelin proteins, have been 
described which can be applied to induce oral tolerance against subsequent EAE 
induction. These peptides include the non-encephalitogenic tolerizing decapeptide 
from MBP and a variety of other MBP sequences (Higgins and Weiner, 1988; Su 
and Sriram, 1991; Avrilionis and Boggs, 1991; Weiner et aI., 1992; Naiki et aI., 1991). 
The production of such peptides by live transformed microorganisms, which are 
administered orally, would prevent their complete degradation by intestinal enzymes 
and would facilitate a continuous delivery of peptide to the intestinal epithelium as 
well. We have shown that GRAS Lactobacillus species are convenient 
microorganisms to a) present and deliver antigens to the immune system via the oral 
route (chapter 4.2) and b) dependent on the adjuvant properties of the Lactobacillus 
strain, Lactobacilli can induce at least a transient state of peripheral tolerance when 
administered orally (chapter 4.4). Therefore, the oral administration of Lactobacillus 
strains, genetically transformed to produce and secrete tolerogenic epitopes, seems 
to be a most promising approach to induce peripheral tolerance without disease 
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exacerbations. 
The ultimate intention of tolerance induction by the oral administration of 
autoantigens is the induction Of re-establishment of natural tolerance in patients with 
disease. Until now most experiments performed wHh animal autoimmune diseases 
were based on the modification of the immune response by oral administration of 
autoantigens before disease induction by the parental route (Nussenblat et a!., 1990). 
Oral administration of MBP in Lewis rats during the pre-clinical period of EAE, did 
lower the incidence and severity of clinical signs of EAE, but was not able to induce 
a state of tolerance similar to that obselved after oral administration of MBP before 
disease induction (Higgins and Weiner, 1988). However, the induction of oral 
tolerance to MBP can be enhanced by the oral co-administration of 
Iipopolysacharide (LPS) as an adjuvant (Khoury et al., 1990), which suggest that 
microorganisms which express LPS may especially be convenient for the oral 
delivery of tolerogenic epitopes in order to induce tolerance against putative eNS 
autoantigens in MS. 
Concluding remarks 
The experiments to study the involvement of autoantibody forming cells in 
immunopathology of MS and the experiments concerning the use of microorganisms 
as antigen presenting vehicle by the oral route have raised many new scientific and 
clinical questions. In the experiments presented in chapter 2, we have limited 
ourselves to the detection of antibody forming cells directed against only one 
putative eNS autoantigen. One specimen of microorganisms was appJied to 
investigate its putative use as an oral delivery sy"tem (chapter 4). Due to these 
limitations and to the fact that this field is evolving rapidly it is very difficult to draw 
definite conclusions. 
However, the presence of myelin basic protein antibody forming cells and B-
cell activation-marker-positive T-ceHs in affected areas of MS patients as was 
demonstrated in this thesis, together with the larg': body of literature on antibody 
mediated demyelination in ill vitro or ill vivo animal experiments strongly suggests 
that myelin basic protein specific antibodies are involved in MS immunopathology. 
The mechanism of action being still unknown. Similarities between the 
immunological anomalies associated with MS and the T-cell mediated demyelinating 
animal model of experimental autoimmune encephalomyelitis, has resuHed in 
focusing of therapeutical approaches on the T-cell. Based on the major role of T-
cells (help to other cells (B-cells), cytotoxicity, suppression) in many immunological 
processes in general, it seems worthwhile to block one or more T-cell related 
functions in a non-antigen specific way, i.e. irrespective of the identity of the putative 
target autoantigen(s). As we have demonstrated in this thesis (chapter 3) the 
blockade of a T-eell membrane marker gp39 by the administration of monoclonal 
antibodies was successful in reduction of disease in EAE animals, even if the 
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antibodies were administered after disease onset. These findings suggest that the 
blockade of cellular interactions, especially if the blockade can be focused within the 
eNS, may be a useful method to interfere in MS immunopathology as well. 
The ultimate goal in MS therapy development will be the restoration of the 
normal adult immune system by the induction of tolerance. A promising approach to 
induce tolerance is the administration of tolerogenic epitopes of selected auto-
antigens by the oral route. In this thesis (chapter 4) we have demonstrated that 
peripheral tolerance can be induced by the oral administration of genetically 
modified Lactobacillus producing antigen. This approach is may be useful to provide 
specific immunotherapy in MS patients as well. 
However, it should be emphasized that the human immune system provides 
several mechanisms which could damage the central nervous system in many ways. 
In other words, numerous different antigens can be the target of different effector 
cells which can produce various effector molecules at the same time. As a 
consequence, the blockade of one single cell interaction or the induction of 
tolerance against one single putative antigen may have some beneficial effect on the 
disease, however these approaches wiIJ never cure the disease. 
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SUMMARY 
Multiple sclerosis (MS) is a chronic disease which affects the central nervous 
system (eNS) and is characterized by demyelinated areas and perivascular 
accumulation of inflamrnatOlY cells. Despite intensive scientific research both 
etiology and pathology of the disease remains largely unknown (chapter 1). Due to 
the complexity of clinical characteristics it is even very difficult to diagnose MS. 
Since several immune abnormalities are related to the diseases it is generally 
accepted that MS is the result of (auto)inllnune mediated demyelination. 
One of the hallmarks of MS is an oligoclonal immunoglobulin banding 
pattern after isoelectric focusing of the cerebrospinal fluid. However, the role of 
humoral immunity in MS is as yet not clearly defined (chapter 2.1). To investigate 
the involvement of autoantigen specific immunoglobulin producing cells in the 
pathology of MS we have started a study to detect antigen specific B-cells in eNS 
tissues of MS patients. The detection of autoantigen specific B-cells and the in silu 
localization of these cells simultaneously can be accomplished by the use of immune-
enzyme cytochemical staining techniques only. In chapter 2.2 we describe the epitope 
specific detection of antibody forming cells (APes) in various tissues based on the 
application of antigen-enzyme conjugates. Using antigen-enzyme conjugates rare 
APes can easily be detected and enumerated. Even multiple antibody specificities 
can be visualized in a single tissue sample and tissue compartments. This approach 
aJlows careful localization and investigation of compartimentation of AFC 
sUbpopulations in human lymphoid and central neIVOUS system tissues in order to 
investigate how B-ceJls may contribute to the pathogenesis of autoimmunity in man. 
The detection of AFCs requires the construction of antigen-enzyme conjuga-
tes. Prior to, during and after the conjugation procedure it is necessary that both 
antigen, enzyme and antigen-enzyme conjugate are dissolvable in the media applied 
for the coupling chemistry. Most conjugation procedures are performed in aqueous 
buffers, which have no or minor intluence on the three dimensional structure of the 
antigen or on the biological activity of the enzyme. Selected peptide sequences, 
representing specific epitopes, due to their hydrofobicity, not always readily dissolve 
in aqueous buffers. Therefore we have developed a new coupling method (chapter 
2.3), which allows the conjugation of peptides, which have only very low solubility in 
aqueous buffers. 
The structural protein components of the myelin sheaths, surrounding the 
neuronal axons, are considered to be putative target antigens for immune competent 
cells, which play a role in the pathogenesis of MS or experimental allergic 
encephalomyelitis (EAE). Whether or not APes directed against these myelin 
protein components play a role in the pathogenesis of MS or EAE is unclear, 
because the experiments performed safar concerned the detection of APCs and 
antibodies (Abs) in the sera and/or cerebrospinal tluid only. The use of myelin 
protein component-enzyme conjugates allows the detection of anti-myelin protein 
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component AFCs locally in the tissues of the CNS, In cilapter 2,4 we describe the 
construction and validation of a conjugate of horseradish peroxidase and myelin 
basic protein (MBP), MBP is one of the major prmein components of CNS myelin, 
The MBP-enzyme conjugates were used to determine the presence of the anti-MBP 
AFes in the spleens of mice and cerebrum of rhesus monkeys after induction of 
EAR To investigate the putative role of anti-MBP AFCs in the pathogenesis of MS, 
we have used these conjugates to detect and localize anti-MBP AFCs in a panel of 
CNS tissues of MS patients, patients with other neurological diseases and healthy 
controls (chapter 2,5), The established presence of wch cells is highly suggestive for 
a role of autoantigen reactive Abs in immunopathology of MS. 
Abs and antibody producing B-cells specific for a variety of putative CNS 
antigens have been detected in both cerebrospinal fluid and sera of MS patients and 
in eNS tissue sections of MS patients as well. However, it is not clear whether the 
antigen specific B-ceHs, present within the eNS tissues of MS patient, will be 
activated by T-cells in the demyelinated areas of the CNS or in peripheral localized 
tissues. Multiple activation signals, surface protein interactions and co-stimulatory 
factors are required for the optimal proliferation R1U differentiation of autoantigen 
specific B-cells, Binding of activation T-cell membrane marker gp39 to its B-cell 
receptor CD40 is one of the requirements for the initiation of activation. In order to 
investigate a possible B-cell activation within CNS tissues of MS patients, CNS tissue 
sections were evaluated with respect to the presence of the gp39 activation marker 
on T-cells, In the experiments described in cilapter 3, we have detected gp39 positive 
T-celJs in the same affected eNS tissue areas of MS patients as were we have 
detected the MBP specific AFCs, This result indicate that autoantigen reactive B-
cells may be activated within the CNS, 
Based on the assumption that MS is an (auto)ill1111Une mediated disease, most 
therapeutic approaches are focused on intervention of the aberrant immune 
response. One of the possibilities to modulate the irnmune response is the blockade 
of co-stimulatmy signals. Recent research has revl~aled that a long term immune 
suppression can be accomplished by the blockade of the gp39 T-cell activation 
marker and its CD40 ligand present on B-cells, In chaptC!' 3 we have shown that, the 
blockade of the gp39/CD40 interaction in EAE mice, by administration of anti-gp39 
Abs, resulted in a significant reduction of clinical characteristics of the disease, even 
when the anti~gp39 monoclonal Abs were administered during disease progression. 
These results indicate that blockade of gp39/CD40 interactions may be use full in the 
treatment of MS as well, 
An other approach of immune modulation is suppression of the immune 
response by induction of tolerance. Tolerance can be induced by oral administration 
of putative autowantigens. Live non~pathogenic microorganisms, transformed to 
produce autowantigens, may be useful for oral delivery of auto~antigens as they have 
many advantages over conventional feeding of auto-antigens (chapter 4.1). As we 
shown in a parallel line of research, the presentation of antigens by the 
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microorganisms to the immune system may also result in the induction of a cellular 
and/or humoral immune response to the antigens delivered. To generate a safe, non~ 
pathogenic, live vector as an oral antigen delivery system, we have developed a 
plasmid transformation system for Lactobacillus species which are natural 
inhabitants of the gastrointestinal tract and generally regarded as safe (chapter 4.2). 
In addition we have examined Lactobacillus for their ability to deliver antigens via 
the oral route to the immune system to generate a humoral immune response to a 
Lactobacillus associated model antigen. trinitrophenyl. The results of this study 
indicate that Lactobacillus are potential antigen carriers to generate immunological 
memory in mucosal as well as in systemical immune responses. 
In chapter 4.3 we describes the routing of Lactobacillus associated antigens 
and the ill situ localization of antigen specific APes in lymphoid organs, after both 
oral administration and intraperitoneal injection of a Lactobacillus trinitrophenyJ 
conjugates. We show that at least a part of the TNP-Lactobacilllls. is transported 
directly to the mesenteric lymph nodes (MLN). as could be concluded from the 
presence of antigen-complexes in MLN tissue sections. 
Microbial products with adjuvanticity have been found to play a role in 
induction of tolerance but can also be used to enhance immune responses in a a-
specific manner. Similarly, the adjuvant properties of microorganisms, which are 
applied as antigen delivery vehicles, may influence the activation or tolerization of 
the immune system. In chapter 4.4 we have studied the differential effect of oral 
administration of antigens, making use of two Lactobacillus strains, which differ in 
their adjuvant properties. In order to induce immunological tolerance Lactobacillus 
p/all(an111'1 80, a strain with relatively low adjuvant properties, was administered 
orally to mice. Lactobacillus plantal1l1ll 80 is transformed for over-production of E. 
coli lacZ, i.e. fJ-galactosidase. The capacity to mount an immune response was 
determined after a fJ-galactosidase challenge injection. The influence of adjuvant 
properties of microorganisms on the induction of oral tolerance was tested with an 
autoimmune disease animal model. The effects on the immune system of oral 
administration of antigen and Lactobacillus case;, a strain with high adjuvant 
properties was studied in EAE mice. The effects of the simultaneous oral delivery of 
an encephalitogenic epitope and Lactobacillus casei prior to disease induction on the 
course of disease were monitored by evaluation of clinical characteristics. In this 
study we have shown that oral administration of genetically modified lactobacilli. 
which secrete antigen, leads to the induction of tolerance. Furthermore, recipient 
mice become tolerant as well after adoptive transfer of donor spleen cells of the 
lolerized mice. 
The experiments decribed in this thesis show that both blockade of 
gp39/CD40 interactions and the induction of oral tolerance by application of 
microorganisms seems rather effective to suppress immune responses in animal 
model systems. Therefore both methods may have a significant potential for future 
treatment of autoimmune phenomena in MS patients as well. 
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SAMENVATIING 
Multiple sclerose (MS) is een chronische ziekte van het centrale zenuwstelsel 
(SZS). Kenmerkend voor de ziekte zijn de ontstekingshaarden en de atbraak van de 
myeHneschede rond de zenuwbanen in het SZS. In de hersenen van MS-paW~nten 
zijn meerdere (multiple) gebieden waarin de myeline is afgebroken als littekens 
(sclerose) zichtbaar. Gndanks intensief wetenschappelijk onderzoek is de etiologie 
en pathologie van MS nag steeds grotendeels onbekend. De enorme variatie en 
complexitcit in klinische verschijnselen maakt het zelfs erg moeilijk om MS te 
diagnostiseren. Aangezien vele afwijkingen met betrekking tot het immuunsysteem 
zijn gerelateerd aan de ziekte, wordt in het algemeen aangenomen dat MS het 
resultaat is van eell (auto)illlmuniteitsreactie. 
Het voorkomen van oligoclonale antHichamen in de cerebrospinale vloeistof is 
eeo van de (immunologische) kenmerken van MS. Het is echter niet bekend tegen 
welke antigenen deze antilichamen zijn gericht en op welke wijze deze antilichamen 
een rol spelen in de pathologie van MS. Om de betrokkenheid van antilichamen in 
MS te bestuderen is een studie gestart naar antilichaamvormende ceBen in de 
weefsels van het SZS van MS patienten. 
Antilichaamvormende cellen kunnen worden gedetecteerd door gebruik te 
maken van immuun-histochemische kleuringstechnieken. Voor de toepassing van 
deze techniek is het noodzakelijk om antigeen-enzym conjugaten te construeren. 
Tijdens de constructie van dergelijke conjugaten is het essentieel dat zowel het 
antigeen als het enzym in oplossing blijven. In deze studie is een nieuwe 
koppelingsmethode ontwikkeld, die het mogelijk maakt om zelfs slecht oplosbare 
peptide-antigenen te conjugeren. 
Er wordt verondersteld dat het immuunsysteem gericht is tegen de structurele 
eiwitten van de myelineschede in het SZS van zowel MS patienten als dieren met 
experimentele allergische encephalomyelitis (EAE), het MS proefdiermodel. Omdat 
tot nu toe al1een cellen werden gedetecteerd in de cerebrospinale vloeistof of in het 
bIDed en niet in de weefsels van het SZS is het nog steeds onduidelijk of deze 
structurele eiwitten inderdaad een rol spelen in MS. Het gebruik van enzym 
conjugaten van myeline component en maakt het mogelijk dergelijke cell en ook ;11 
silu te detecteren. 
In deze studie is een conjugaat van het enzym peroxidase en een van de 
hoofdbestanddelen van de myelineschede, nl. het myeline basisch eiwit (MBP), 
geconstrueerd. Om de veronderstelde rol van antilichaamvonnende cellen gericht 
tegen het MBP eiwit in de pathogenese van MS te bestuderen is het MBP-enzyme 
conjugaat gebruikt voor de detectie en lokalisatie van anti-MBP 
antilichaamvonnende ceHen in een panel van SZS weefsels van MS patienten, 
patH~nten met andere neuroiogische ziekten en gezonde personen. De anti-MBP 
antilichaamvormende cellen zijn aileen waargenornen in het SZS van MS patienten 
en niet in de weefsels van het SZS van beide controle groepen. 
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Vaar eeo effectieve activering van de antilichaamvormende cellen zijn T~ 
cellen noodzakelijk. Binding van het T-ce! membraaneiwit gp39 met het CD40 
membraaneiwit van de B-cel is essentieel voar de uiteinlielijke activering van de B-
eel. In deze studie is aangetoond uat gp39 positieve T-cellen aanwezig zijn in 
bescbadigd hersenweefsel van MS patienten. Dit resultaat is eell indicatie dat anti-
MBP antilichaamvOl'l11ende cellen lokaal, l11.a.w. in het SZS, geactiveerd kunnen 
worden. 
Ol11dat verondersteld wordt dat MS een (auto)immuniteitsziekte is, zijn de 
meeste therapeutische behnndelingen van MS gericht op de modulatie van het 
immuunsysteem. Een van de mogelijkheden om de (afwijkende) il11l11uunrespons te 
moduleren is het blokkeren van de activeringssignalen tussell de cellen van het 
immuunsysteem onderling. In deze studie is aangetoond dat de blokkade van de 
gp39/CD40 interacties in EAE muizen leidt tot eeo afname van de klinische 
verschijnselen van EAE, zelfs als de blokkade wordt gestart tijdens de ontwikkeling 
van de ziekte. Deze resultaten sllggereren dat de blokkade van gp39/CD40 
interacties als methode van immuun-suppressie toepasbaar is in MS. 
Een andere methode van modulatie van het immuunsysteem is het opwekken 
van tolerantie. Tolerantie tegen (allto)antigenen kan worden gejnduceerd door het 
oraal toedienen van de vermoedelijke (auto)antigenen. Levende niet-ziekte 
velwekkende microorganismen, zodanig gemodificeerd dat zij (auto )antigenen 
produceren, kunnen worden gebruikt voor zowel een effectieve produktie als vool' 
presentatie van antigenen aan het immuunsysteem via de orale route. In eeo 
parallelle lijn van ooderzoek is tevens aangetoond dat de presentatie van antigenen 
via de orale route door microorganismen aan het immuunsysteem kan resulteren in 
de inductie van een immuunrespons gericht tegen het antigeen dat door het micro-
organisme is gepresenteerd. Stimulatie van het immuunsysteem dan weI het 
induceren van tolerantie door gebruik te maken van microorganismen is o.a. 
aflmnkelijk van de adjuvant activiteit van het microorganisme die het antigeen 
produceert/presenteert. Het effect van de adjuvant activiteit op tolemntie 
inductie/immuun stimulatie is bestudeerd door gebruik te maken van twee 
Laclobacillus stammen die beide verschillen in adjuvant activiteit. In deze studie is 
aangetoond dat de orale toediening van een genetisch gemodificeerde Laclobacillus 
starn, met een relatief lage adjuvant activiteit, leidt tot de inductie van tolerantie. 
Tevens is aangetoond dat deze tolerantie kan worden overgedragen door transfusie 
van de miltcellen van de tolerante muizen naar nai'eve ontvanger ll1uizen. 
Daarentegen leidt de orale toediening van eeo Laclobacillus stam, met een hoge 
adjuvant activiteit, juist tot stimulatie van het immuunsysteem. 
De resultaten van deze studie tanen aan dat zowel de blokkade van 
gp39/CD40 interacties als de inductie van tolerantie met behulp van 
microorganismen via de orale route effectief zijn in de suppressie van ziekte in 
proefdieren. Mogelijk zijn dergeJijke method en van immuun-modulatie oak effectief 
toepasbaar in MS. 
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ABBREVIATIONS 
Ab antibody HLA human lymphocyte antigen 
ACTH adrenocorticotropic hormone HF hydrogen tluoride 
ADCC antibody dependent cellular HRP horseradish peroxidase 
cytotoxicity KLH keyhole limpet haemocyanin 
AFC antibody forming cells Mab monoclonal antibody 
AP alkaline phosphatase MAG myelin associated glycoprotein 
BALT bronchus associated lymphoid MBP myelin basic protein 
tissues MHC major histocompatibility 
BSA bovine serum albumin complex 
CFA complete Freunds adjuvant MLN mesentheric lymph nodes 
CFU colony forming units MOG myelin oligodendrocyte 
CNS central nelVOUS system glycoprotein 
CR cronic relapsing remitting MRI magnetic resonance imaging 
CSF cerebrospinal fluid MS multiple sclerosis 
CT computerized tomography OND other neurological diseases 
DAS disability scale PBS phosphate buffered saline 
DMF dimethylformamide PLP myelin proteolipid protein 
EAE experimental autoimmune PVC polyvinyl chloride 
encephalomyelitis RR relapsing remitting 
EDC l-ethyl-3-(3-dimethyl- SP spleen 
aminopropyl)-carbodiimide T tween-20 
ELISA enzyme linked immuno sorbent TCR T-cell receptor 
assay Tc cytotoxic T-cell 
FCA Freunds complete adjuvant TD thymus dependent 
G gelatine Th T-helper cell 
GA glutaraldehyde TNBS 2,4,6-trinitrophenyl sulfonic 
GALT gut associated lymphoid tissues acid 
GL {i-galactosidase TNP trinitrophenyl 
GRAS generally recognized as safe 
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